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The human organic cation transporter 1 (OCT1) is strongly expressed in the sinusoidal 
membrane of hepatocytes. OCT1 mediates the uptake of drugs and exogenous substances 
with cationic or weak basic structures into the liver. The OCT1 gene has high genetic 
variability with five common amino acid substitutions R61C, C88R, G401S, G465R and 
the deletion of M420del that are known to cause loss of OCT1. The loss of OCT1 function 
decreases the hepatic uptake of drugs like morphine, tropisetron, and O-desmethyltramadol 
(the active metabolite of tramadol) and increases their plasma concentrations. This may 
result in increased efficacy of these drugs, but also increases the risk of adverse effects. In 
Caucasians, 9 % of the individuals carry two inactive OCT1 alleles and further 42 % carry 
only one inactive OCT1 allele. Recent next-generation resequencing analyses of 53 global 
populations as well as the existing data of 14 populations of the 1000 Genomes project led 
to the identification of additional amino acid substitutions predicted to affect OCT1 
function.  
In the first part of this thesis, 19 amino acid variants in OCT1 (including the 5 common, 
5 novel, and 9 population-specific) were functionally characterized using a broad spectrum 
of structurally diverse OCT1 substrates. The aim was to generate a world map of 
genetically-determined loss of OCT1 function. This world map might shed light on the 
potential role of OCT1 polymorphisms in interethnic differences in drug therapy. 
Furthermore, the global distribution of loss of OCT1 function might point to a selection 
pressure for either retention or loss of OCT1 activity. 
Targeted genomic integration was used to generate HEK293 cell lines overexpressing 
OCT1 allelic variants. The cells were used to measure the effect of the variants on the 
uptake of the model substrates MPP+, TEA+, ASP+ as well as of the drugs morphine, 
metformin, tropisetron, debrisoquine, and O-desmethyltramadol. The subcellular 
localization of OCT1 was analyzed by western blot analysis and immunofluorescence 
staining detected by confocal microscopy.  
Fifteen major OCT1 alleles causing a more than 50 % decrease or increase of the wild type 
transport activity were identified. An additional 6 sub-alleles were identified that did not 
substantially affect the transport properties of the major allele. Four major alleles OCT1*5 
Abstract 
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(G465R/M420del), OCT1*6 (C88R/M420del), OCT1*12 (S29L), and OCT1*15 (E284K) 
showed complete substrate-wide loss of activity caused by improper membrane localiza-
tion of the protein. Three alleles OCT1*3 (R61C), OCT1*4 (G401S), and OCT1*14 
(R206C/M420del) showed strong substrate-wide decrease in transport activity. Of these, 
OCT1*3 and OCT1*14 showed reduced plasma membrane localization. A substantial num-
ber of alleles (5 out of 19 tested) showed substrate-specific loss of activity: OCT1*2 
(M420del), OCT1*7 (S14F), OCT1*10 (S189L), OCT1*11 (I449T), and OCT1*13 
(T245M). Two alleles OCT1*8 (R488M) and OCT1*9 (P117L) showed more than 50 % 
increase in activity for at least one substrate tested. A world map of genetically-determined 
loss of OCT1 function, which was generated based on these analyses, showed strong varia-
bility in the loss of OCT1 function among different world regions. Almost all individuals 
in East Asia and Oceania carry two active OCT1 alleles. In contrast, more than 80 % of the 
Surui Indians, a Native American tribe in the Amazon, carried two loss-of-function alleles. 
These findings should be taken into consideration for recommendations of individualized 
adjustment of drug medication in specific populations. 
This work provides functional analysis of existing OCT1 allelic variants on a broad 
spectrum of structurally diverse substances revealing strong differences in the effect of 
these variants on transporter function. The high number of substrate-specific loss of 
function variants suggests that it is not sufficient to test single OCT1 substrates in order to 
predict the effect of OCT1 variants.  
Among the substrate-specific loss-of-function alleles OCT1*2 (M420del) was by far the 
most common one. It was ubiquitously observed across tested populations and was the only 
loss-of-function OCT1 variant observed in Surui Indians. In the second part of the thesis 
the structural mechanism underlying the highly substrate-specific effects of M420del was 
analyzed. 
First, it could be shown that the substrate-specific effects of M420del are not caused by an 
unspecific reduction of the protein chain but rather due to the deletion of the amino acid at 
codon 420. The transport activity of the mutants L427del and H428del, which were 
expected to show transport activity similar to M420del, did not differ from wild type. The 
mutant insertion of alanine after proline425 (A426ins) on M420del background, which was 
expected to restore wild type activity, showed the similar activity as M420del. 
Furthermore, the mutant M420A showed no differences in the uptake kinetics compared to 
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M420del using structurally different OCT1 substrates. Furthermore, neither isoleucine, nor 
threonine, nor cysteine at position 420 could restore wild type transport activity. This data 
confirmed that the effects of M420del are caused by a specific loss of the methionine side 
chain.  
Finally, interactions of methionine420 with amino acids in the 7th transmembrane domain 
(L364 and H367) were analyzed. An interaction between M420 and L364 or H367 could 
not be confirmed, as a mutation of these amino acids resulted in a general reduction of 
OCT1 uptake. Analyses of interactions between methioine420 and amino acids known to be 
involved in substrate binding and translocation suggest complex interaction of M420del 
with D474, but not with W217 and F159.  
Taken together, it could be shown that the substrate-specific effects of M420del are caused 
by the specific loss of the methionine side chain and indirect interactions with essential 
transport domains were suggested. Further experiments applying detailed homology 
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1.1 OCT1 is an organic cation transporter from the SLC22 family 
Four main steps, known as ADME, determinate the pharmacokinetics of drugs in the 
human body: absorption, distribution, metabolism, and excretion. During this process drugs 
pass through a number of membrane barriers and cell monolayers including epithelial cells, 
intestinal mucosa, and alveolar epithelium. Due to their low membrane permeability, 
hydrophilic and charged substances require carrier-mediated transport to penetrate cell 
membranes.  
Increasing evidence underlines the importance of membrane transporters like OCT1 in 
drug disposition and response (Gong and Kim, 2013; Tzvetkov et al., 2016). The route of 
orally administered drugs through the body is influenced by various factors upon 
administration: transporters located in the intestine determine the reabsorption of a drug 
and its uptake in the circulation system. At this point pre-systemic elimination via bile 
excretion can already negatively influence the bioavailability of a drug (Sparreboom et al., 
1997). Furthermore, transporters localized in the liver and kidneys mediate drug clearance. 
Transporters located in membranes of the blood-brain barrier or the blood-placental barrier, 
at so called immune-privileged sites, stringently restrict access of drugs to these special 
compartments (Kim et al., 1998; de Boer et al., 2003; Molsa et al., 2005; Vahakangas and 
Myllynen, 2009). Considering efflux pumps they decrease the intracellular concentration 
and may impair drug efficacy. Finally, co-administered drugs may affect pharmacokinetics 
as they can act as inhibitors of transporters (Shitara et al., 2003). Therefore, next to the 
expression profile of a transporter in various tissues and its substrate specificity, factors 
like genetic variability, cooperation with other transport systems as well as drug-drug 
interactions play a crucial role when analyzing the pharmacokinetics and pharmacodyna-
mics of a drug.  
The uptake and excretion of positively charged drugs and weak bases at physiological pH 
is mediated by members of the organic cation transporters of the SLC22 family (solute 
carrier family 22) as well as by members of the multidrug and toxin extrusion family 
SLC47 (recently reviewed in (Motohashi and Inui, 2016)).  
Introduction 
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The SLC22 family is part of the major facilitator superfamily (MFS), which is one of the 
largest families of membrane transporters, next to the ATP-binding cassette superfamily 
(ABC family). The MFS family comprises 74 families containing uniporters, symporters, 
and antiporters (Reddy et al., 2012). Members of the MFS are found in bacteria, archaea, 
and eukaryotes (Pao et al., 1998). In contrast to the ABC family, members of the MFS are 
single polypeptide secondary active transporters that only transport small molecules in 
response of a chemiosmotic ion gradient (Pao et al., 1998).  
The SLC22 family of the MFS contains organic cation transporters (OCTs), organic 
zwitterionic and cationic transporters (OCTNs), and organic anion transporters (OATs) (for 
a recent overview see (Koepsell, 2013)). The organic cation transporters of the SLC22 
family comprise three transporters: OCT1, OCT2, and OCT3. These three transporters are 
characterized by electrogenic, reversible, and Na+-independent transport (Gorboulev et al., 
1997; Nagel et al., 1997; Koepsell and Endou, 2004). All three transporters OCT1, OCT2, 
and OCT3 are poly-specific. They are characterized by different but partially overlapping 
substrate specificities (Nies et al., 2011; Hendrickx et al., 2013; Sala-Rabanal et al., 2013; 
Ciarimboli, 2016). OCT1, OCT2, and OCT3 are tissue-specifically expressed: Whereas 
OCT1 is predominantly expressed in the sinusoidal membrane of hepatocytes (Figure 1.4), 
OCT2 is specifically expressed in the basolateral membrane of tubular epithelial cells 
(Zhang et al., 1997; Motohashi et al., 2002; Nies et al., 2009; Tzvetkov et al., 2009). In 
contrast, OCT3 transcripts are detectable in several tissues (Zhang et al., 1997; Wu et al., 
2000; Motohashi et al., 2002; Nies et al., 2009).  
OCT1 is a facilitated diffusion system whose transport mechanism is described with the 
help of the alternating access model (Figure 1.1) (Volk et al., 2009): This model suggests 
that the binding site of OCT1 is accessible from both sides of the membrane. For 
translocation of a substrate from the extracellular to the intracellular side, the substrate 
needs to be bound to the extracellular facing substrate binding site of the transporter. 
During translocation of the substrate across the plasma membrane the transporter passes 
through a state described as “occluded state”, in which the substrate is enclosed by the 
transporter. After the transporter achieved its inward-facing conformation the substrate is 
released to the intracellular side. Finally, the empty transporter flips back to its outward-
facing conformation (Koepsell, 2011). While the transporter resides in the open outward or 
open inward conformation, the individual transmembrane domains are not bent. Instead, 
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the translocation process of a bound substrate, especially when concerning the occluded 
state, requires large structural changes of the transporter (Gorbunov et al., 2008; 
Egenberger et al., 2012).  
There were no restrictions in vitality and fertility in Oct1-/- knock out mice (Jonker et al., 
2001), but differences in the pharmacokinetics of drugs, exogenous substances, and toxins 
were reported (Shu et al., 2007; Nies et al., 2008; Chen et al., 2014). Hence, although 
membrane transporters just seem to be a small part of the complex interplay of different 
factors that need to be considered when evaluating the profile of a drug, membrane 
transporters represent a key role as they mediate the first step of metabolism and excretion 







Figure 1.1 (previous page) Structure and function of OCT1. (A) The proposed secondary structure of 
OCT1. The OCT1 protein consists of 12 transmembrane helices with an intracellularly located N-terminal 
and C-terminal end. The big extracellular loop between the 1st and 2nd transmembrane domain contains 
putative glycosylation sites (ψ). The big intracellular loop between the 6th and 7th transmembrane domain 
contains putative phosphorylation sites (P). In rat Oct1 the amino acids F160, W218, Y222, T226, R440, 
L447, Q448, and D475 were reported to be located in the substrate binding region and to be involved in 
substrate binding and/or translocation (Gorboulev et al., 1999; Popp et al., 2005; Gorbunov et al., 2008; Volk 
et al., 2009). The corresponding amino acids in the human ortholog are indicated with green triangles. The 
corresponding amino acids in the human ortholog are: F159, W217, Y221, T225, R439, L446, I447, and 
D474. (B) Schematic representation of the alternating access model: During the outward open conformation a 
substrate binds at the binding cleft. This induces conformational changes leading to translocation of the 
substrate to the intracellular side and thereby the transporter passes through an occluded state. The substrate 
dissociates from the binding site and is released to the cytosol. The transporter flips back from its inward 
open conformation to the extracellular side. Based on (Koepsell and Keller, 2016). (C) Homology model of 
the outward and inward open conformation of rat Oct1. Outward open conformation of rat OCT1 from the 
side and from extracellular showing the substrate binding cleft. Inward open conformation of rat OCT1 from 
the side and from the intracellular showing the substrate binding cleft. The amino acids F160, W218, Y222, 
R440, L447, Q448, and D475, which are known to be involved in transport mechanism, are labeled in the 
substrate binding cleft shown from the extracellular and intracellular side. The transmembrane domains are 
colored as indicated. The 3D model of rat Oct1 is based on the crystal structure of LacY of E.coli (Popp et 
al., 2005; Gorbunov et al., 2008). The PDB file was kindly provided by Prof. Thomas Mueller from the 
University of Würzburg. Presentation and editing was made using Swiss Pdb Viewer v4.1  
 
Rat Oct1 was the first gene of SLC22 transporters cloned and characterized in 1994 
(Grundemann et al., 1994). The human OCT1 gene was cloned together with OCT2 in 
1997 (Gorboulev et al., 1997; Zhang et al., 1997). The human OCT3 gene was cloned in 
1998 (Grundemann et al., 1998). The human OCT1 protein shares 71 % and 50 % identical 
amino acids with the two other human paralogs OCT2 and OCT3, respectively (OCT1: 
NP_003048.1, OCT2: NP_003049.2, OCT3: NP_068812, protein alignment using 
http://blast.ncbi.nlm.nih.gov). The secondary structure of the OCT1 protein is characterized 
by 12 transmembrane helices with an intracellularly located amino and carboxyl terminus 
(Figure 1.1).  
In human, the genes encoding OCT1, OCT2, and OCT3 are clustered together on the long 
arm of chromosome six (6q26-q27). Each gene compromises 10 introns and 11 exons. The 
OCT1 protein is characterized by a pseudosymmetric structure, which is common for all 
members of the MFS. Both, the N-terminal and C-terminal part, comprise six 
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transmembrane domains (Koepsell and Keller, 2016). There is a big extracellular loop 
between the first and second transmembrane helix in OCT1 containing putative 
glycosylation sites according to the motive N-X-S/T at position N71, N96, and N112 (X 
means any amino acid) (Zhang et al., 1997). The largest intracellular loop between the 6th 
and 7th transmembrane domain contains putative phosphorylation sites at position S285, 
S291, T327, T340, and T524 (Gorboulev et al., 1997; Zhang et al., 1997). 
 
1.2 Structure-to-function relationships in OCT1 
Intense mutagenesis analyses have been performed on rat Oct1 to investigate the structure-
function relation. Because so far no crystal structure of OCT1 is available, structural 
properties underlying function of OCT1 are based on a model derived from the crystal 
structure of lactose permease LacY of E. coli (Figure 1.1) (Popp et al., 2005) or of a 
phosphate transporter of fungus Piriformospora indica (PiPT) (Pedersen et al., 2013). 
Between LacY and rat Oct1 12.4 % of the amino acids are identical and 28.8% were 
similar (Popp et al., 2005). The homology model was used in order to generate the inward 
open as well as the outward open conformation of rat Oct1 (Popp et al., 2005; Gorbunov et 
al., 2008). Recently, a 3D model of human OCT1 was derived from the crystal structure of 
a phosphate transporter of fungus Piriformospora indica (PiPT) (Pedersen et al., 2013). 
PiPT (accession number A8N031) and human OCT1 (accession number O15245) show 
21 % amino acid identity (alignment using http://blast.ncbi.nlm.nih.gov). Both, LacY and 
PiPT are members of the MFS (Abramson et al., 2003; Pedersen et al., 2013).  
The binding site of human OCT1 is suggested to rather have the shape of a pocket instead 
of a plane (Bednarczyk et al., 2003). In the outward open conformation of rat Oct1 the 
proposed binding cleft has a size of about 20 x 60 Å and is formed by the 1st, 2nd, 4th, 5th, 
7th, 8th, 10th, and 11th transmembrane domain (Gorboulev et al., 2005; Popp et al., 2005). 
More than one molecule can bind to the binding cleft of rat Oct1 (Keller et al., 2011). The 
binding sites differ in their affinities: they are referred to as high and low affinity binding 
sites (Gorbunov et al., 2008). For the inhibitor substrate TBuA (tetrabutyl ammonium) 
three binding sites within the outward facing conformation of rat Oct1 were suggested. 
These binding sites differ in their affinity for TBuA as suggested by highly different 
dissociation constants (Kd= 0.3 µM, 0.4 µM, and 2 pM, respectively) (Gorbunov et al., 
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2008). It is assumed that in order to initiate the translocation process, first a low affinity 
binding site needs to be occupied by the substrate (Gorbunov et al., 2008; Koepsell and 
Keller, 2016). The data of the study by Gorbunov et al. also suggested that F483 and F486 
are involved in the conformational change during the translocation process. Furthermore, 
their predicted model of rat Oct1 suggests that F483 and/or F486 in the 11th transmembrane 
domain interact with W147 in the 2nd transmembrane domain in the inward facing, but not 
in the outward facing conformation (Gorbunov et al., 2008). The interaction of the 2nd and 
the 11th transmembrane domain seem to be important for the stabilization of rat Oct1 
conformation. Hence, this interaction seems to be involved in conformational changes 
during the translocation process (Gorbunov et al., 2008).  
Additionally, the 11th transmembrane domain contains a hinge domain containing glycine 
residues (C474-N475-L476-G477-G478), which is involved in conformational changes 
during the translocation process after substrate binding (Egenberger et al., 2012). As the 
hinge domain provides flexibility in a protein, it allows substrate occlusion during 
transport. So far it could be shown that at least three transmembrane domains (the 5th, 8th, 
and 11th) are involved in conformational changes during translocation. The 5th and the 8th 
transmembrane domain are suggested to be involved in structural changes depending on 
the transported substrate, whereas the 11th transmembrane domain is suggested to be 
involved in structural changes independent of the transported substrate (Egenberger et al., 
2012; Koepsell and Keller, 2016). Site-directed mutagenesis experiments on rat Oct1 
revealed that the amino acids F160 (TMD 2), W218 (TMD 4), Y222 (TMD 4), T226 
(TMD 4), R440 (TMD 10), A443 (TMD 10), L447 (TMD 10), Q448 (TMD10), C451 
(TMD10), and D475 (TMD 11) are involved in translocation (Gorboulev et al., 1999; Popp 
et al., 2005; Gorbunov et al., 2008; Volk et al., 2009). These amino acids are all located in 
the predicted binding cleft of rat Oct1 (Popp et al., 2005). Among them, F160, W218, and 
D475 were suggested to be directly involved in substrate binding (Gorboulev et al., 1999; 
Popp et al., 2005; Volk et al., 2009). Replacement of alanine443, leucine447 or glutamine448 
in rat Oct1 by the respective amino acid of rat Oct2 (isoleucine443, tyrosine447 or 
glutamate448, respectively) increased the affinity for corticosterone in rat Oct1 (Gorboulev 
et al., 2005). The results indicated that the 10th transmembrane domain is involved in 
substrate binding. However, as indirect effects of these mutations on the binding site of the 
transporter cannot be excluded, the data do not provide clear evidence that the amino acids 
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alanine443, leucine447, and glutamine448 are directly involved in binding of corticosterone 
(Koepsell and Keller, 2016). 
When the amino acid aspartate475, which is located in the 11th transmembrane domain, was 
mutated to glutamate, the Km for TEA+ but not MPP+ was strongly decreased. Furthermore, 
the IC50 values for TBuA (tetrabutyl ammonium), TPrA (tetrapropylammonium), and 
TPeA (tetrapentylammonium), which are inhibitors of rat Oct1, were also decreased. These 
findings indicated that aspartate475 is involved in binding of TEA+, TBuA, TPrA, and TPeA 
(Gorboulev et al., 1999).  
Further studies revealed that in the outward-facing conformation of rat Oct1, TEA+ and 
MPP+ share common binding domains (Popp et al., 2005). The Km value for both 
substrates was reduced after tryptophan218 and tyrosine222 were mutated to tyrosine and 
leucine, respectively. In contrast, mutagenesis experiments revealed only a decreased Km 
value for MPP+ when tyrosine226 was mutated to alanine suggesting involvement of 
tyrosine226 in MPP+ but not TEA+ transport (Popp et al., 2005). These findings suggested 
that different substrates do not have identical but rather overlapping binding sites allowing 
poly-specificity of rat Oct1.  
The extracellular loop of OCT1 is involved in oligomerization of rOct1 (Keller et al., 
2011). The oligomerization of the transporter is pivotal for its membrane localization. 
Disulfide bonds in the extracellular loop mediate its structural integrity and are essential 
for transporter oligomerization. However, oligomerization is not required for Oct1 function 
as no differences between oligomerized and non-oligomerized transporters in substrate 
affinity were observed (Keller et al., 2011). Moreover, each monomer of the oligomer 
complex seems to transport its bound substrate independent of the other one. The uptake 
for TEA+ was reduced when the extracellular domain of rat Oct1 was replaced by the 
extracellular domain of rat Oct2 or Oat1, underlining its importance for transport function 
(Keller et al., 2011). Also for hOCT2 the importance of cysteines in the extracellular loop 
in protein folding, oligomerization and hence correct plasma membrane localization was 
shown before (Brast et al., 2012). 
Concerning short term regulation of OCT1 function, the big intracellular loop between the 
6th and the 7th transmembrane domain comprises putative protein kinase C (PKC) 
phosphorylation sites suggesting protein kinase mediated regulation of OCT1 (Gorboulev 
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et al., 1997; Mehrens et al., 2000). In rat Oct1 the uptake of ASP+ was stimulated by 
protein kinase C after phosphorylation of a serine residue in Oct1. Furthermore, the affinity 
of rat Oct 1 for TEA+ increased after PKC stimulation (Mehrens et al., 2000). But as in the 
study of Mehrens et al. an antibody-specific for serine phosphorylation was used, it was 
not possible to specify the exact serine residue that was phosphorylated.  
 
1.3 Polyspecificity of OCT1  
OCT1 is predominantly expressed in the sinusoidal membrane of human hepatocytes 
(Zhang et al., 1997; Nies et al., 2009). This position may be essential for controlling the 
hepatic uptake and following detoxification of a number of drugs and other xenobiotics. 
OCT1 has been reported to mediate the uptake of structurally diverse organic substances 
that are completely or partially positively charged at physiological pH (Table 1.1) but with 
broadly varying structures. Therefore, OCT1 should be able to bind to a broad spectrum of 
chemically different structures but without changing its substrate selectivity. This 
polyspecificity is achieved by binding sites, which allow binding of more than one ligand 
and separate but partially overlapping binding sites (Gorboulev et al., 1999; Gorboulev et 
al., 2005; Popp et al., 2005). Polyspecific binding sites were suggested by mutagenesis 
analysis, in which the affinity for individual cations was changed, e.g. by mutation of 
glutamate475 to aspartate the affinity for TEA+ increased, whereas the affinity for MPP+ 
was not changed (Gorboulev et al., 1999). This data indicate that D475 is important for 
substrate selectivity. Moreover, the mutation D475E did not only increase the affinity for 
the transported substrate TEA+ but also for the non-competitive inhibitor TPeA 
(tetrapentylammonium) (Gorboulev et al., 1999). 
OCT1 is a facilitative diffusion system that transports cations in both directions. Crucial 
factors are substrate concentration and membrane potential (Egenberger et al., 2012). The 
translocated substrates are mainly characterized by primary to tertiary or quaternary amine 
groups. Whereas the protonation of the primary to tertiary amine groups is dependent on 
their pKa values and the pH of the medium, quaternary amines are permanently charged 
independent of the pH. Already 15 years ago polyspecificity of OCT1 was acknowledged 
and first attempts were made to classify different groups of substrates. For rat Oct1, 
organic cations have been classified as type I and type II (van Montfoort et al., 2001). 
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Organic cations type I are substrates of OCT1. They are characterized by high 
hydrophilicity and are mostly below 500 Da, e.g. TEA+ and MPP+. In contrast, type II 
organic cations are less hydrophilic and more bulky such as quinine and quinidine (van 
Montfoort et al., 2001). Type II organic cations are not translocated by rat Oct1 (Nagel et 
al., 1997).  
Concerning the classification of drugs, Wu et al. developed the Biopharmaceutics Drug 
Disposition Classification System (BDDCS) in order to predict drug disposition and drug-
drug-interaction in the intestine and the liver in humans (Wu and Benet, 2005). The 
BDDCS focuses on the elimination route of a drug: Drugs displaying high intestinal 
permeability are mainly eliminated via metabolism, whereas drugs with weak intestinal 
permeability are mainly eliminated as unchanged drug in the urine and the bile (Wu and 
Benet, 2005). The classification is a modification of the Biopharmaceutics Classification 
System (BCS), which is based on evaluating the permeability and solubility of a drug 
(Amidon et al., 1995). The classification of the BDDCS comprises 4 classes. According to 
the BDDCS drugs of the class 3, which are characterized by high solubility and poor 
metabolism such as ranitidine and metformin, are substrates of OCT1 (Bourdet et al., 2005; 
Wu and Benet, 2005; Shu et al., 2007). 
Next to the intense study of the structure-function relationship of OCT1, also structural 
properties of substrates that inhibit OCT1 mediated transport were analyzed in detail. Ahlin 
et al. screened 191 structurally diverse compounds for their ability to inhibit OCT1 
mediated transport of ASP+. Of these, 62 were OCT1 inhibitors and 47 of them were novel 
inhibitors (Ahlin et al., 2008). According to their analyses, good inhibitors are 
hydrophobic, lipophilic, and positively charged substances. Instead, polar compounds with 
many hydrogen bond donor and acceptor moieties did not inhibit OCT1 (Ahlin et al., 
2008). It needs to be pointed out that Ahlin et al. did not define the inhibitory mechanism 
of the identified inhibitors such as competitive and non-competitive inhibitors. 
Furthermore, they did not analyze if the inhibitory compounds are themselves transported 
by OCT1. More recently Hendrix et al. have performed comparative high throughput 
analyses of substrates of OCT1 and OCT2 (Hendrickx et al., 2013). According to their 
study, molecular volume and positive charge determine if a substance is transported by 
OCT1. Molecules with a molecular weight not greater than 500 Da are considered as 
possible substrates of OCT1 (Hendrickx et al., 2013).  
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Table 1.1 Selected substrates and inhibitors of human OCT1 
Substrates of human OCT1 PubChem CID1 Reference 
Model substrates   
ASP+ 6438078 (Ahlin et al., 2011) 
MPP+ 39484 (Zhang et al., 1997; Shu et al., 2003) 
TEA+ 5413 (Sakata et al., 2004) 
Drugs   
Acyclovir 2022 (Takeda et al., 2002) 
Debrisoquine 2966 (Saadatmand et al., 2012) 
Ganciclovir 3454 (Takeda et al., 2002) 
Metformin 4091 (Shu et al., 2007; Tzvetkov et al., 2009; Yoon et al., 2013) 
Morphine 5288826 (Tzvetkov et al., 2013) 
O-desmethyltramadol 130829 (Tzvetkov et al., 2011) 
Tropisetron 656665 (Tzvetkov et al., 2012) 
Hormones   
Adrenaline 5816 (Breidert et al., 1998) 
Prostaglandin E2 5280360 (Kimura et al., 2002) 
Prostaglandin F2α 5280363 (Kimura et al., 2002) 
Neurotransmitter   
Acetylcholine 187 (Lips et al., 2005) 
Dopamine 681 (Breidert et al., 1998) 
Vitamins   
Thiamine 1130 (Chen et al., 2014) 
Phytochemicals   
Atropine 174174 unpublished Data Chen et al. 
Monocrotaline 9415 (Tu et al., 2013) 
Others   
DAPI 2954 (Yasujima et al., 2011) 
Tyramine 5610 (Breidert et al., 1998; Seitz et al., 2015) 
Inhibitors of human OCT1   
Drugs   
Amitriptyline 2160 (Ahlin et al., 2011) 
Codeine 5284371 (Tzvetkov et al., 2013) 
Ondansetron 4595 (Tzvetkov et al., 2012) 
Prazosin 4893 (Hayer-Zillgen et al., 2002) 
Quinidine 441074 (Shu et al., 2007) 
Verapamil 2520 (Zhang et al., 1998; Ahlin et al., 2011) 
Hormones   
Corticosterone 5753 (Hayer-Zillgen et al., 2002) 
β-estradiol 5757 (Ahlin et al., 2008) 
Others   
Decynium D22 5484462 (Zhang et al., 1997) 
1 PubChem CID…Compound Identifier on https://pubchem.ncbi.nlm.nih.gov/ for details about 2D structure  
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1.4 Genetic variability of OCT1  
The OCT1 gene is highly genetically variable. In a study by Leabman et al., genetic 
variants of OCT1 and further 23 membrane transporters of the SLC family as well as of the 
ABC family were analyzed. OCT1 had the highest genetic variability among the organic 
cation transporters of the SLC22 family with a non-synonymous nucleotide diversity of 
5.11 × 10 −4 and a ratio of non-synonymous to synonymous nucleotide diversity of 0.46 
(Leabman et al., 2003). Furthermore, analyses of the available 1000 genomes data showed 
that OCT1 has the highest genetic variability among the organic cation transporters of the 
SLC22 and SLC47 families (Tzvetkov et al., 2016).  
The first systematic studies on the genetic variability in OCT1 were performed more than 
10 years ago by Kerb et al. (Kerb et al., 2002) and Leabman et al. (Leabman et al., 2003). 
Kerb et al. re-sequenced OCT1 coding and promoter regions in 57 Caucasians and 
identified 25 genetic variations, which were analyzed regarding their population frequency 
(Kerb et al., 2002). They further analyzed 190 Caucasians for 16 variants of which 8 were 
found in the coding region of OCT1 leading to amino acid exchanges. The four amino 
substitutions R61C, C88R, F160L, G401S, and the deletion of methionine420 were found to 
have an allele frequency of 9.1, 0.6, 22, 3.2, and 16 %, respectively. Among them, R61C, 
C88R, and G401S were found to affect OCT1 mediated uptake of MPP+ (Kerb et al., 
2002). Leabman et al. screened for genetic variants in the coding region of OCT1 in 247 
unrelated individuals containing 100 European Americans, 100 African Americans, 30 
Asians, 10 Mexicans, and 7 Pacific Islanders. The group identified 15 non-synonymous 
variants in OCT1 from which five were found to strongly decrease or even to completely 
abolish OCT1 activity (R61C, G220V, P341L, G401S, and G465R) (Leabman et al., 2003; 
Shu et al., 2003).  
Besides Caucasians, several studies analyzed the genetic variability of OCT1 in Asians. 
There seem to be inter-ethnic differences in the frequency of loss of OCT1 activity as the 
amount as well as the frequency of genetic variants in OCT1 was much lower in Asians 
than in Caucasian populations (Itoda et al., 2004; Chen et al., 2010; Yoon et al., 2013). In 
48 Japanese unrelated individuals, 29 single nucleotide polymorphisms have been 
identified in OCT1, of which three were found in the coding region of OCT1 leading to 
non-synonymous substitutions (Saito et al., 2002). Among the analyzed genetic variants, 
the genetic variants P283L and R287G were restricted to the Asian population (Saito et al., 
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2002; Takeuchi et al., 2003; Sakata et al., 2004). In a study of Chen et al., the group 
identified and functionally characterized loss-of function polymorphisms in OCT1 in a 
sample set of 30 samples of Chinese in Beijing, 30 Japanese in Tokyo (both from the 1000 
Genomes project) (Chen et al., 2010) and 66 Japanese patients (Shu et al., 2003). They 
identified the three non-synonymous substitutions Q97K, P117L, and R206C with a minor 
allele frequency of 0.017 and 0.02 for Q97K and P117L, respectively. The variant R206C 
was only found as a single individual in a heterozygous form (Chen et al., 2010). 
Most of the population genetic data about loss-of function polymorphisms were limited to 
specific populations. Recently, our group analyzed the frequency of loss-of function 
polymorphisms on a global scale (Seitz et al., 2015). The functional characterization of 
these variants described in this thesis was part of this study. The complete coding sequence 
of the OCT1 gene and its flanking regions was resequenced in 2171 unrelated individuals 
from 67 populations worldwide using semiconductor-based massively parallel sequencing. 
From 85 identified variants, 44 variants have been found in the coding region of OCT1. Of 





Figure 1.2 Haplotype combinations constituting 16 major and 14 sub-alleles of OCT1. Amino acid 
substitutions (shown in yellow) that cause a more than 50 % decrease or increase of transport activity in 
comparison to the reference OCT1*1 allele for at least one substrate tested were designated as major alleles. 
The sub-allele differs from the appropriate major allele by amino acid substitutions (shown in white) that do 
not affect OCT1 activity. From Seitz et al. (Seitz et al., 2015). 
 
1.4.1 Impact of coding genetic polymorphisms on OCT1 function 
The first effort to predict the effect of coding genetic variants on OCT1 function was the 
analysis using the amino acid scoring systems Grantham and BLOSUM62 (Leabman et al., 
2003). Lower Grantham values indicate chemical similarity, whereas higher values indicate 
radical chemical changes (Grantham, 1974). A more negative BLOSUM62 value indicates 
an evolutionary unfavorable change (Cargill et al., 1999; Shu et al., 2003). Nevertheless, in 
order to definitely characterize the effect of genetic polymorphism in OCT1, functional 
studies of these variants are unavoidable. Out of the available studies about the genetic 
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variability in OCT1 (Kerb et al., 2002; Shu et al., 2003; Shu et al., 2007; Tzvetkov et al., 
2009), one deletion and four amino acid substitutions were of special interest as they were 
frequently observed and associated with reduced transport activity of OCT1: the deletion of 
methionine in codon 420 (M420del) and the substitutions R61C, C88R, G401S, and 
G465R. 
 
Figure 1.3 Minor allele frequencies of 16 OCT1 polymorphisms in 39 different populations worldwide. 
Shown are 39 populations from Sub-Saharan Africa, North Africa and the Middle East, Central Asia, Europe, 
and America. The M420del variant was the most frequent and the only ubiquitously observed among the 
worldwide populations studied. From Seitz et al. (Seitz et al., 2015) 
 
M420del 
The deletion of methionine420 is the most common and the only ubiquitously observed 
variant in OCT1 (Figure 1.3), (Shu et al., 2003; Shu et al., 2007; Seitz et al., 2015). The 
affected methionine420 is located in the 9th transmembrane domain of the OCT1 protein and 
M420del apparently does not affect subcellular localization of OCT1 (Ahlin et al., 2011). 
Recently, genetic analyses in humans revealed that the M420del only exists in combination 
with the M408V polymorphism (Tzvetkov et al., 2014).  
In-vitro functional analyses revealed highly substrate-specific effects regarding loss of 
activity of the M420del variant: The uptake of the model substrates MPP+ and ASP+ did 
not significantly differ from wild type OCT1 (Kerb et al., 2002; Shu et al., 2003; Ahlin et 
al., 2011). The transport of debrisoquine was slightly decreased due to reduced vmax. The 
Km of debrisoquine was not affected (Saadatmand et al., 2012). In contrast, the M420del 
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variant significantly decreased the uptake of metformin and morphine uptake was 
decreased by more than 60 % (Shu et al., 2007; Tzvetkov et al., 2013). The uptake of 
tropisetron was reduced by more than 80 % (Tzvetkov et al., 2012). Moreover, the 
M420del variant showed complete lack of transport activity for the uptake of O-
desmethyltramadol (Tzvetkov et al., 2011). Up to now, structural mechanisms underlying 
the substrate-specific effect of M420del are not known (Shu et al., 2007).  
Although the uptake of ASP+ did not significantly differ between the M420del variant and 
wild type OCT1, the M420del variant was shown to be more susceptible to inhibition of 
ASP+ uptake, showing up to 14 times lower IC50 values than wild type OCT1 using 
different inhibitors of OCT1 (Ahlin et al., 2011). This finding indicates increased potency 
of some inhibitors to inhibit transport of M420del. Similar to this finding, the M420del 
variant was more susceptible to the inhibition of metformin uptake by verapamil (Ahlin et 
al., 2011). These findings suggest complex drug-drug interactions at the binding site of the 
M420del variant.  
 
R61C 
The amino acid substitution R61C is a common OCT1 variant observed in Caucasians, but 
not in Africans or Asians (Figure 1.3). The affected arginine61 is located in the big 
extracellular loop between the 1st and the 2nd transmembrane domain. The R61C variant is 
less expressed on the plasma membrane displaying a more diffuse localization and 
cytosolic retention than reference wild type OCT1 (Shu et al., 2007; Ahlin et al., 2011). 
The R61C variant strongly decreased transport activity of OCT1 in in-vitro for all 
substrates tested: The uptake of the model substrates MPP+ and ASP+ was strongly reduced 
by more than 70 % and 60 %, respectively (Kerb et al., 2002; Shu et al., 2003; Ahlin et al., 
2011). The uptake of morphine was reduced by 86 % and the uptake of tropisetron and O-
desmethyltramadol was completely abolished (Tzvetkov et al., 2011; Tzvetkov et al., 2012; 
Tzvetkov et al., 2013). Comparable to M420del, the R61C variant was more susceptible to 
inhibition of ASP+ transport. The IC50 values were up to 23 times lower than for wild type 
reference (Ahlin et al., 2011). The uptake of debrisoquine was strongly reduced although 
the Km was not affected (Saadatmand et al., 2012). The uptake of metformin was decreased 




The C88R substitution is one of the rarest OCT1 variants and is only observed in 
Caucasians (Figure 1.3). The variant was only detected in 8 individuals in a sample set of 
1079 individuals (Seitz et al., 2015). Genetic analysis revealed that the C88R substitution is 
only observed in combination with the M420del variant (also known as OCT1 allele *6) 
(Tzvetkov et al., 2012). The affected cysteine88 is located in the big extracellular loop 
between the 1st and the 2nd transmembrane domain. Previously it was shown that the 
cysteines located in the extracellular loop of OCT1 are involved in formation of disulfide 
bonds, which are crucial for homo oligomerization and localization of the transporter in the 
plasma membrane (Keller et al., 2011). Mutation of cysteine89 in human OCT2 (the analog 
of cysteine88 in OCT1) to alanine was retained in the cortisol (Brast et al., 2012). The 
C88R variant showed lack of transport activity for the uptake of debrisoquine, tropisetron, 
and morphine (Saadatmand et al., 2012; Tzvetkov et al., 2012; Tzvetkov et al., 2013). 
 
G401S 
The amino acid substitution G401S is observed in Caucasians but not in African or Asian 
populations (Figure 1.3). The affected glycine401 is located in the small intracellular loop 
between the 8th and the 9th transmembrane domain. Glycine401 is conserved among the 
other two paralogs OCT2 and OCT3 (Shu et al., 2003). The variant G401S as well as the 
variants G220V and G465R change evolutionary conserved glycine residues and strongly 
reduce transport activity. Hence, it was suggested that evolutionary conserved glycine 
residues are important for OCT1 function and that substitution of these strongly affect 
OCT1 activity (Shu et al., 2003). In-vitro studies revealed that the G401S variant showed a 
strong reduction in the transport of all substances tested: The G401S variant almost 
completely lacked uptake of MPP+ and tropisetron (Shu et al., 2003; Tzvetkov et al., 2012). 
The uptake of debrisoquine, metformin, morphine, and O-desmethytramadol was strongly 






The amino acid substitution G465R is a variant, which is only observed in Caucasian 
population (Figure 1.3). The affected glycine465 is located in the 11th transmembrane 
domain of the OCT1 protein. The affected glycine465 is also present in OCT2, OCT3, 
OAT1-3 and also in OCTN2 and therefore may be of generally importance for transporter 
function (Shu et al., 2003). The G465R variant completely fails to localize in the plasma 
membrane (Shu et al., 2003). Therefore it causes complete lack of transport activity for all 
substrates previously tested: MPP+, metformin, debrisoquine, tropisetron, O-desmethyl-
tramadol, and morphine (Shu et al., 2003; Shu et al., 2007; Tzvetkov et al., 2011; 
Saadatmand et al., 2012; Tzvetkov et al., 2012; Tzvetkov et al., 2013). Haplotype analyses 
suggested that G465R is inherited only in a combination with the M420del variant 
(referred also as OCT1 allele *5) (Tzvetkov et al., 2012). 
 
Further common OCT1 variants 
The variant P341L was commonly observed in Asians (Saito et al., 2002; Shu et al., 2003; 
Itoda et al., 2004). The variant F160L was commonly observed in Caucasian and Asian 
populations (Shu et al., 2003; Sakata et al., 2004). Both variants were shown not do affect 
OCT1 activity: For P341L the uptake of TEA+, MPP+ and metformin was only slightly 
decreased, whereas F160L did not affect the uptake of these substrates (Shu et al., 2003; 
Takeuchi et al., 2003; Sakata et al., 2004; Shu et al., 2007). The P341L and F160L did not 
alter the subcellular localization of OCT1 (Sakata et al., 2004).  
The OCT1 allelic variant S14F was commonly observed in Africa (Figure 1.3). Also for 
S14F substrate-specific effects were reported: whereas the uptake of MPP+ was increased 
in relation to wild type reference, S14F significantly reduced the uptake of metformin (Shu 




Very rare OCT1 variants  
A number of rare OCT1 variants have been functionally characterized in vitro. Takeuchi et 
al. demonstrated lack of TEA+ transport for the amino acid exchanges P283L and R287G 
although membrane localization of the transporter in these variants was not altered 
(Takeuchi et al., 2003). A possible impact of these variants on transporter function was 
already hypothesized earlier, as the variants P283L and R287G were found to change 
conserved amino acids among the organic cation transporters (Saito et al., 2002). The 
variants P283L and R287G were only observed in the Asian population (Saito et al., 2002; 
Takeuchi et al., 2003; Sakata et al., 2004).  
The variant P117L is a very rare variant that was identified in a sample set of 116 Japanese 
individuals for the first time (Itoda et al., 2004). The affected proline117 is conserved 
among the mammalian OCTs (Itoda et al., 2004). The uptake of metformin was 
significantly reduced, although membrane localization was not altered (Chen et al., 2010).  
The variants R206C and Q97K were found in Japanese population (Chen et al., 2010). The 
affected arginine206 is highly conserved among mammalian OCTs, whereas glutamine97 is 
only highly conserved among OCT1 orthologs and in OCT2. The uptake of metformin is 
significantly decreased in R206C and Q97K variants. The decrease in metformin uptake by 
R206C was due to reduced vmax and by Q97K due to increased Km. Analysis of the sub-
cellular localization revealed decreased membrane localization and retention in the 
endoplasmic reticulum for the R206C variant, whereas the membrane localization of the 
Q97K variant was not affected (Chen et al., 2010).  
Other variants analyzed showed a substrate-specific decrease in transport activity: the 
variant S189L showed no differences in the uptake of MPP+ compared to the wild type 
reference, but a significant decrease in the uptake of metformin due to reduced vmax (Shu et 
al., 2003; Shu et al., 2007). The variants S189L was only observed in Caucasians (Shu et 
al., 2003; Tzvetkov et al., 2014). 
The variants R342H and R488M were observed in African populations and were shown 
not to affect the uptake of MPP+ and metformin (Shu et al., 2003; Shu et al., 2007; Seitz et 
al., 2015).  
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1.4.2 Impact of genetic variation in OCT1 on drugs pharmacokinetics and 
response 
Single nucleotide polymorphisms in OCT1 affect transporter function (Figure 1.4). There-
fore, they may cause inter-individual variations in drug response and may influence 
pharmacotherapy. Any of the polymorphisms R61C, C88R, G401S, G465R, or a deletion 
of methinone420 (M420del) causes partial or complete loss of OCT1 function. In 
Caucasians the frequency of these variants have been reported to be on average 9.6 %, 
0.6 %, 2.8 %, 1.8 %, and 15.4 %, respectively (Kerb et al., 2002; Tzvetkov et al., 2012). 
Individuals can be divided to carriers of zero, one, or two loss-of function alleles in OCT1. 
In Caucasians 42 % of the individuals carry one and further 9 % two loss-of-function 
OCT1 alleles (Shu et al., 2007; Tzvetkov et al., 2012). Data is rapidly accumulating that 
this genetically-determined loss of OCT1 activity may affect the pharmacokinetics, 
efficacy, and toxicity of drugs that are metabolized or act in the liver. Affected are cationic 
and weak basic like the opioids morphine and tramadol, the antiemetics tropisetron and 





Figure 1.4 Localization and function of OCT1 in hepatocytes. (A) OCT1 is mainly expressed in the 
sinusoidal membrane of human hepatocytes. Next to OCT1, the following uptake transporters are expressed 
in the sinusoidal membrane: the organic anion transporter 2 (OAT2;SLC22A7) and 7 (OAT7; SLC22A9), 
three members of organic anion transport polypeptides (OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), 
OATP2B1 (SLCO2B1), and the uptake transporter sodium/taurocholate co-transporting peptide (NTCP; 
SLC10A1). Transporters in the basolateral membrane are the efflux transporters multidrug resistance protein 
MRP3 (ABCC3), MRP4 (ABCC4), and MRP6 (ABCC6). Transporters in the canalicular membrane are the 
efflux pumps multidrug resistance 1 transporter (MDR1; ABCB1), the bile-salt export pump (BSEP; 
ABCB11), the breast cancer resitance protein (BCRP; ABCG2), MRP2 (ABCC2), and the multidrug and 
toxin extrusion protein 1 (MATE1; SLC47A1), the heteromeric organic solute transporter (OSTα-OSTβ; 
SLC51a/Slc51b) is located in the apical membrane. (B) OCT1 as a mediator of drugs as the first step of 
metabolism and excretion. For drugs that rely on OCT1 uptake, e.g. morphine, tropisetron, and O-
desmethyltramadol, as the first step of metabolism and excretion, loss of OCT1 function lead to higher 
plasma levels of these drugs. This results in higher efficacy, but also increases the risk of adverse effects. 
Drugs like metformin rely on OCT1 uptake in order to reach their side of action. Loss of OCT1 function 
decreases metformin efficacy.  
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Morphine is a natural opioid analgesic, which directly acts on the central nervous system 
(Mayer and Price, 1976). Codeine is the pro-drug of morphine and needs to be metabolized 
to morphine by CYP2D6. Morphine and codeine are used for treatment of moderate to 
serve pain e.g. during surgery or cancer therapy (Hanks et al., 2001). Polymorphisms in the 
CYP6D6 gene were associated with increased risk of morphine adverse effects (Gasche et 
al., 2004; Kirchheiner et al., 2007; Crews et al., 2012). But polymorphisms in the CYP2D6 
gene could only partially explain the high morphine plasma concentrations after treatment 
with codeine (Lotsch et al., 2009; Sistonen et al., 2012). Morphine is a hydrophilic, weak 
base that is positively charged at physiological pH (pKa = 7.4). Morphine is a substrate of 
OCT1 whereas the uptake of the pro-drug codeine into hepatocytes is not OCT1 dependent 
(Tzvetkov et al., 2013). Codeine is highly membrane permeable and enters hepatocytes by 
passive diffusion. Moreover, codeine was shown to inhibit OCT1 transport activity 
(Tzvetkov et al., 2013). Recently, the increase in morphine plasma concentration was also 
related to higher sensibility to adverse effects in healthy volunteers (Tzvetkov et al., 2013). 
Therefore, the knowledge of individual OCT1 genotypes may help to adjust drug 
medication also in regard of adverse effects. Similar effects were also observed in patients. 
Children with loss of function alleles in OCT1 showed increased morphine plasma 
concentrations after morphine administration. Moreover, it was shown that these patients 
had reduced levels of morphine 3-glucoronid, the main metabolite of morphine generated 
in hepatocytes (Fukuda et al., 2013).   
Tramadol is a synthetic opioid analgesic used in the treatment of moderate pain. It is a 
prodrug that needs to be metabolized to its active metabolite O-desmethyltramadol, which 
binds with high affinity to the µ-opioid receptor (Sevcik et al., 1993). The reaction is 
catalyzed by CYP2D6 in hepatocytes (Paar et al., 1997). Polymorphisms in the CYP2D6 
gene were shown to affect tramadol pharmacokinetics. But these polymorphisms could just 
partially explain inter-individual differences in subgroups defined as individuals with high, 
intermediate or low CYP2D6 activity (Stamer et al., 2003; Kirchheiner et al., 2008). 
Whereas tramadol can cross plasma membranes by carrier independent passive diffusion, 
the uptake of its hydrophilic metabolite O-desmethyltramadol into hepatocytes depends on 
OCT1 (Tzvetkov et al., 2011). After re-uptake of O-desmethyltramadol into hepatocytes it 
is bio-inactivated by glucuronidation by UGT2B7 (Lehtonen et al., 2010). Individuals 
carrying two loss-of-function OCT1 alleles showed higher plasma levels of O-desmethyl-
tramadol (Tzvetkov et al., 2011). In line with the increased plasma concentrations tramadol 
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induced miosis, which was used as an indicator of opioid effects, was stronger and 
prolonged in these individuals. Hence, the pharmacokinetic of tramadol is not only 
influenced by polymorphisms in the CYP2D6 gene but also by polymorphisms in the 
OCT1 gene as OCT1 is assumed as the rate limiting step of O-desmethyltramadol bioin-
activation (Tzvetkov et al., 2011). 
Tropisetron is a serotonin antagonist of the 5-hydroxytryptamine 3 receptor (5-HT3 
receptor) (Simpson et al., 2000). It is used as an antiemetic for the treatment of 
chemotherapy induced and postoperative nausea and vomiting (Simpson et al., 2000). The 
5-HT3 receptor mediates nausea and vomiting in the peripheral and central nervous system. 
Although tropisetron was shown to be effective in treatment of nausea, some patients still 
do not respond sufficiently to tropisetorn therapy (Bruntsch et al., 1993; Adams et al., 
1995; Mystakidou et al., 1998). Genetic polymorphisms in the metabolizing enzyme 
CYP2D6 are well known to strongly contribute, but could not completely explain the 
observed strong inter-individual differences in response to tropisetron (Kees et al., 2001; 
Kaiser et al., 2002; Kim et al., 2003; Pickering et al., 2012). More recently also genetically-
determined loss of OCT1 activity was associated with a variation in the pharmacokinetics 
and activity of tropisetron and ondansetron (Tzvetkov et al., 2012). In a study of Tzvetkov 
et al. 253 patients were genotyped for five common amino acid substitutions that are 
associated with reduced activity of OCT1: R61C, C88R, G401S, M420del or G465R. Of 
these patients 12 % carried two loss-of-function OCT1 alleles, further 38 % carried one. In 
patients carrying two loss-of-function alleles the plasma concentration of tropisetron after 3 
and 6 hours of administration was higher than in patients with only one variant allele or 
two active OCT1 alleles. Moreover, these patients showed greater therapeutic effect of 
tropisetron treatment as vomiting was less observed than in patients carrying two active 
OCT1 alleles (Tzvetkov et al., 2012). 
Next to opioids and antiemetics, metformin was also shown to be a substrate of OCT1 (Shu 
et al., 2007). Metformin is a hydrophilic cation with a biguanide structure, which is widely 
used for the treatment of diabetes type 2 (Tahrani et al., 2011). Metformin leads to 
decreased absorption of glucose in the intestine and reduces gluconeogenesis (Ikeda et al., 
2000; Kim et al., 2008; Foretz et al., 2010). The exact molecular mechanism underlying 
metformin action remains partially understood (An and He, 2016). It is assumed that it acts 
via activation of AMP-activated protein kinase (AMPK), which inhibits enzymes 
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responsible for gluconeogenesis and leads to an increased uptake of glucose into muscle 
and liver cells (Sarabia et al., 1992; Abbud et al., 2000; Zhou et al., 2001; Zhang et al., 
2009). Metformin is a substrate of OCT1 and genetic polymorphisms in OCT1 were shown 
to affect metformin uptake in vitro (Shu et al., 2007). When performing an oral glucose 
tolerance test in healthy volunteers that were carriers of loss-of-function OCT1 alleles, the 
plasma glucose level was significantly higher after 180 min of metformin administration 
than in carriers of the OCT1 wild type reference (Shu et al., 2007; Chen et al., 2010). In 
contrast, the variant P341L was not shown to influence metformin pharmacokinetics in 
healthy volunteers (Yoon et al., 2013). Metformin is primarily eliminated by renal 
excretion (Pentikainen et al., 1979). Although in much lower levels as in the liver, the 
human OCT1 protein was detected in apical membrane of proximal and distal renal tubules 
(Tzvetkov et al., 2009). It was shown in a study of healthy male Caucasians that metformin 
clearance significantly increased in carriers of loss of function OCT1 alleles and account 
for 9.1 % of inter-individual variation in metformin clearance (Tzvetkov et al., 2009). 
 
1.5 Aim of this work  
One of the major problems in prediction of the effects of OCT1 single nucleotide 
polymorphisms leading to non-synonymous amino acid exchanges in OCT1 on transporter 
function is the limited number of substrates analyzed. Most of the available functional in 
vitro studies on OCT1 transport activity were performed using either one or two model 
substrates (usually TEA+ or MPP+) or a single drug. Studies comparing the effect of single 
nucleotide polymorphism on OCT1 activity for a broad spectrum of substrates especially 
drugs are missing. So far, the OCT1 variants M420del, S14F, and S189L were reported to 
have highly substrate-specific effects on OCT1 activity, but so far, substrate-specific 
effects of single nucleotide polymorphisms in OCT1 were not systematically analyzed and 
some highly substrate-specific effects may still be undetected. 
The first aim of this thesis was to characterize in detail the substrate-specific and substrate 
overlapping effects of non-synonymous single nucleotide polymorphisms on OCT1 
function. Comparative analyses were performed on all non-synonymous single nucleotide 
polymorphisms identified worldwide using a broad spectrum of OCT1 substrates. These 
results of this part of the work might give insight into population-specific differences in 
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loss of OCT1 function, which could be furthermore used for optimized dose administration 
in drug treatment. 
The deletion of methionine420 is one of the most common and the only ubiquitously 
observed variant in OCT1 (Figure 1.3) leading to substrate-specific loss of OCT1 activity. 
Hence, the second aim of this work was to identify possible mechanisms underlying 
M420del substrate-specific effects. Two main hypotheses were generated. First, we 
analyzed if the observed substrate-specific loss of function activity is due to the reduction 
of the protein chain caused by the deletion itself independent on the amino acid deleted. 
Second, we analyzed if the M420del effects are rather caused by the specific loss of the 
methionine side chain. In order to test the hypotheses, different mutants of OCT1 
overexpressing HEK293 cells were generated and analyzed regarding their transport 
activity and subcellular localization. This approach might help to understand the impact of 
M420del on transport function using multiple substrates. We hoped that these initial 
analyses may shed light on the mechanism enabling the poly-specificity of OCT1 and 
might identify specific structural properties of OCT1 substrates that are affected of by 








3130xl Genetic Analyzer Applied Biosystems, Darmstadt, Germany 
7900 HT Fast Real Time PCR System Thermo Fisher Scientific, Darmstadt, Germany 
API 4000 LC-MS/MS system AB Sciex, Darmstadt Germany 
Autoclave Laboklav 55-195 SHP Steriltechnik, Detzel Schloss, Germany 
Balance BP210S Sartorius, Göttingen, Germany 
Balance M-Pact AX2202 Sartorius, Göttingen, Germany 
Biological Safety Cabinet: CleanAir NSF 49 Cleanair, Woerden, Netherlands 
BioPhotometer Eppendorf, Hamburg, Germany 
Brownlee SPP RP-Amide Column PerkinElmer, Waltham, USA 
Centrifuge 58010R Eppendorf, Hamburg, Germany 
Centrifuge Heraeus Fresco 17 Thermo Fisher Scientific, Darmstadt, Germany 
Centrifuge J2-21 M/E Beckman Coulter, Krefeld, Germany 
Centrifuge JA-20 rotor Beckman Coulter, Krefeld, Germany 
CO2 incubator BBD6220 Thermo Fisher Scientific, Darmstadt, Germany 
Degasser 310SP ERC, Riemerling, Germany 
Diaphragm pump MZ 2C Vacuumbrand, Wertheim, Germany 
Dri-Block® heater DB3 Techne, Stone, UK 
Electrophorese chamber PeqLab, Erlangen, Germany 
Electroporator Gene Pulser II BioRad, Munich, Germany 
Fluor-STM Multi Imager BioRad, Munich, Germany 
Heating Plate OTS 40 Medite, Burgdorf, Germany 
Heraeus Multifuge X3 Thermo Fisher Scientific, Darmstadt, Germany 
Hybridization oven Binder, Tuttlingen, Germany 
Incubator Hood Incudrive H Schütt, Göttingen, Germany 
LaChrom fluorescence detector L-7400 Merck Hitachi, Darmstadt, Germany 
LaChrom HPLC System: interface D-7000, pump 
L-7100, autosampler L-7200, degasser L-7614 
Merck Hitachi, Darmstadt, Germany 
LaChrom ultraviolet detector - L-7400 Merck Hitachi, Darmstadt, Germany 
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Laser Scanning Microscope LSM710 Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
LiChrospher 100 CN column Merck, Darmstadt, Germany 
LiChrospher 100 CN guard column Merck, Darmstadt, Germany 
LiChrospher 100 reverse phase-18e Merck, Darmstadt, Germany 
Magnetic stirrer IKA, Staufen, Germany 
Mastercycler gradient Eppendorf, Hamburg, Germany 
Microscope Axiovert 40 CFL Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Mini Laboratory Centrifuges Spectrafuge™ Labnet, Edison, USA 
MS2 mini shaker IKA, Staufen, Germany 
MultiScreen Column Loader Merck, Darmstadt, Germany 
Nanodrop cuvette Implen, Munich, Germany 
Neubauer cell chamber Carl Roth, Karlsruhe, Germany 
Orbital shaker KS 260 basic IKA, Staufen, Germany 
Platform Shake Polymax 1040 - Heidolph Instruments, Schwabach, Germany 
PTC-200 Thermal Cycler BioRad, Munich, Germany 
QIAcube robot Qiagen, Hilden, Germany 
QIAvac 24 Plus vacuum manifold Qiagen, Hilden, Germany 
Sample Concentrator Techne, Stone, UK 
Scintillation Counter LS6500 Beckman Coulter, Krefeld, Germany 
Semi-dry blotter Fastblot B43 Biometra, Göttingen, Germany 
Sequence Detection System Applied Biosystems, Darmstadt, Germany 
Sequrity Guard C18 pre-column Phenomenex, Aschaffenburg, Germany 
SpeedVac® Plus SC110A concentrator Savant Instruments, Holbrook, USA 
Standard Power Pack P25 Biometra, Göttingen, Germany 
Tecan Ultra Microplate Reader Tecan Group AG, Männedorf, Switzerland 
Thermal Cycler DNA Engine® BioRad, Munich, Germany 
Thermomixer® Comfort Eppendorf, Hamburg, Germany 
Transilluminator TI 2 Biometra, Göttingen, Germany 
Vertical Electrophoresis Chambers mighty  
small II 
Amersham Biosciences, San Francisco, USA 




2.2 Consumables  
Material Manufacturer 
  
384 well PCR plate  Thermo Fisher Scientific, Darmstadt, Germany 
96 well filter plate MAHV N45 plate Merck, Darmstadt, Germany 
96 well PCR plate Thermo Fisher Scientific, Darmstadt, Germany 
Adhesive sealing sheets   Thermo Fisher Scientific, Darmstadt, Germany 
Cell culture flask 25 cm2 Sarstedt, Nümbrecht, Germany 
Cell culture flask 75 cm2 Greiner Bio-One, Frickenhausen, Germany 
Cell scraper 25 cm  Sarstedt, Nümbrecht, Germany 
Cell strainer, 40 µM BD Biosciences, Heidelberg, Germany 
Centrifuge tube 15 ml Greiner Bio-One, Frickenhausen, Germany 
Centrifuge tube 50 ml Sarstedt, Nümbrecht, Germany 
Combitips (500 µl, 2.5 ml, 5 ml) Eppendorf, Hamburg, Germany 
Corning® 96 well microplates, black Corning, Wiesbaden, Germany 
Cover slip Gerhard Menzel, Braunschweig, Germany 
Dialysis membrane filter 0.025 µm Merck, Darmstadt, Germany 
Electroporation cuvettes – 2mm PeqLab, Erlangen, Germany 
Filter Paper Nr. 2668 Schleicher und Schuell, Dassel, Germany  
Filter Paper Nr. 2CHR Schleicher und Schuell, Dassel, Germany 
Filter pipette tip,sterile (1000, 100 and 10 µl) Kisker, Steinfurt, Germany 
Flat cap strips, 8er Thermo Fisher Scientific, Darmstadt, Germany 
FrameStar 384 PCR Plate 4titude, Wotton, UK 
GelSaver II Spitzen 1-200µl Kisker, Steinfurt, Germany  
Glass Pasteur pipette 230 mm Brand, Wertheim, Germany 
Lab-Tek®II Chamber Slide Thermo Fisher Scientific, Darmstadt, Germany 
Minisart-plus, 0,2 µM Sartorius, Göttingen, Germany 
Nunc® CryoTubes® 1.8 ml Thermo Fisher Scientific, Darmstadt, Germany 
NunclonTM Multidishes 6 and 12 wells Thermo Fisher Scientific, Darmstadt, Germany 
Optical clear adhesive seal  Thermo Fisher Scientific, Darmstadt, Germany 
Petri dish for cell culture, 100 mm BD Biosciences, Heidelberg, Germany  
Petri dish, 100 mm Sarstedt, Nümbrecht, Germany 
Pipette tip (10, 100 and 1000 µl,) Sarstedt, Nümbrecht, Germany 
Pipette tip 2500 µl Eppendorf, Hamburg, Germany 
Plate retainer for sequencing Applied Biosystems, Darmstadt, Germany 
Imobilon-P Membrane, PVDF, 0.45 µM Merck, Darmstadt, Germany 
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Reaction tubes (1.5 ml , 2 ml) Sarstedt, Nümbrecht, Germany 
Reaction tubes (5 ml)  Eppendorf, Hamburg, Germany 
Screw-cap micro tube with skirted base 2ml Sarstedt, Nümbrecht, Germany 
Serological pipettes (5ml, 10 ml, 20 ml) Sarstedt, Nümbrecht, Germany 
Syringe Discardit II 20 ml BD Biosciences, Heidelberg, Germany 
TC Plate 96 well Sarstedt, Nümbrecht, Germany 
 
2.3 Chemicals, reagents and drugs used 
Chemicals and Reagents Manufacturer 
  
2-Propanol ≥ 99.9% AppliChem, Darmstadt, Germany 
2x Multiplex Master Mix Qiagen, Hilden, Germany 
4-Di-1-ASP Thermo Fisher Scientific, Darmstadt, Germany 
Acetonitril LGC Promochem, Wesel, Germany 
Acrylamide 4K - Solution (40 %) AppliChem, Darmstadt, Germany 
Agar Bacteriology grade AppliChem, Darmstadt, Germany 
Agarose ultrapure Invitrogen, Darmstadt, Germany 
Ammonium persulfate ≥ 98%  Sigma-Aldrich, Taufkirchen, Germany 
Ampicillin Sodium Salt AppliChem, Darmstadt, Germany 
Aquasafe 500 Plus liquid scintillator Zinsser Analytics, Frankfurt am Main, Germany 
Bicinchoninic Acid  Sigma-Aldrich, Taufkirchen, Germany 
Big Dye® Sequencing Kit Applied Biosystem, Darmstadt, Germany 
Boric acid Merck, Darmstadt, Germany 
Bovine serum albumin Sigma-Aldrich, Taufkirchen, Germany 
Bromophenol blue sodium salt Carl Roth, Karlsruhe, Germany 
Chloroform J.T. Baker, Phillipsburg, USA 
Copper sulfate pentahydrate Sigma-Aldrich, Taufkirchen, Germany 
DAPI Thermo Fisher Scientific, Darmstadt, Germany 
Dimethylsulfoxid AppliChem, Darmstadt, Germany 
DMEM cell culture medium Gibco, Darmstadt, Germany 
DNA Ladder 100 bp Thermo Fisher Scientific, Darmstadt, Germany 
DNA Ladder 1kb Thermo Fisher Scientific, Darmstadt, Germany 
DNeasy blood and tissue kit Qiagen, Hilden, Germany 
dNTP Set (dATP, dCTP, dGTP and dTTP,  
100 mM each) 
Thermo Fisher Scientific, Darmstadt, Germany 
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DTT Invitrogen, Darmstadt, Germany 
EDTA Lösung, pH 8.0 (0.5 M) AppliChem, Darmstadt, Germany 
Ethanol  Merck, Darmstadt, Germany 
Ethanol, denatured 99% Central Pharmacy, Clinic Hospital Göttingen 
Ethidium bromide Merck, Darmstadt, Germany 
Expand long template PCR system  Roche Diagnostics, Mannheim, Germany  
Fetal Bovine Serum Thermo Scientific, Darmstadt, Germany 
Fluoromount-GTM Southern Biotech, Birmingham, USA 
Formic acid Merck, Darmstadt, Germany 
FuGENE® 6 Transfection Reagent Promega, Mannheim, Germany 
GeneScan™ 120 LIZ™ dye Size Standard Thermo Fisher Scientific, Darmstadt, Germany 
Glycerol 85% Central Pharmacy, Clinic Hospital Göttingen 
Glycine AppliChem, Darmstadt, Germany 
Halt™ Protease Inhibitor Cocktail Thermo Fisher Scientific, Darmstadt, Germany 
HBSS Thermo Fisher Scientific, Darmstadt, Germany 
HEPES Sigma-Aldrich, Taufkirchen, Germany 
Hexanucleotide random Primer Roche Diagnostics, Mannheim, Germany 
Hi-Di™ Formamide Thermo Fisher Scientific, Darmstadt, Germany 
Hydrochloric acid 32% Merck, Darmstadt, Germany 
Hygromycin B Invitrogen, Darmstadt, Germany 
Isoamylalcohol 98% Merck Schuchardt, Hohenbrunn, Germany 
KOD Hot Start DNA Polymerase Kit Merck, Darmstadt, Germany 
Ligate-IT Rapid Ligation Kit Affymetrix, Santa Clara, USA 
Lipofectamine® 2000 Transfection Reagent Thermo Fisher Scientific, Darmstadt, Germany 
Magnesium sulfate ≥ 99,5% Merck, Darmstadt, Germany 
Methanol LGC Promochem, Wesel, Germany 
MPP dihydrochloride hydrate ≥97% Sigma-Aldrich, Taufkirchen, Germany 
MPP+, N-[methyl-3H], 80 Ci/mmol Hartmann Analytic, Braunschweig, Germany  
Nonidet®P40 Substitute 
(Nonylphenylethylenglycol) 
Fluka/ Sigma-Aldrich, Taufkirchen, Germany 
PBS buffer (10-fold Dulbecco's), powder AppliChem, Darmstadt, Germany 
Penicillin – Streptomycin solution Thermo Fisher Scientific, Darmstadt, Germany 
Phenylmethanesulfonyl fluoride Sigma-Aldrich, Taufkirchen, Germany 
Plasmid midi prep Kit  Qiagen, Hilden, Germany 
Poly D-lysine hydrobromide, 1000-4000 g/mol Sigma-Aldrich, Taufkirchen, Germany 
Ponceau S solution (0.2 %) Serva Electrophoresis, Heidelberg, Germany 
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QIAquick Gel Extraction Kit Qiagen, Hilden, Germany 
qPCR Master Mix Primer Design, Southhampton, UK 
Q-solution Qiagen, Hilden, Germany 
RNase A AppliChem, Darmstadt, Germany 
Rnase Inhibitor Affymetrix, Santa Clara, USA 
RNaseZAP™ Sigma-Aldrich, Taufkirchen, Germany 
RNeasy Plus Mini Kit Qiagen, Hilden, Germany 
Roti®-Block (10x) Carl Roth, Karlsruhe, Germany 
Roti®-Histofix 4 %, phosphate-buffered 
formaldehyde solution  
Carl Roth, Karlsruhe, Germany 
SeeBlue Plus2 Prestained Protein Standard Thermo Fisher Scientific, Darmstadt, Germany 
Sephadex G50 Superfine GE Healthcare, Solingen, Germany 
Skim milk powder Milupa, Bad Homburg, Germany 
SNaPshotTM Multiplex Kit Applied Biosystems, Darmstadt, Germany 
Sodium chloride  Merck, Darmstadt, Germany 
Sodium deoxycholate Sigma-Aldrich, Taufkirchen, Germany 
Sodium dihydrogen phosphate Merck, Darmstadt, Germany 
SDS AppliChem, Darmstadt, Germany 
Sodium hydrogen phosphate Merck, Darmstadt, Germany 
Sodium hydroxide Merck, Darmstadt, Germany 
SuperScript® II Reverse Transcriptase Kit Thermo Fisher Scientific, Darmstadt, Germany 
SuperSignal West Femto Substrate Trial Kit Thermo Fisher Scientific, Darmstadt, Germany 
SuperSignal West Pico Substrate Trial Kit Thermo Fisher Scientific, Darmstadt, Germany 
TEMED ≥ 99% Sigma-Aldrich, Taufkirchen, Germany 
TEA [ethyl-1-14C], 55 mCi/mol Hartmann Analytic, Braunschweig, Germany 
Tetraethylammonium chloride ≥99.0% Sigma-Aldrich, Taufkirchen, Germany 
Tris base Carl Roth, Karlsruhe, Germany 
Triton-X-100 Carl Roth, Karlsruhe, Germany 
Trypan Blue solution, 0.4 % Sigma-Aldrich, Taufkirchen, Germany 
TrypLE™ Express Thermo Fisher Scientific, Darmstadt, Germany 
Tryptone AppliChem, Darmstadt, Germany 
Tween 20 (Polyoxyethylen-Sorbit-Monolaurat) BioRad, Munich, Germany 
Yeast extract AppliChem, Darmstadt, Germany 








Atropine Sigma-Aldrich, Taufkirchen, Germany 
Buformine hydrochloride Wako Chemicals, Neuss, Germany 
Chlorguanide-d6 hydrochloride (Proguanil-d6) Biozol Diagnostica, Eching, Germany 
Debrisoquine sulfate Sigma-Aldrich, Taufkirchen, Germany 
Fenoterol Sigma-Aldrich, Taufkirchen, Germany 
Metformin hydrochloride Sigma-Aldrich, Taufkirchen, Germany 
Metformin hydrochloride, [biguanidine-14C], 
90 mCi/mmol 
Hartmann Analytic, Braunschweig, Germany 
Morphine, [N-methyl-14C], 55 mC/mmol Hartmann Analytic, Braunschweig, Germany 
Ondansetron hydrochloride dihydrate Sigma-Aldrich, Taufkirchen, Germany 
Proguanil hydrochloride Sigma-Aldrich, Taufkirchen, Germany 
Sumatriptan-d6 Santa Cruz Biotechnology, Heidelberg, Germany 
Sumatriptan succinate Sigma-Aldrich, Taufkirchen, Germany 
Tropisetron monohydrochloride Sigma-Aldrich, Taufkirchen, Germany 
Tyramine [8-14C] hydrochloride,  
55 mCi/mmol 
Hartmann Analytic, Braunschweig, Germany 





DpnI New England Biolabs, Frankfurt am Main, Germany 
EcoRI Thermo Fisher Scientific, Darmstadt, Germany 
EcoRV Thermo Fisher Scientific, Darmstadt, Germany 
Endo H New England Biolabs, Frankfurt am Main, Germany 
ExoI Thermo Fisher Scientific, Darmstadt, Germany 
FastAP (alkaline phosphatase) Thermo Fisher Scientific, Darmstadt, Germany 
HindIII Thermo Fisher Scientific, Darmstadt, Germany 
PNGase F New England Biolabs, Frankfurt am Main, Germany 
PstI Thermo Fisher Scientific, Darmstadt, Germany 
SalI Thermo Fisher Scientific, Darmstadt, Germany 






Primary antibody Manufacturer 
Dilution 
WB IS 
Monoclonal mouse anti - human GAPDH 
(6C5) 
Zytomed Systems, Berlin, 
Germany 
1:10 000 - 
Monoclonal mouse anti - human OCT1 
(2C5) (range of immunogen used: 284 – 347 
amino acid) 
Novus Biologicals, Abingdon, 
UK 
1:500 1:500 
Monoclonal rabbit anti - Na+/K+ ATPase 
(EP1845Y) 
Abcam, Cambridge, UK - 1:200 
Polyclonal rabbit anti - Calnexin Abcam, Cambridge, UK - 1:1000 
Secondary antibody Manufacturer 
Dilution 
WB IS 
    
Peroxidase-conjugated rabbit anti-mouse 
(pAb), polyclonal 
Dianova, Hamburg, Germany 1: 10 000 - 
Alexa Fluor® 546 goat anti - rabbit IgG 
(H+L), polyclonal 
Thermo Fisher Scientific, 
Darmstadt, Germany 
- 1:400 
Alexa Fluor® 488 goat anti - mouse IgG 
(H+L), polyclonal 




All Primers used were obtained from Eurofins Genomics, Ebersberg, Germany. The 
primers were delivered as lyophilisates and were solved in ddH2O to reach a concentration 




Table 2.1 Primer for site-directed mutagenesis  
















































































* Affected codons are underlined and mutated bases are highlighted in bold 




Table 2.2 SNaPshotTM primers 
 








   
87 µl 
ddH2O 
 S14F gaTCTGGAGCAGGTTGGGGAGT 22 1 µl 
 S189L gagatcAGAAGGCCATGAGCACGCCC 26 1 µl 
 T245M gatcgatcgatcgTAAGCGCCACCAGCCCCACC 33 2 µl 
 P117L gatcgatcgatcgatcgCACCAACAGGAGCCACCTGC 37 3 µl 
 I449T gatcgatcgatcgatcgatcGCTCAGCATTCACCAGGCAG 40 6 µl 
 M420del gatcgatcgatcgatcgatcgatcgatGCGGGGGCAGCCTGCCTCGTCAT 50 2 µl 
Mix 
B 
   
87 µl 
ddH2O 
 E284K gatcgatcgaTAACAGCCACCRAGGGGACT 30 2 µl 
 G414A gatcgatATGGCCRTGTCAAATTTGTTGGCRG 32 6 µl 
 R206C gatcgatcgatcgatcgatcGACCAGGCCCTGCAGCAGGC 40 1 µl 
 M420del gatcgatcgatcgatcgatcgatcgatGCGGGGGCAGCCTGCCTCGTCAT 50 2 µl 
* Small letters indicate the sequence-unspecific part of the SNaPshotTM primer. Degenerate bases used at 
positions known to be polymorphic are highlighted in bold.   
 
Table 2.3 Primers for validation PCRs 
















2.7 Gene expression assays 







     
SLC22A1 Hs00427552_m1 6-7 FAM™ Applied Biosystems 









     
Hu TBP M55654.1 4326322E VIC Applied Biosystems 
 
2.8 Bacterial strain 
Bacterial strain Origin Feature Manufacturer 
    
TOP10 
(One Shot® TOP10 E. coli) 
Escherichia coli Electro-competent  Thermo Fisher Scientific  
 
2.9 Plasmids 
Table 2.4 Purchased plasmids 
Plasmids Obtained from 
pOG44 Thermo Fisher Scientific 





Table 2.5 pcDNA3.1 plasmids 
pcDNA3.1 plasmids Obtained from 
pcDNA3.1::hOCT1 Hermann Koepsell, Institute of Anatomy 














pcDNA3.1::hOCT1- M408V pcDNA3.1::hOCT11 
pcDNA3.1::hOCT1-M408V-M420del pcDNA3.1::hOCT1-M420del2 
pcDNA3.1::hOCT1- G414A pcDNA3.1::hOCT11 









1 provided by Hermann Koepsell, University of Würzburg 
2 generated by Ali Reza Saadatmand as previously described (Saadatmand et al., 2012) 
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Table 2.6 pcDNA5 plasmids 
pcDNA5 plasmids Obtained from 
pcDNA5::hOCT1-S14F Ali Reza Saadatmand1 
pcDNA5::hOCT1-S14F-R342H-M408V 
Generated in this work 
pcDNA5::hOCT1-S29L 
pcDNA5::hOCT1-P117L 
Ali Reza Saadatmand1 
pcDNA5::hOCT1-S189L 
pcDNA5::hOCT1-R206C-M408V-M420del 







pcDNA5::hOCT1-M420del Ali Reza Saadatmand2  
pcDNA5::hOCT1-I449T 























1 generated by Ali Reza Saadatmand, Institute of Clinical Pharmacology, University Medical Center 
Göttingen 
2 generated by Ali Reza Saadatmand, Institute of Clinical Pharmacology, University Medical Center, as 
previously described (Saadatmand et al., 2012) 
3 in close collaboration with Marleen Meyer, Institute of Clinical Pharmacology, University Medical Center, 
Göttingen 
 
2.10 Cell lines 
Cell line Obtained from 
Flp-In™ T-REx™ 2931  
(further referred to as HEK293)  
Thermo Fisher Scientific 
HEK293 - pcDNA5 
Ali Reeza Saadatmand2 
HEK293 - hOCT1 
HEK293 - hOCT1-S14F  
HEK293 - hOCT1-S29L Generated in this work 
HEK293 - hOCT1-R61C 
Ali Reeza Saadatmand2* 
HEK293 – hOCT1-C88R-M420del 
HEK293 - hOCT1-P117L 
Generated in this work HEK293 - hOCT1-F159Y-M408V 
HEK293 - hOCT1-F159Y-M408V-M420del 
HEK293 - hOCT1-F160L Sherin Pojar3 
HEK293 - hOCT1-S189L 
Generated in this work 
HEK293 - hOCT1-R206C-M408V-M420del 
HEK293 - hOCT1-W217Y-M408V 
HEK293 - hOCT1-W217Y-M408V-M420del 
HEK293 - hOCT1-T245M 
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HEK293 - hOCT1-E284K Generated in this work 
HEK293 - hOCT1-P341L-M408V Sherin Pojar3 
HEK293 - hOCT1-L364A-M408V-M420del 
Generated in this work 
HEK293 - hOCT1-H367A-M408V-M420del 
HEK293 - hOCT1-G401S 
Ali Reeza Saadatmand2 
HEK293 - hOCT1-M420del 
HEK293 - hOCT1-M408V 
Generated in this work 
HEK293 - hOCT1-M408V-M420del 
HEK293 - hOCT1-G414A 
HEK293 - hOCT1-G414A-M408V-M420del 
HEK293 - hOCT1- M420A-M408V 
HEK293 - hOCT1- M420I-M408V 
HEK293 - hOCT1-A426ins-M408V-M420del 
HEK293 - hOCT1- L427del-M408V 
HEK293 - hOCT1- H428del-M408V 
HEK293 - hOCT1-I449T 
HEK293 - hOCT1-R488M 
Sherin Pojar3 
HEK293 - hOCT1-R488M-M408V 
HEK293 - hOCT1-G465R-M420del Ali Reeza Saadatmand2 
HEK293 - hOCT1-D474E-M408V 
Generated in this work 
HEK293 - hOCT1-D474E-M408V-M420del 
HEK293 - mOct1 
Helen Massy4 
HEK293 - mOct1-F160Y 
HEK293 - mOct1-W218Y 
HEK293 - mOct1-D475E 
HEK293 – rOct1 
1 human embryonic kidney cells 293 containing a Flp Recombination Target site (FRT site) for stable 
transfection, only cell line used in this study 
2 Ali Reeza Saadatmand; Institute of Clinical Pharmacology, University Medical Center Göttingen, 2* cell 
lines generated as previously described (Saadatmand et al., 2012) 
3 Sherin Pojar, Institute of Clinical Pharmacology, University Medical Center Göttingen (Pojar, 2015) 




2.11 Software and databases 
 
Software Company 
3130xl Data Collection Software v3.0 Applied Biosystems, Darmstadt, Germany 
Adobe Photoshop CS2 v9.0 Adobe Systems GmbH, Munich, Germany 
Clone Manager 6, v6.0 Sci Ed Central 
CorelDraw X3, v13 Corel Corporation, Munich, Germany  
EndNote X7 Thomson Reuters, New York, USA 
Eppendorf BioPhotometer Online v1.01 Eppendorf, Hamburg, Germany 
GeneMapper Software v3.7 Applied Biosystems, Darmstadt, Germany 
Graph Pad Prism, v5.01 GraphPad Software, San Diego California, USA 
ImageJ v1.46r National Institute of Health, Bethesda, USA  
Microsoft Office 2007 Microsoft Corporation, Redmond, USA 
Quantity One v4.2.3 and v4.6.7 BioRad, Munich, Germany 
Sequencing. Analysis Software v5.2 Applied Biosystems, Darmstadt, Germany 
SigmaPlot, v12.5 Systat Software, San Jose, California,US 
Staden Package  SourceForge.ne 
Swiss Pdb Viewer v4.1 Swiss Institute of Bioinformatics, Switzerland 
XFluor4 v4.40 Tecan Group AG, Männedorf, Switzerland 
ZEN 2012 (black edition) v8.0 Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Database URL 
National Center for Biotechnology Information  http://www.ncbi.nlm.nih.gov/ 








3.1 Recombinant DNA techniques 
3.1.1 Agarose gel electrophoresis 
 
1 x TBE buffer (pH 8.3) 
Substance Concentration [mM] 
Tris 100 
Boric acid 100 
EDTA 3 
 
5 x Loading buffer 
Substance Concentration  
Glycerol 30 % (v/v) 
EDTA 50 mM 
Bromophenol blue 0,25 %(v/v) 
Using gel electrophoresis, DNA samples were separated according to their size using an 
agarose gel. The DNA with its negatively charged backbone moves in an electric field 
towards the anode. According to the expected DNA fragment size a concentration of 0.8 % 
to 1.5 % agarose in TBE buffer was used. The agarose gel was made by adding the 
appropriate amount of agarose to 70 ml of 1 x TBE buffer: 560 mg for a 0.8 %, 700 mg for 
1% or 1005 mg for a 1.5 % gel. The agarose was dissolved in 1 x TBE buffer by heating up 
the solution in a microwave until boiling. After the solution cooled down at room 
temperature for 10 min, 5 µl of ethidium bromide was added. The solution was cooled 
down for an additional 10 min and then poured in a gel tray with gel combs. As soon as the 
agarose gel became solid the gel combs were removed and the tray was placed in an 
electrophoresis gel chamber filled with 1 x TBE buffer supplemented with 0.5 % ethidium 
bromide (v/v). DNA samples were mixed with 5 x loading buffer and applied on the gel. 
The electrophoresis was carried out at 120 V until the dye front reached the bottom of the 
gel. The ethidium bromide-stained DNA was visualized under UV light using the Fluor-
STM Multi Imager with the Quantity One v4.2.3 software. 
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3.1.2 Extraction of DNA fragments from agarose gel 
For extraction of DNA from an agarose gel the QIAquick Gel Extraction Kit (Qiagen) was 
used according to the manufacturer’s instructions. Briefly, the agarose gel slice containing 
the desired DNA fragment was cut under UV light using the Transilluminator TI 2 and was 
placed in a 2 ml reaction tube. The DNA was extracted from the agarose gel using the 
QIAcube robot (Qiagen) and eluted with 50 µl elution buffer. 
 
3.1.3 Capillary sequencing analysis  
The order of nucleotides in a DNA sequence can be analyzed by capillary sequencing. The 
principle of capillary sequencing is based on the dideoxy sequencing method developed by 
Sanger and Coulson (Sanger et al., 1977). During DNA replication the DNA polymerase 
catalyzes the formation of a phosphodiester bond between the 3' - hydroxyl group of a 
nucleotide with the 5' - phosphate group of a newly added nucleotide. By applying dideoxy 
sequencing, the reaction contains both dNTPs and dideoxynucleotides (ddNTPs), which 
can be incorporated by the DNA polymerase but due to the missing 3' – hydroxyl group in 
the ddNTPs no further nucleotide can be added. This leads to termination of DNA 
synthesis. Because the ddNTPs are incorporated randomly, different DNA fragment sizes 
are generated, which can be separated by capillary electrophoresis according to their size. 
In this work the Big Dye® Sequencing Kit (Applied Biosystems) was used, which contains 
different florescent labeled ddNTPs that were used to detect different DNA fragments. 
In this work capillary sequencing was applied to verify the correctness of OCT1 variants 
either from overexpressing plasmids or from total genomic DNA. The primers used are 
summarized in Table 3.1. In case of genomic DNA, OCT1 was amplified before 
sequencing by performing PCR 2 as described in chapter 3.1.6. For capillary sequencing 
the 3130xl Genetic Analyzer (Applied Biosystems) was used.  
In order to sequence the complete coding region of OCT1 the following primers, which 
were also used for site-directed mutagenesis, were used: S29L forward, C88R forward, 
C88R reverse, T245M forward, T245M reverse, L364A forward, L364A reverse, M408V 




Table 3.1 Sequencing Primers used to detect single nucleotide exchanges leading to non-synonymous 
amino acid exchanges in OCT1  
Mutation 
Sequencing primer  
      Name Sequence (5’ → 3’) 
S14F C88R reverse ACTTCATAGCGCCTGCGCTGGCCAAGGAAGGCC 
S29L 





T245M L364A reverse GCCCATGTGCAGGATGGCCCCCTGATAGAGCACA 
E284K 
L364A E284K forward CTACTGGTGTGTGCCGAAGTCCCCTCGGTGGCT 
H367A   


















Reaction mixture for capillary sequencing 
Reagent Volume [µl] 
ddH2O 2.25 
DMSO 0.25 
Sequencing primer (10 µM) 0.5 
Big Dye® 1 
DNA 1 
Total volume 5 
 
Reaction conditions for capillary sequencing 
Phase Temperature Time  
Initial denaturation 94 °C 2 min  
Denaturation 96 °C 15 sec 
x 25  Annealing 56.5 °C 15 sec 
Elongation 60 °C 4 min 
Final elongation 72 °C 7 min  
 
The sequencing reaction product was purified from unincorporated nucleotides and salts 
from the reaction buffer via size exclusion chromatography. For preparation of the 
Sephadex column, 35 mg of Sephadex G50 Superfine (the Sephadex was portioned with 
the help of a multiscreen column loader) was applied on a 96 well filter plate (MAHV 
N45). Three hundred µl ddH2O was added and incubated for 3 h. The water was removed 
by centrifugation at 700 g for 5 min and 150 µl ddH2O was added to the Sephadex and was 
incubated for further 30 min. The water was removed by centrifugation at 700 g for 5 min.  
The sequencing reaction product was diluted in 35 µl ddH2O and applied on the Sephadex 
column. By centrifugation at 700 g for 5 min the purified sequencing reaction product was 
collected in a new 96 well plate. The plate was loaded onto a plate retainer and sequencing 
analysis was performed using the 3130xl Genetic Analyzer. The sequencing data was 




3.1.4 Single base primer extension (SNaPshotTM) 
The SNaPshotTM Multiplex Kit (Applied Biosystems) is based on the single base primer 
extension method. Its principle is based on the incorporation of fluorescence labeled 
ddNTPs, which lead to termination of DNA elongation. In contrast to capillary sequencing 
described in chapter 3.1.3, the reaction mixture contains only ddNTPs and no dNTPs. As a 
result the reaction terminates after the addition of a single ddNTP. Special SNaPshotTM 
primers were designed (Table 2.2), which ends one nucleotide upstream of the expected 
nucleotide exchange. The reaction mixture can contain several primers so that different 
nucleotide exchanges can be analyzed at ones (Primer Mix A or B as shown in Table 2.2). 
These primers differ in their length so that they can be separated by capillary sequencing 
according to their size. 
SNaPshotTM was used in this work to validate the presence of single nucleotide 
polymorphisms in OCT1. 
Prior to the SNaPshotTM reaction the OCT1 gene was amplified with PCR 2 and the PCR 
product was enzymatically purified as described in chapter 3.1.6. After purification, 2 µl 
was added to 3 µl of the following SNaPshotTM reaction mixture: 
 
Reagent Volume [µl] 
ddH2O 1 
2x SNaPshotTM Reaction Mix 1.5 
10x SNaPshotTM Primer Mix 0.5 




The reaction was run under the following conditions:  
 
Phase Temperature Time  
Initial denaturation 96 °C 2 min  
Denaturation 96 °C 10 sec 
25 x Annealing 50 °C 5 sec 
Elongation 60 °C 30 sec 
 
The SNaPshotTM reaction was purified from unincorporated nucleotides prior to capillary 
electrophoresis. Therefore, 1 µl of the following purification mixture was added to the 




Reagent Volume [µl] 
FastAP buffer 0.5 
FastAP 0.5 
Total volume 1 
 
The reaction was stopped by heat inactivation at 80 °C for 15 min. 
Finally, the sample was prepared for analysis by adding 10 µl of the following loading 
solution: 
 
Reagent Volume [µl] 
Hi-Di™ Formamide 10 
GeneScan-120LIZ® 
(Molecular size standard) 
0.2 





The sample was incubated at 95 °C for 5 min to denature the DNA. Following incubation, 
the sample was immediately stored on ice for 10 min.  
The sample was analyzed via capillary electrophoresis using the 3130xl Genetic Analyzer 
with 50 cm capillaries and data was analyzed using the GeneMapper Software v3.7. 
 
3.1.5 Site-directed mutagenesis  
Using site-directed mutagenesis PCR, single nucleotide exchanges were introduced into 
pcDNA3.1::hOCT1 and pcDNA3.1::hOCT1-M420del plasmids using site-directed 
mutagenesis primer (Table 2.1). The amplification of the whole plasmid was carried out 
using the KOD Hot Start DNA polymerase, which is a high fidelity polymerase with 3'→ 
5' exonuclease activity. The template plasmids used were obtained from dam+ E.coli strain 
TOP10 (chapter 2.8). This bacteria strain shows a specific methylation pattern due to the 
expression of the dam methylase encoded by the dam gene. The dam methylase 
specifically transfers a methyl group from S-adenosylmethionine to an adenosine residue in 
the sequence GATC. Using the methylation sensitive endonuclease DpnI, which only cuts 
methylated adenosine residues, the template plasmid can be degraded after PCR.  
In order to determine the optimal annealing temperature of each primer pair a gradient PCR 
was performed. Different annealing temperatures in a range of 50 °C to 70 °C degree 
(50 °C, 53.2 °C, 58.4 °C, 64.6 °C and 70 °C) were tested. Primers and the optimal 




Site-directed mutagenesis PCR mixture: 
Reagent Volume [µl] 
ddH2O 11.2 
Q-solution (Qiagen) 5 
10 x KOD Buffer 2.5 
dNTPs (2mM) 2.5 
MgSO4 1 
Forward primer (10 µM) 0.65 
Reverse primer (10 µM) 0.65 
Template DNA (50 ng/µl) 1 
Hot Start KOD Polymerase 0.5 
Total volume 20 
 
Site-directed mutagenesis PCR conditions: 
Phase Temperature Time  
Initial denaturation 95 °C 3 min  
Denaturation 95 °C 30 sec 
x 19 Annealing 50-70 °C 30 sec 
Elongation 72 °C 4 min 
 
 
The PCR resulted in an amplification product of about 7193 bp. After amplification, the 
plasmid template was digested with DpnI. Therefore, 2µl of DpnI was added to the PCR 
product and incubated for 1 h at 37 °C. Following initial digestion, an additional 1 µl DpnI 
was added and the reaction was incubated for another hour at 37 °C. Alternatively an 
overnight incubation at 37 °C with 3 µl DpnI was performed. 
The successful amplification was proven using agarose gel electrophoresis. Therefore, 
10 µl of the reaction was run on a 0.8 % agarose gel together using a 1 kb DNA ladder as a 
molecular size marker (see chapter 3.1.1).  
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3.1.6 Validation PCRs of stable transfected HEK293 cell lines 
The successful integration of the expression plasmid pcDNA5 containing the gene of 
interest into the genome of T-REx™ 293 cells after stable transfection was confirmed by 
three integration-specific PCRs. For this propose total genomic DNA was extracted from 
untransfected T-REx™ 293 cells, T-REx™ 293 cells stably transfected with the empty 
expression vector pcDNA5 or transfected with pcDNA5 containing OCT1 (chapter 2.9). 
The genomic DNA of untransfected T-REx™ 293 cells was used as a negative control. The 
first PCR reaction verified the integration of pcDNA5 into the genome of T-REx™ 293 
cells and resulted in an amplification product of 518 bp. The second PCR detected the gene 
of interest within the integration site and resulted in amplification products of 1376 bp and 
of about 3140 bp for T-REx™ 293 cells stably transfected with the empty expression 
vector pcDNA5 and for T-REx™ 293 cells stably transfected with pcDNA5 containing 
OCT1, respectively. The binding sites of primer pairs of both PCR reactions are 
schematically shown in (Figure 3.1). The third PCR was performed in order to identify 
possible multiple tandem integration of the expression vector pcDNA5 containing OCT1 
into the genome of T-REx™ 293 cells. In case of multiple tandem integration the PCR3 
resulted in an amplification product of 214 bp (Figure 3.1). The primer sequences of 







Figure 3.1 (previous page) Schematical presentation of primer binding sites of validation PCR 1, PCR 
2, and PCR 3. (A) Schematic presentation of the expression plasmid pcDNA5 (black) integrated into the 
pFRT/lacZeo site of the genome of HEK293 cells (gray). The positions of the primers of PCR 1 and PCR 2 
are indicated. PCR 1 resulted in an amplification product of 519 bp and PCR 2 resulted in an amplification 
product of 1376 bp (empty pcDNA5 vector) or about 3140 bp (pcDNA5 containing OCT1 or its allelic 
variants). Taken from (Seitz et al., 2015). (B) Schematic presentation of PCR 3 that was performed to 
identify clones with multiple tandem integration of the expression plasmid pcDNA5. Shown are two 
expression plasmids pcDNA5::OCT1 (dark and light blue) integrated at the FRT site of T-REx™ 293 cells 
(black). Annealing positions of the primers (PFRT_f and PHyr_r) are indicated. Amplification resulted in a 
214 bp product. 
 
The PCR reactions were performed as follows:  
 
PCR 1: reaction mixture  
Reagent Volume [µl] 
ddH2O 8.8 
Q-solution 4.4 
10 x KOD Buffer 2.2 
dNTPs (2mM) 2.2 
MgSO4 0.9 
Primer PSV40 (100 µM) 0.5 
Primer Hyg_r2 (100 µM) 0.5 
Genomic DNA  2 
Hot Start KOD Polymerase 0.5 
Total volume 22 
 
PCR 1: reaction conditions  
Phase Temperature Time  
Initial denaturation 95 °C 2 min  
Denaturation 95 °C 30 sec 
x 34  Annealing 64 °C 30 sec 
Elongation 72 °C 1 min 




PCR 2: reaction mixture  
Reagent Volume [µl] 
ddH2O 9.8 
Q-solution 5.6 
10 x Expand long Buffer 2.8 
dNTPs (2mM) 4.5 
MgSO4 1 
Primer PCMV (100 µM) 0.5 
Primer LacZ (100 µM) 0.5 
Genomic DNA  3 
Expand Long Polymerase Mix 0.3 
Total volume 28 
 
PCR 2: reaction conditions  
Phase Temperature Time  
Initial denaturation 94 °C 2 min  
Denaturation 96 °C 30 sec 
x 35  
Annealing and Elongation 68 °C 4 min 
Final elongation 68 °C 10 min  
 
The successful amplification of both PCRs was confirmed using 10 µl of each sample, 
which was analyzed on a 0.8 % agarose gel using a 1 kb DNA ladder as a molecular size 
marker (chapter 3.1.1).  
The PCR product of the second PCR was further used in downstream applications like 
capillary sequencing (chapter 3.1.3) and SNaPshotTM (chapter 3.1.4). To this end, the PCR 
product needed to be enzymatically purified using ExoI and SAP. Exonuclease I (ExoI) 
degrades single-stranded DNA in 3' → 5' direction removing unincorporated primers and 
any remaining single-stranded DNA. The shrimp alkaline phosphatase (SAP) removes 
remaining dNTPs from the reaction mixture of the former PCR that would interfere with 
downstream analyses. To 18 µl of PCR product 3 µl of the following mix was added to 
enzymatically purify the PCR product:  
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Reagent Volume [µl] 
SAP 2 
ExoI 0.3 
10 x SAP buffer 0.7 
Total volume 3 
 
The reaction mixture was added to 18 µl of the PCR product of PCR 2 and the reaction was 
incubated for one hour at 37 °C. The reaction was terminated by incubation at 80 °C for 
15 min. 
 
PCR 3: reaction mixture 
Reagent Volume [µl] 
2 x Multiplex Master Mix 5.5 
Q-solution 2.2 
10 x Primer mix  
(2 µM PFRT_f and 2 µM PHyr_r) 
1.1 
H2O 1.2 
Genomic DNA 1 
Total Volume 11 
 
The 10 x Primer Mix containing 2 µM of PFRT_f and 2 µM of PHyr_r (for primer 
sequences see Table 2.3) was made by diluting the primer stock of each primer with a 
concentration of 100 µM 1:50 in ddH2O. Therefore, 5 µl of each primer was added to 
240 µl of ddH2O. 
PCR 3: reaction conditions  
Phase Temperature Time  
Initial denaturation 95 °C 15 min  
Denaturation 94 °C 30 sec 
x 30  Annealing  58 °C 1 min 30 sec 
Elongation 72 °C  2 min 
Final elongation 72 °C 10 min  
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The successful amplification of the third PCR was analyzed on a 1.5 % agarose gel 
together with a 100 bp DNA ladder (see chapter 3.1.1).  
 
3.1.7 Isolation of total genomic DNA 
For isolation of total genomic DNA the DNeasy blood and tissue kit (Qiagen) was used 
following the manufacturer’s instructions. One to two million HEK293 cells were 
harvested in a 2 ml screw-cap micro tube and centrifuged for 4 min at 500 g. The cell pellet 
was dissolved in 100 µl PBS buffer. The total genomic DNA was automatically extracted 
using the QIAcube robot (Qiagen) and eluted in 100 µl elution buffer. Typically 
concentrations between 100 and 200 ng/µl were obtained. 
 
3.1.8 Photometric quantification of nucleic acid 
Photometrical determination of nucleic acid concentration was performed by applying 3 µl 
sample of DNA or RNA solution on a Nanodrop cuvette (Implen) and absorption at 
260 nm was measured using the Biophotometer (Eppendorf). The absorption was 
calculated using the BioPhotometer Online v1.01 software according to the Lambert-Beer 
law and the concentration of nucleic acid was then calculated according to the formula:  
c [μg/ml] = OD260 x F x DF where OD260 is the absorption at 260 nm, DF is the dilution 
factor and F is the conversion factor. The conversion factor is the concentration of nucleic 
acid, which results in an absorption of 1 (50 µg/ml for double stranded DNA and 40 µg/ml 
for RNA). 
The purity of the nucleic acid sample can be evaluated by analyzing the ratio 260/280. 
Proteins have an absorption maximum at a wavelength of 280 nm. While nucleic acids 
have an absorption maximum at 260 nm, but also have a substantial absorption at 280 nm, 
the absorption ratio between 260 nm/280 nm for pure DNA is 1.8 and for RNA is 2.0. A 
ratio smaller than 1.8 for DNA and 2.0 for RNA indicates protein contamination. Samples 
with such ratios were not used in further analyses. Another ratio, which can be used to 
evaluate the purity of nucleic acid preparation, is the ratio 260/230. A ratio of 2.0 to 2.2 
indicates pure nucleic acid preparation. A higher value indicates contamination with 
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substances that absorb at 230 nm like EDTA and phenol that can occur from extraction 
procedures.  
 
3.1.9 Analytical restriction digestion 
An analytical restriction digestion was performed in order to validate DNA preparations 
based on their specific restriction fragments after restriction digest using endonucleases. 
The reaction mixture was made as follows: 
 
Reagent Volume [µl] 
Buffer 1 
Restriction enzyme 1 
DNA 1 
H20 7 
Total volume 10 
 
The buffers were enzyme-specific and supplied together with the enzyme. The reaction 
was incubated for one hour at 37 °C. Afterwards the DNA fragments were analyzed on an 
agarose gel (see chapter 3.1.1). 
After ligation reaction (chapter 3.1.11), successful ligation of the insert into pcDNA5 was 
validated using the restriction enzymes EcoRV and HindIII, as well as PstI, SalI, and 
EcoRI. The double digest using EcoRV and HindIII was performed in order to proof 
insertion of the insert into the vector. PstI, SalI, and EcoRI were used in order to 
distinguish between pcDNA3.1::hOCT1 and pcDNA5::hOCT1 due to different restriction 




Table 3.2 Analytical restriction digest of pcDNA3.1::hOCT and pcDNA5::hoCT1 and expected 








10x Buffer R 1814, 5379 1814, 5017 
PstI 10x Buffer O 68, 168, 929, 1385, 4649 68, 168, 929, 964, 4702 
SalI  10x Buffer R 34, 2188, 4977 2188, 4643 
EcoRI 10x Buffer EcoRI 7193 879, 5952 
 
*purchased together with the respective enzyme from Thermo ScientificTM 
 
 
3.1.10 Preparative restriction digest 
To prepare plasmids or DNA fragments for cloning procedures a preparative restriction 
digest was performed. For this work a double restriction digest with the endonucleases 
EcoRV and HindIII was performed as follows: 
 





Total volume 50 
 
The restriction digest was incubated for 2 h at 37 °C. Afterwards additional 2 µl of each 
enzyme was added and the reaction was incubated for another hour. The complete reaction 
was applied on a 1 % agarose gel (see chapter 3.1.1). The agarose gel with the desired 
DNA fragment was extracted from the agarose gel using the QIAquick Gel Extraction Kit 





During a ligation reaction DNA fragments with complementary ends are covalently bound 
(ligated). The reaction is catalyzed by enzymes called ligases (e.g. T4 ligase), which 
catalyze the formation of a phosphodiester bond between the 3' hydroxyl end of one and 
the 5' phosphate end of another DNA fragment. This method is used to ligate a DNA 
fragment (insert) into a linearized vector. Because the reaction needs complementary DNA 
ends of the insert and the vector used, both are digested with restriction enzymes producing 
blunt or sticky ends. Therefor both, the DNA fragment (insert) and the vector were 
prepared by preparative restriction digest (chapter 3.1.10) 
Prior to ligation, the DNA was concentrated using vacuum centrifugation. The reaction 
tube containing the DNA eluate was placed opened in the SpeedVac® Plus SC110A 
vacuum centrifuge pre-warmed (setting: high) for 10 min. The samples were centrifuged 
for about 10 min under vacuum until approximately 14 µl were left. Afterwards the 
samples were immediately placed on ice. The condensed water made the DNA pellet 
visible. With 2 µl of ddH2O the DNA was washed from the wall of the reaction tube and 
added to the remaining solution. If necessary the volume was adjusted with ddH2O to 14 
µl. For the ligation reaction the Ligate-IT Rapid Ligation Kit (Affymetrix) was used. The 
following reaction mix was prepared: 
  
Reagent Volume [µl] 
DNA fragment (insert) 14 
Linearized vector  1 
5x Ligase Buffer 4 
T4 Ligase 1 
Total volume 20 
 
As a negative control for ligation reaction 14 µl ddH2O was used instead of the DNA 
fragment. The negative control was used to analyze the amount of self-ligated vector 
molecules. The ligation reaction was incubated for 10 min at room temperature and the 
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samples were immediately stored on ice. After dialysis (chapter 3.1.12), samples could be 
used for transformation into E.coli (chapter 3.3.5).  
 
3.1.12 Dialysis 
The technique described here is called “drop dialysis”. Samples were applied on top of a 
dialysis membrane filter (0.025 µM, Merck) that floated in a vessel filled with ddH2O. The 
samples were dialyzed for 30 min at room temperature. The diluted DNA was carefully 
removed from the membrane and transferred to a reaction tube. 
 
3.2 Quantification of mRNA expression 
While working with RNA it was very important to avoid RNase contamination that would 
lead to RNA degradation. Hence, the working place and all pipettes used were cleaned with 
RNaseZAP™, a RNase decontamination solution. All working steps were carried out under 
the hood that was provided only for work that dealt with RNA. Furthermore gloves should 
be worn at any time and while working with RNA samples, RNAse free water and RNAse 
free materials should be used.  
 
3.2.1 Isolation of total RNA 
Total RNA was isolated using the RNeasy Plus Mini Kit (Qiagen) according to the 
manufacturer’s instructions. A cell suspension of 1 to 2 x106 HEK293 cells was harvested 
in a 2 ml reaction tube and centrifuged at 500 g for 4 min. The supernatant was discarded 
and 350 µl of the lysis buffer RLT buffer supplemented with 1 % β-mercaptoethanol (v/v) 
(further referred to as RLT buffer plus) was added to the cell pellet and resuspended by 
vortexing. The RLT buffer stabilized and protected RNA from degradation. The pellet 
dissolved in RLT buffer plus was immediately used for RNA isolation or stored at -20 °C. 
During extraction, genomic DNA was removed with the help of a genomic DNA 
eliminator spin column provided by the kit. The isolation was automatically performed 
using the QIAcube robot (Qiagen) and RNA was eluted in 50 µl of RNase free ddH2O.  
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3.2.2 Reverse transcription reaction  
A reverse transcription reaction is used for the synthesis of complementary DNA (cDNA) 
from a RNA template. The reaction is catalyzed by the enzyme reverse transcriptase, a 
RNA dependent DNA polymerase. This method is used for mRNA expression analysis in 
downstream applications like real-time PCR (chapter 3.2.3). For cDNA synthesis the 
SuperScript® II Reverse Transcriptase Kit (Thermo Fisher Scientific) and the RNase 
Inhibitor (Affymetrix) was used. One µg of RNA was diluted in a final volume of 17.75 µl 
of RNase free ddH2O and 1 µl of random hexamer nucleotide primers was added. The 
reaction mixture was incubated at 70 °C for 10 min. During this step RNA was denatured 
and hexamer nucleotide primers annealed to RNA molecules. For cDNA synthesis, 
11.25 µl of the following reaction mixture was added to each sample: 
 
Reagent Volume [µl] 
5 x RT buffer 6 
DTT (0.1 M) 3.5 
dNTPs (10 mM) 1 
RNase Inhibitor 0.5 
Super Script II Reverse Transcriptase 0.25 
Total volume 11.25 
 
The reverse transcription reaction was incubated for one hour at 42 °C. The cDNA samples 
were diluted in 70 µl of ddH2O. Samples were stored at -20 °C. 
 
3.2.3 Real-time PCR (qPCR) using TaqMan® Assay 
Real Time PCR is used to analyze mRNA expression. During real-time PCR it was 
possible to detect incremental PCR products over time using florescent labeled probes. To 
detect the gene of interest the TaqMan® assays as listed in chapter 2.7 were used. The 
expression assay Hs00427552_m1, which detects a sequence located in the exon border of 
exon 6 and exon 7 of OCT1, was used for the expression analysis of OCT1 allelic variants 
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presented in chapter 4.1.1. The OCT1 expression of mutants, which were analyzed in 
chapter 4.4, was analyzed using the expression assay Hs00427550_m1 (SLC22A1_new). 
This probe detects a sequence located in the exon border of exon 4 and exon 5. The former 
assay could not be used, as one of the introduced mutations in OCT1 (leading to the amino 
acid exchange H367A) interfered with assay binding. The expression of TBP was used as 
an internal control. 
The TaqMan® gene expression assay probes consisted of a fluorescent dye at their 5' 
terminal end and a quencher dye at their 3' terminal end, which quenches the fluorescent 
signal. The probes are complementary to a specific sequence of the gene of interest and are 
within the amplicon. During PCR the 5' → 3' nuclease activity of the DNA polymerase 
cleaves the 5' end of the probe and releases the fluorescent dye which leads to a fluorescent 
signal as it is not further suppressed by the quencher dye The increase of fluorescent signal 
is proportional to the increase of PCR product. 
The real-time PCR reaction was carried out in a 384 well PCR plate. The PCR reaction was 
set up as follows: 
 
Reagent Volume [µl] 
2 x qPCR Master Mix  9 
20 x Gene expression assay Mix 0.9 
cDNA 3 
ddH2O 5.1 
Total volume  15 
 
The qPCR Master Mix used contained the thermostable Taq polymerase, buffer, MgCl2 
and dNTPs and was obtained ready to use from PrimerDesign. All samples were measured 
in triplicates. The 384 well plate was covered with an optical clear adhesive seal and the 
real-time PCR was performed using the 7900 HT Fast Real Time PCR System (Thermo 
Fisher Scientific) with the following conditions:  
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Phase Temperature Time  
Initial denaturation and Taq- 
polymerase activation 
95 °C 10 min  
Denaturation 95 °C 15 sec 
40 x 
Primer annealing and elongation 60 °C 1 min 
 
For this work the expression of OCT1 was relatively quantified using TBP as an internal 
control according to the ∆∆CT method as described by Livak and Schmittgen (Livak and 
Schmittgen, 2001) and was calculated with the following equation: 
Relative expression = 2-[Ct(OCT1) – Ct(TBP)] – [Ct(control) – Ct(TBP)] 
The value for CT gives the number of amplification cycles needed to reach a fluorescent 
signal greater than a certain threshold. As control cDNA samples from T-REx™ 293 cells 
transfected with the empty expression vector pcDNA5 were used. 
 
3.3 Microbiological techniques used 
3.3.1 Growth media and culturing conditions 
In this work One Shot® TOP10 Electrocomp™ E. coli (Thermo Fisher) were used for 
transformation via electroporation. The TOP10 E.coli were used for high transformation 
efficiency and allowed stable replication of a high number of plasmids. 




Tryptone  10 g 
Yeast extract 5 g 
NaCl 5 g 
ddH2O Add 1000 ml 
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The substances were dissolved in 1000 ml ddH2O and immediately autoclaved. The liquid 
LB medium was stored at 4 °C. 
For agar plates 14 g of agarose was added to 1 l of LB media before autoclaving. The 
solution was autoclaved and after cooling down to at least 55°C ampicillin as the selective 
antibiotic was added to a final concentration of 100 µg/ml. 
 
3.3.2 Bacterial solid culturing 
Streaking the bacteria on an agar plate, a glass Pasteur pipette was formed into a Drigalski 
spatula above a flame. Before use the heated spatula need to be cooled to room temperature 
in order to not risk killing the bacteria. Different volumes (50 µl, 100 µl, and 200 µl) of a 
bacterial solution were pipetted on the plate and equally spread by moving the Drigalski 
spatula back and forth while simultaneously rotating the agar plate. The bacteria were 
grown over night at 37 °C. Bacterial colonies grown on LB agar plates could be stored up 
to 4 weeks at 4 °C. 
 
3.3.3 Bacteria liquid culture 
In order to prepare a liquid culture of bacteria, ampicillin was added to 5 ml of LB medium 
in a 15 ml centrifugation tube to a final concentration of 100 µg/ml. A single bacteria 
colony, picked from an LB agar plate using a sterile pipette tip, was resuspended in the LB 
medium. The bacterial suspension was grown under shaking and sufficient oxygen supply 
over night at 37 °C.  
 
3.3.4 Long time storage of bacterial strains 
Bacterial glycerol stock solutions were made for long time storage of generated plasmids. 
Stock solutions were prepared by mixing 600 µl of fresh bacterial overnight culture with 




3.3.5 Transformation of bacteria by electroporation 
Transformation of plasmids into bacteria was performed by electroporation using electro-
competent One Shot® TOP10 E. coli cells (Thermo Fisher Scientific). Prior to electropo-
ration, plasmids, bacteria, and the electroporation cuvette were kept on ice. One aliquot of 
TOP10 E. coli consisted of 40 µl bacterial solution and was diluted 1:4 by adding 120 µl 
ddH2O. From this dilution, 40 µl was pipetted into an electroporation cuvette and 1 µl of 
plasmid was added. The plasmid sample was dialyzed prior to transformation in order to 
remove salts from upstream applications. Electroporation was performed using the 
Electroporator Gene Pulser II (BioRad) with the following parameters: voltage: 2.5 kV, 
capacitance: 25 µF, resistance 200 Ω. 
Immediately after the electroporation, 800 µl of pre-warmed LB medium (37°C) was added 
to the suspension. The suspension was incubated for one hour at 37°C to allow bacteria to 
recover from electroporation and to express the plasmid encoded ampicillin resistance gene 
bla. Afterwards 50 µl, 100 µl, and 200 µl of bacterial suspension were streaked on agar 
plates containing ampicillin. Ampicillin was used as the selective antibiotics. The plates 
were incubated over night at 37°C. On the next day ampicillin resistant bacterial colonies 
were used for preparation of an overnight liquid culture (chapter 3.3.3) in order to isolate 
plasmids from bacteria via chloroform extraction (see chapter 3.3.6; mini-preparation/ 
mini-prep). 
 
3.3.6 Isolation of plasmid DNA by alkaline lysis 
Small-scale isolation of plasmid DNA from bacteria was performed using alkaline lysis 




Tris-HCl, pH 8.0 50 mM 
EDTA 10 mM 
RNase A 100 µg/ml 
 





NaOH 200 mM 




Potassium acetate, pH 7.5 3 M 
 
Chloroform/ isoamyl alcohol (24:1) 
Substance Volume  
Chloroform 96 ml 
Isoamyl alcohol 4 ml 
 
Plasmid DNA was extracted from 5 ml of fresh overnight bacterial culture. After overnight 
cultivation, 5 µl of bacterial suspension was plated on a LB agar plate (chapter 3.3.2) to 
save bacteria. The remaining bacterial suspension was centrifuged at 4000 rpm for 10 min 
at room temperature. The supernatant was discarded and the pellet was resuspended in 
250 µl of resuspension buffer. The solution was transferred into a 1.5 ml reaction tube and 
250 µl of lysis buffer consisting of SDS and NaOH was added. The SDS in the lysis buffer 
acts as a detergent disrupting membranes. The sodium hydroxide in the lysis buffer 
denatures both, chromosomal and plasmid DNA. However, plasmid DNA remains stable. 
The solution was mixed by inverting the tube up to 8 times. Afterwards 350 µl of 
neutralization buffer was added to neutralize the basic pH so that DNA is able to renature. 
Due to its size this is not possible for chromosomal DNA. The potassium acetate 
precipitates the SDS along with lipids, proteins, and chromosomal DNA, whereas the 
plasmid DNA stays in solution.  
The mixture was kept on ice for about 5 min and was afterwards centrifuged at 13.000 g 
for 10 min at 4°C. The supernatant was carefully transferred into a new 1.5 ml reaction 
tube taking care not to transfer any precipitate. Five hundred µl of chloroform/ isoamyl 
alcohol mixture (24:1) was added. The solution was mixed by inverting the tube 10 times. 
The solution was centrifuged at 13 000 g for 5 min at 4 °C. This liquid-liquid extraction led 
to the generation of two liquid phases and an interphase. The upper aqueous phase 
Methods 
66 
contained the plasmid DNA, whereas remaining proteins were in the interphase. The 
aqueous phase was transferred into a new 1.5 ml reaction tube. The plasmid DNA was 
precipitated by adding 650 µl ice-cold 2-propanol. After mixing the solution by repeatedly 
inverting the tube, the solution was centrifuged at 13.000 g for 15 min at 4 °C. The 
supernatant was discarded. The plasmid DNA pellet was washed two times by adding 
800 µl of 70 % ethanol and inverting the tube until the pellet “floated” in the solution. The 
tube was centrifuged at 13.000 g for 5 min at 4°C. The ethanol was carefully removed. The 
plasmid DNA pellet was air-dried, and finally dissolved in 50 µl ddH2O. An analytical 
restriction digestion was performed to analyze the correctness and for semi-quantification 
of the obtained plasmid (chapter 3.1.9).  
 
3.3.7 Isolation of high quality plasmid DNA by solid extraction (midi prep) 
For plasmid preparation of high purity and concentration a plasmid midi-preparation (midi-
prep) was performed. A 5 ml liquid pre-culture of bacteria was prepared as described in 
chapter 3.3.3 and was shaken for 8 hours at 37°C. Thirty µl of bacteria pre-culture was 
added to 30 ml of LB medium supplemented with 100 µg/ml ampicillin. The bacteria were 
cultured over night at 37 °C on a shaking platform at 200 rpm. On the next day, the midi-
prep was performed using the Plasmid Plus Midi Kit (Qiagen) following the 
manufacturer’s instruction. After isolation, the DNA plasmid concentration was 
photometrically determined as described in chapter 3.1.8. The plasmid DNA of midi-prep 
quality was used for transient and stable transfection (see chapter 3.4.6 and 3.4.5). 
 
3.4 Mammalian cell culturing and transfection 
All work with mammalian cells was performed under sterile conditions using a biosafety 
cabinet. Surfaces and pipettes were cleaned with 70 % ethanol. According to S1 laboratory 
guidelines the complete waste was collected and sterilized prior disposal. Solid waste was 
autoclaved and liquid trash from cell culturing was treated with the disinfectant Helipur® 
(Braun) by collecting liquid waste after aspiration in a vessel filled with Helipur®. 
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3.4.1 Cell culturing conditions 
T-REx™ HEK293 cells and all stably transfected cell lines derived from them were 
cultured in DMEM supplemented with 10 % fetal bovine serum (FBS) and 1 % penicillin/ 
streptomycin solution (v/v) under 5 % CO2 and 95 % humidity at 37°C in a CO2 incubator 
BBD6220 (Thermo Fisher Scientific). When cells reached 80 % to 90 % confluence they 
were split and sub-cultured at a concentration of 1:6 in a new flask. To do so, the old 
medium was removed from the cells and the cells were resuspended in 12 ml medium from 
which 2 ml of cell suspension was pipetted into the new flask containing 15 ml of pre-
warmed (37 °C) medium. Cells with a passage 30 or lower were used in the experiments. 
 
3.4.2 Freezing mammalian cell lines   
For preservation of T-REx™ HEK293 cells and generated cell lines, cells were frozen and 
stored in liquid nitrogen at -170 °C. Cryo-medium consisting of FBS supplemented with 
10 % DMSO was prepared and pre-cooled to 4°C on ice. DMSO acts as a cryo-protective 
agent preventing formation of ice crystals, which would destroy cell membranes.  
Cells from a T75 cell culture flask with 80 % to 90 % confluence were resuspended in the 
medium contained in the flask. The cell suspension was transferred into a 50 ml 
centrifugation tube and centrifuged at 300 g for 3 min at room temperature. The 
supernatant was removed and the cell pellet was carefully resuspended in 7.2 ml ice-cold 
cryo-medium and aliquoted into four cryo-tubes each containing 1.8 ml of cell suspension. 
Cryo-tubes were placed on an ice-water vessel containing ice, water, and sodium chloride 
for one hour. Afterwards, cells were stored at -80 °C for a week before they were 
transferred to a liquid nitrogen tank for long time preservation.  
 
3.4.3 Thawing mammalian cell lines  
To thaw cells that are stored in liquid nitrogen, a cryo- tube containing the cells was slewed 
for 2 min in a water bath (37 °C). Because DMSO is toxic to the cells the thawed cell 
suspension was immediately diluted in 10 ml of pre-warmed cell culture medium. The cell 
suspension was centrifuged at 300 g for 3 min at room temperature. The supernatant was 
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discarded and the cell pellet was carefully resuspended with 6 ml of pre-warmed cell 
culture medium. The cell suspension was transferred into a T25 cell culture flask. After one 
day of culturing, the cell culture medium was changed. To do so, the old medium was 
aspirated and 6 ml of fresh pre-warmed cell culture medium was carefully pipetted to the 
cells. As soon as the cells reached up to 80 % confluence, they were transferred into a T75 
cell culture flask.  
 
3.4.4 Determination of cell count 
For plating the exact number of cells for chapter 3.4.5, 3.4.6, 3.5.5, and 3.6, the cell count 
was determined using the Neubauer chamber. The medium from a cell culture flask was 
removed and 3.5 ml of trypsin (TrypLE™ Express) was added and the flask was incubated 
for 4 min in the CO2 incubator. The reaction was stopped by adding 10 ml of medium and 
the cell suspension was transferred to a 50 ml centrifugation tube, which was centrifuged at 
300 g for 3 min at room temperature. The supernatant was discarded and the cell pellet was 
resuspended in 12 ml medium. For cell counting, 20 µl of cell suspension was mixed with 
40 µl of 0.4 % trypan blue solution and 20 µl medium in a 1.5 ml reaction tube and 10 µl 
of this suspension was applied on a Neubauer chamber. After counting the cells in four big 
squares, the cell concentration was determined as follows: 
 
Number of cells/ml =




The chamber factor for the Neubauer chamber used was 104 (each square has an area of 
0.01 cm2 and a depth of 0.1 mm, which results in a volume per square of 0.1 µl). The 




3.4.5 Stable transfection of T-REx™ 293 cells 
Stable transfection of T-REx™ 293 cells was achieved through targeted chromosomal 
integration of the expression plasmid pcDNA5. For this purpose, the Flp/ FRT 
recombination site specific system was used and FuGENE® 6 (Promega) was used as the 
transfection agent. 
The genetically modified T-REx™ 293 cells carry a FRT site in their genome. The FRT 
site is also present in the expression vector pcDNA5. These artificially introduced FRT 
sites are the target sequences for the Flp recombinase, which is encoded by the helper 
plasmid pOG44. The Flp recombinase mediates the DNA recombination and therefore 
leads to the integration of pcDNA5 into the genome of T-REx™ 293 cells. Figure 3.2 
schematically shows the principle of the integration of pcDNA5 into the genome of T-
REx™ 293 cells. 
The stable transfection was carried out as follows: 1 x 106 T-REx™ 293 cells were plated 
per well on a 6 well plate. The plate should not be pre-coated with poly D-lysine. The cells 
were incubated for 24 hours. On the day of transfection, 100 µl of DMEM w/o 
supplements was added to a 1.5 ml reaction tube and 400 ng of plasmid DNA and 3.6 µg of 
the helper plasmid pOG44 (both in midi-prep quality) was added. In another 1.5 ml 
reaction tube containing 100 µl pure DMEM and 12 µl FuGENE® 6 were added. After 
5 min pre-incubation at room temperature the content of both tubes was mixed with each 
other by pipetting up and down five times. The mixture was incubated for 15 min at room 
temperature. Meanwhile the cells were washed once with 2 ml DMEM containing 10 % 
FBS (v/v) and 2 ml DMEM with 10 % FBS (v/v) was pipetted to the cells and they were 
placed back in the CO2 incubator. After 15 min incubation was over, 200 µl of the DNA - 
FuGENE® 6 - reaction mixture was pipetted dropwise to the cells and the cells were 
incubated overnight in the CO2 incubator. One day after transfection, the medium was 
changed to DMEM medium with 10 % FBS (v/v) and 1 % penicillin/ streptomycin (v/v).  
Two days after transfection, cells were transferred from the 6 well plate to a 100 mm Petri 
dish. Therefore the medium from the 6 well plate was removed and the cells were detached 
from the plate with 2 ml cell culture medium and transferred to a 100 mm Petri dish 
containing 18 ml cell culture medium. The cells were distributed by gently shaking the 
Petri dish left to right, back and forth. The cells were incubated overnight in the CO2 
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incubator. On the third day after transfection, 120 µl of 50 mg/ml hygromycin B solution 
(final concentration 300 µg/ml) was added to the cells dropwise. Hygromycin B acted as 
the selective antibiotic as just successfully stable transfected T-REx™ 293 cells expressed 
the hygromycin B resistance gene, which was encoded by the expression plasmid pcDNA5. 
The DMEM medium with 10 % FBS (v/v), 1 % penicillin/ streptomycin (v/v), and 
300 µg/ml hygromycin B was renewed four days after adding hygromycin B for the first 
time. Ten days after adding hygromycin B for the first time, single cell colonies appeared. 
Up to 24 colonies were selected and transferred to a 12 well plate containing 2 ml of 
DMEM medium with 10 % FBS (v/v), 1 % penicillin/ streptomycin (v/v), and 100 µg/ml 
hygromycin B per well. Cells were grown in the 12 well plate until they reached 80 % to 
90 % confluence and were then transferred to a 6 well plate. Cells were grown in a 6 well 
plate until they reached 80 % to 90 % confluence and were then transferred to a T25 cell 
culture flask.  
As soon as the cells needed to be passaged for the first time to a new T25 cell culture flask, 
samples for DNA and RNA isolation were taken as described in chapter 3.1.7 and 3.2.1. 
These samples were used for validation of the generated stable transfected T-REx™ 293 
cells (for details se chapter 3.1.6, 3.2.2, and 3.2.3). Eight to 10 clones were used for 
validation.  
 
3.4.6 Transient transfection of T-REx™ 293 cells 
Transient transfection introduces plasmid DNA into T-REx™ 293 cells without integration 
into the genome of the cells. Hence, the genetic information is not passed to the next 
generation after cell division and the plasmid molecules are diluted out. In contrast to the 
generation of stable transfected T-REx™ 293 cells (chapter 3.4.5.), transfient transfection 
is a time sparing method to overexpress a gene of interest in T-REx™ 293 cells and to 
analyze its function. 
For transient transfection the Lipofectamine® 2000 (Thermo Fisher Scientific) reagent was 
used. The principle of this reagent is that it consists of lipids, which form liposomes and 
thereby include the plasmid DNA. The liposomes fuse with the plasma membrane of T-
REx™ 293 cells and thereby release the plasmid DNA into the cytosol of the cells. For 
transient transfection plasmid DNA of midi-prep quality was used (chapter 3.3.7).  
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Five hundred thousand cells per well were plated on poly D-lysine pre-coated 12 well 
plates. For coating the plates, 500 µl of 0.2 % poly D-lysine solution was pipetted into each 
well and incubated for 30 min at 37 °C in a CO2 incubator. Afterwards the poly D-lysine 
was removed and the plates were dried under the biosafety cabinet. The cells were plated 
and grown over night.  
For transient transfection, the reaction per well was performed as follows: 100 µl of 
DMEM medium (without serum and antibiotics) was mixed with 5 µl Lipofectamine® 
2000 reagent. The mixture was incubated for 5 min at room temperature. Afterwards, 2 µg 
of plasmid DNA was added and the mixture was incubated for 20 min at room temperature. 
Meanwhile the cells were washed with 1 ml DMEM medium containing 10 % FBS (v/v). 
After washing the cells, 900 µl of DMEM medium containing 10 % FBS (v/v) was added 
to the cells and the cells were placed back in the CO2 incubator until the end of incubation 
time. After 20 min, 100 µl of DMEM- Lipofectamine® 2000-DNA mixture was added 
dropwise to the cells. After 6 h the medium was changed to DMEM supplemented with 
10 % FBS (v/v) and 1 % penicillin/ streptomycin solution (v/v). 
The cells were cultured for 48 h before to be used for transport experiments (chapter 3.4.6). 
 
3.4.7 Generation of stable transfected cell lines  
For the generation of HEK293 cells stably or transiently transfected to overexpress OCT1 
variants, point mutations were introduced into pcDNA3.1 plasmids by site-directed 
mutagenesis (chapter 3.1.5). After site-directed mutagenesis, PCR products were digested 
with DpnI, dialyzed (chapter 3.1.12), and transformed into E.coli by electroporation 
(chapter 3.3.5). After plasmids were isolated from bacteria by alkaline lysis (chapter 3.3.6), 
an analytical restriction digest was performed with EcoRV and HindIII (chapter 3.1.9) in 
order to verify plasmid preparation. The correctness of OCT1 variants from overexpressing 
plasmids was verified with capillary sequencing (chapter 3.1.3). According to this 
procedure, pcDNA3.1 plasmids have been generated as listed in Table 2.5. 
The mutated OCT1 genes were re-cloned into pcDNA5 (chapter 3.1.11). Therefore a 
preparative restriction digestion (chapter 3.1.10) was performed using EcoRV and HindIII 
and cutting both, the mutated pcDNA3.1 plasmid carrying OCT1 and the pcDNA5 
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plasmid. The DNA fragments were separated on a gel by electrophoresis (chapter 3.1.1) 
and the respective DNA fragments were extracted from the gel (chapter 3.1.2). The 
mutated OCT1 genes were re-cloned in pcDNA5 (chapter 3.1.11). After ligation the 
plasmids were dialyzed (chapter 3.1.12). Finally, the generated pcDNA5 plasmids were 
transformed into E.coli by electroporation (chapter 3.3.5). Plasmids were isolated from 
bacteria by alkaline lysis followed by chloroform extraction (chapter 3.3.6). In order verify 
successful re-cloning analytical restriction digests were performed with PstI, EcoRI, SalI, 
or EcoRV in combination HindIII (chapter 3.1.9). The correctness of OCT1 variants from 
overexpressing plasmids was verified with capillary sequencing (chapter 3.1.3). According 
to this procedure, pcDNA5 plasmids were generated as listed in Table 2.6 and used for 
transfection (chapter 3.4.5 and 3.4.6). For transfection, pcDNA5 plasmids of high quality 
preparation (midi prep, chapter 3.3.7) were used. According to this procedure, HEK293 
cell lines were generated as listed in chapter 2.10. From each generated mutation, two 
clones have been saved and the validation of the respective clone, which was used for 





Figure 3.2 Schematical representation of the generation of stably transfected HEK293 cell lines. Using 
site-directed mutagenesis PCR, single nucleotide exchanges were introduced in OCT1 leading to non-
synonymous amino acid exchanges (mutation indicated in green). After preparative restriction digest of 
pcDNA3.1::hOCT1 and pcDNA5 using EcoRV and HindIII, the fragment of OCT1 was re-cloned into the 
expression plasmid pcDNA5. For integration of pDNA5 in the genome of HEK293 at the FRT site, the Flp 
recombinase was used, which is encoded by the helper plasmid pOG44. The Flp recombinase recognizes the 
FRT site, which is present in the expression plasmid pcDNA5 and in the genome of T-REx™ 293 cells 
(shown in dark blue). Via DNA recombination the expression plasmid is stably integrated at the FRT site of 




3.5 Protein analyses 
3.5.1 Determination of protein concentration  
The bicinchoninic acid (BCA) assay was performed to determine the protein concentration 
of cell lysates. This colorimetric method was first described by Smith et al. (Smith et al., 
1985). It is based on the reduction of Cu2+ ions to Cu+ by peptide bonds. This reaction is 
proportional to the amount of protein in the sample. After reduction, two molecules of 
bicinchoninic acid chelate a Cu+ ion and form a purple-colored product whose absorption 
can be measured at a wavelength of 570 nm. 
To obtain whole cell protein lysates, cells were lysed in RIPA buffer. Cell debris were 
removed by centrifugation at 16500 g for 10 min and the supernatant was transferred to a 
new 1.5 ml reaction tube. If necessary, protein samples were diluted in ddH2O. The linear 




Tris HCl pH 7.4 50 mM 
NaCl 150 mM 
EDTA 1 mM 
NP-40 1 % (v/v) 
Sodium deoxycholate 0.25 % (w/v) 
SDS 0.1 % (w/v) 
 
BCA reaction solution 
Substance Amount 
BCA 50 parts 




The BCA assay was performed in a 96 well plate. Five µl of protein sample was pipetted in 
triplicates into separate wells. To determine protein concentration a standard curve with 
increasing amounts of BSA (0 µg, 1 µg, 3 µg, 5 µg, 10 µg, and 15 µg) was used. A 
standard BCA solution with a concentration of 1 mg/ ml BSA dissolved in water was used. 
Two hundred µl of a BCA reaction solution was added to each. The BCA reaction solution 
was prepared by adding 1 part of a 4% copper sulfate pentahydrate solution (v/v) to 50 
parts of BCA.  
The reaction was incubated for 30 min at 37 °C. The absorbance at 570 nm was measured 
using the Tecan Ultra Microplate Reader.  
 
3.5.2 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
The separation of proteins in an electric field using a discontinuous polyacrylamide gel and 
SDS as a denaturing agent is called SDS-PAGE. SDS provides the denatured proteins with 
a constantly negative charge so that they are moving towards the anode only depending on 
the difference in their size but not in their charge. The discontinuous gel is made of a 
stacking gel, a low concentrated gel, which concentrates the loaded protein sample to a 
tight band, and a resolution gel a higher concentrated gel, which separates the proteins 
according to their size. Bigger proteins move slower in the polyacrylamide gel matrix than 
smaller proteins.  
The stacking gel and the resolution gel were made as follows:  
 
Stacking gel, 4 % 
Substance Volume [µl] 
ddH2O 1625 
1.5 M Tris HCl, pH 8.8  625 
10 % SDS 25 
40 % Acrylamide 250 





Resolution gel, 12 % 
Substance Volume [µl] 
ddH2O 2180 
1.5 M Tris HCl, pH 8.8  1250 
10 % SDS 50 
40 % Acrylamide 1500 
10 % APS 25 
TEMED 2.5 
 
4 x Sample buffer* 
Substance Concentration 
Tris HCl, pH 6.8 240 mM 
DTT 400 mM 
Bromphenol blue 0.008 % (w/v) 
Glycerol 28 % (v/v) 
SDS 8 % (w/v) 
ddH2O Add 25 ml* 




Tris HCl, pH 8.4 25 mM 
Glycine 19.2 mM 
SDS 0.1 % (w/v) 




Tris HCl, pH 8.3 25 mM 
Glycine  192 mM 
Methanol 10 % (v/v) 





Roti®-Block (10x) 5 ml 
ddH2O 45 ml 
 
Total cell lysates were analyzed. Approximately 2 mio cells were lysed in RIPA buffer 
supplemented with 1 mM phenylmethanesulfonylfluoride (PMSF) and Halt™ Protease 
Inhibitor Cocktail (Thermo Fisher Scientific). 
The cells were lysed by incubation on ice for 30 min with pulse-vortexing every 5 min. 
Cellular debris were removed by centrifugation at 13 000 g for 10 min at 4 °C and the 
supernatant containing the proteins was transferred to a new 1.5 ml reaction tube. The 
protein concentration of cell lysates was determined using BCA assay (chapter 3.5). 
Protein samples were prepared for SDS-PAGE by adding 5 µl of 4 x sample buffer to 15 µl 
of protein sample. The proteins were denatured by incubating the samples at 95 °C for 
5 min. Afterwards, protein samples were immediately stored on ice. For analysis, 10 µg of 
total protein was applied to the gel and 5 µl of SeeBlue® Plus2 Prestained Protein Standard 
(Thermo Fisher) was used as a molecular weight marker. 
Electrophoresis was performed using the Vertical Electrophoresis Chambers mighty 
small II (Amersham) filled with running buffer. The gel was run at an electric current of 
20 A until the dye front reached the boarder of the stacking gel. Then the electric current 
was increased to 35 A. The gel was run until the dye front reached the bottom of the gel. 
The gel was used for western blot analysis (chapter 3.5.3). 
 
3.5.3 Western Blot 
Western blot analysis was performed following SDS-PAGE in order to transfer electropho-
retically separated proteins to a membrane and to identify single proteins using specific 





3 Layers of thick filter paper (Nr. 2CHR) 
1 Layer of thin filter paper (Nr. 2668) 
Gel 
PVDF membrane 
1 Layer of thin filter paper 




For western blot analysis a PVDF membrane (Imobilon-P, Merck) was used, which was 
soaked for 1 min in methanol in order to activate the hydrophobic membrane. The 
methanol was removed by washing the membrane with water. Afterwards, all filters and 
the PVDF membrane were equilibrated for 10 min in transfer buffer and the blot was 
constructed as indicated above. A semi-dry blot was performed using the Fastblot B43 
(Biometra). The membrane was blotted for 1.5 h with an electric current of 50 A.  
Successful protein transfer to the membrane was verified by unspecific staining of protein 
on the membrane with Ponceau S solution. The membrane was incubated in Ponceau S 
solution for 10 min on a shaking platform. Afterwards the Ponceau S solution was removed 
by washing the membrane with water.  
To block the membrane, it was incubated in blocking buffer for 1 h at room temperature on 
a shaking platform. The primary antibodies (see chapter 2.5) were diluted in TBST 
supplemented with 5 % non-fat dry milk. The antibodies were diluted 1:400 and 1:10 000 
for anti-OCT1 and anti-GAPDH, respectively. The membrane was incubated with the 
primary antibody overnight at 4 °C. On the next day the membrane was washed with TBST 
three times for 5 min at room temperature on a shaking platform. The membranes were 
incubated for 1 h with the secondary antibody (see chapter 2.5) diluted in TBST 
supplemented with 0.5 % non-fat dry milk. The secondary antibody was a horseradish 
peroxidase-conjugated anti-mouse antibody, which was diluted 1:10 000. Afterwards the 
membrane was washed with TBST three times for 5 min at room temperature on a shaking 
platform. A final washing step was performed with TBS for 5 min at room temperature on 
a shaking platform.  
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Horseradish peroxidase activity was detected by chemiluminescence using SuperSignal® 
West Pico Kit for detecting GAPDH or SuperSignal® West Femto Kit for OCT1 (both 
Thermo Fisher Scientific) for detecting OCT1 according to the manufacturer’s instructions. 
The signal was visualized using the VersaDocTM imaging system with Quantity One 
software v4.6.7 (BioRad). 
10 x TBS* 
Substance Concentration 
Tris HCl, pH 7.6 200 mM 
NaCl 1.5 M 
ddH2O Add 1 l 
*to get 1 x TBS dilute 1:10 in ddH2O 
 
1 x TBST 
Substance Concentration 
Tris HCl, pH 7.6 20 mM 
NaCl 150 mM 
Tween 20 0.1 % (v/v) 
ddH2O Add 1 l 
 
3.5.4 Deglycosylation with PNGase F and Endo H 
The glycosidases Peptid-N-Glykosidase F (PNGaseF) and Endo-β-N-acetylglucose-
aminidase H (Endo H, both New England Biolabs) were to identify and analyze glycosyla-
tion of proteins. PNGaseF cleaves between the innermost N-acetylglucosamine and 
asparagine residues of high mannose and complex oligosaccharides from N-linked 
glycoproteins. Endo H cleaves within the chitobiose core of high mannose and some hybrid 
oligosaccharides from N-linked glycoproteins (reviewed in (Maley et al., 1989)).  
Protein samples prepared as described in chapter 3.5.2 were glycosylated following the 
manufacturer’s instructions of New England Biolabs. Briefly, 22 µg of total protein was 
denatured by incubation for 5 min at 95 °C in sample buffer for SDS PAGE (chapter 
3.5.2). For deglycosylation with Endo H, 1250 units Endo H and sodium citrate to a final 
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concentration of 50 mM were added. For deglycosylation with PNGase F, 500 units 
PNGaseF, NP-40 and sodium citrate were added to a final concentration of 1 % and 
50 mM, respectively. The reactions were incubated for 1 hour at 37 °C. The deglycosylated 
samples were directly applied to SDS-PAGE and were analyzed by western blotting (see 
chapter 3.5.2 and 3.5.3). 
 
3.5.5 Immunostaining  
 
10 x Blocking buffer 
Substance Concentration 
FBS 5 % (v/v) 
BSA 1% (w/v) 
Triton X-100 0.5 % (v/v) 
PBS Add 50 ml 
 
Immunostaining using fluorescent labeled secondary antibodies was performed followed 
by visualization with confocal microscopy. The method was used to analyze cellular 
localization of the protein of interest in detail. 
For immunostaining 0.2 x 106 cells were plated on a poly D-lysine pre-coated chamber 
slide (Lab-Tek®II Chamber Slide, Thermo Fisher). To do so, the cells were trypsinized and 
counted. The cells were passed through a 40 µm strainer (BD Falcon), plated and cultured 
overnight in a CO2 incubator.  
The staining was performed as follows: Cells were washed once with 1 ml sterile PBS. 
Afterwards 1 ml of Roti®-Histofix, a 4 % formaldehyde solution, was added and incubated 
for 20 min at room temperature to fix the cells. The fixed cells were washed twice with 
PBS and permeabilized with 1 ml of 1 x blocking buffer (10 x blocking buffer diluted 1:10 
with PBS) for 15 min at room temperature.  
The blocking buffer was removed and the cells were incubated with the primary antibody. 
The primary antibodies and dilution factors used are listed in chapter 2.5. Dilution was 
performed with 1x blocking buffer. Calnexin was used as a marker for the endoplasmic 
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reticulum and Na+/K+ ATPase was used as marker for the plasma membrane. The cells 
were incubated with 200 µl of primary antibody dilution for 1 h at room temperature on a 
shaking platform. Afterwards, cells were washed three times with 1 ml of 1 x blocking 
buffer for 5 min at room temperature on a shaking platform. After that, the cells were 
incubated with the secondary antibodies Alexa Fluor® 488 goat anti-mouse, or Alexa 
Fluor® 546 goat anti-rabbit IgG, both diluted 1:500 in 1 x blocking buffer. The cells were 
simultaneously stained with DAPI, a fluorescent DNA-binding dye, which was used to 
stain the cell nucleus. DAPI was diluted 1:2000 in 1x blocking buffer. The cells were 
incubated with 200 µl of secondary antibody dilution and DAPI dilution for 1 h at room 
temperature on a shaking platform protected from light. Afterwards, the cells were washed 
three times with 1 ml of 1 x blocking buffer for 5 min at room temperature on a shaking 
platform. A final washing step was performed with 1 ml PBS for 5 min at room 
temperature on a shaking platform. In order to avoid fading of the fluorescent dyes, the 
samples were protected from light during all washing steps. Finally the cells were mounted 
with Fluoromount-G™.  
The samples were analyzed using the laser scanning microscope LSM 710 and images 
were processed using ImageJ software v. 1.47 for additional contrast adjustment for each 
channel. 
 
3.6 Transport experiments 
To analyze transport activity of OCT1 and its variants, uptake measurements were 
performed using the OCT1 model substrates MPP+, TEA+, and ASP+, the drugs morphine, 
metformin, tropisetron, O-desmethyltramadol, debrisoquine, sumatriptan, fenoterol, and 
proguanil, and the exogenous substance tyramine. The intracellular accumulation of the 
substrates was quantified using scintillation counting (MPP+, TEA+, morphine, metformin, 
tyramine), fluorescence measurement (ASP+), HPLC (debrisoquine, O-desmethyltrama-
dol), or LC-MS/MS (sumatriptan, proguanil, fenoterol, metformin). Details about the 
different quantification methods are described in the chapter 3.6.1, 3.6.2, 3.6.3, and 3.6.4. 
For data analysis a standard curve was run in the same experiment (see Table 3.3) and the 
intracellularly accumulated substrate was normalized to the total amount of protein as 
determined by BCA assay (chapter 3.5). Using concentration dependent uptake 
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measurements, the Km and vmax values of substrates were calculated by non-linear regres-
sion and Michaelis Menten equation using Graph Pad Prism v5.01. 
 
Table 3.3 Linear range of substrates used for uptake measurements 
Substrate Detection method Linear range 
Debrisoquine HPLC 0.03 µM – 2.825 µM 
Fenoterol LC-MS/MS 2*10-4 µM – 2 µM 
Metformin Scintillation counting 5*10-5 µM – 0.5 µM 
Metformin LC-MS/MS 0.2 µM – 30 µM 
Morphine Scintillation counting 10-5 µM – 1 µM 
MPP+ Scintillation counting 10-4 µM – 1 µM 
O-Desmethyltramadol LC-MS/MS 0.002 µM – 0.3 µM  
Proguanil LC-MS/MS 0.001 µM – 1 µM 
Sumatriptan LC-MS/MS 0.01 µM – 5 µM 
TEA+ Scintillation counting 10-5 µM – 0.5 µM 
Tropisetron HPLC 0.07 µM – 3.515 µM 
 
To this end, 0.6 x 106 cells or 9 x 106 cells were plated per well of a 12 well plates or on a 
Petri dish, respectively. The plates and Petri dishes have been pre-coated with poly D-
lysine. For coating the plates, 500 µl or 4 ml of 0.2% poly D-lysine solution was pipetted 
into each well of a 12 well plat or a Petri dish, respectively. The poly D-lysine was 
incubated for 30 min at 37 °C in a CO2 incubator. Afterwards the poly D-lysine was 
removed and the plates were dried under the biosafety cabinet. Cells were trypsinized and 
counted as described in chapter 3.4.4. The plated cells were cultured in a CO2 incubator for 
48 h prior to transport experiments. For transport experiments, HBSS supplemented with 
10 mM HEPES (pH 7.4, further referred to as HBSS+) was used for washing steps and 
substrate dilutions. The pH of HBSS+ was adjusted to 7.4-7.6 with HCl individually before 
the transport experiment. 
For uptake measurements performed in 12 well plates, the experiment was performed as 
follows: The 12 well plates was placed on a heating plate (37° C). Starting the experiment, 
the medium was removed and the cells were washed once with 2 ml pre-warmed HBSS+ 
(37° C). The uptake reaction was started by adding 400 µl of substrate solution and the 
substrate solution was incubated for 2 min (MPP+, TEA+, morphine, metformin, tyramine, 
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sumatriptan, proguanil, fenoterol) or 1 min (O-desmethlytramadol). The uptake was 
stopped after 2 min or 1 min by adding 2 ml of ice-cold HBSS+ (4°C) and taking the plate 
off the heating plate. The cells were washed twice with 2 ml ice-cold HBSS+. For 
scintillation counting, the cells were lysed in 500 µl of 0.1 N NaOH containing 0.1 % SDS. 
For fluorescent measurement, cells were lysed with 500 µl of RIPA buffer (chapter 3.5). 
For LC-MS/MS detection, the samples for protein quantification were lysed in 500 µl of 
RIPA buffer and the samples for LC-MS/MS detection were lysed in lysis buffer 
containing 80 % acetonitrile and the respective internal standard (see chapter 3.6.4). 
For uptake measurements performed in Petri dishes, the experiment was performed as 
follows: Starting the experiment, the medium was removed from the plates and the cells 
were washed with 10 ml pre-warmed HBSS+ (37 °C). The uptake reaction was started by 
adding 5 ml of substrate diluted in HBSS+ (37 °C). The reaction was stopped by adding 
20 ml ice-cold HBSS+ (4 °C) after 3 min for tropisetron and after 1 min for debrisoquine. 
The cells were washed once with 20 ml of ice-cold HBSS+. Afterwards, 2 ml of ice-cold 
HBSS+ was added to the plates. With a cell scraper the cells were scraped into solution and 
transferred to a 2 ml reaction tube. The sample of this tube was used for HPLC analysis. 
From the 2 ml cell suspension, 500 µl were transferred to a 1.5 ml reaction tube. This 
aliquot was used to determine the protein concentration of the sample. Both tubes were 
centrifuged at 300 g for 10 min at 4 °C. The supernatant was discarded. The cell pellet of 
the 1.5 ml reaction tube used for protein quantification was lysed in 500 µl of 0.1 N NaOH 
containing 0.1 % SDS and protein concentration was determined using BCA assay as 
described in chapter 3.5. The cell pellet of the 2 ml reaction tube containing the sample for 
HPLC analysis was lysed in 1 ml of lysis buffer for HPLC analysis (see chapter 3.6.3) 
 
3.6.1 Scintillation counting 
The intracellular accumulation of MPP+ and TEA+ as well as of morphine, metformin, and 
tyramine was quantified using scintillation counting. The substrates were either labeled 
with 3H (MPP+) or with 14C (TEA+, morphine, metformin, and tyramine). 
The transport experiments were performed using 12 well plates as described above. 
Finally, 400 µl of the cell lysate was transferred to a 20 ml poly-vial and mixed with 9 ml 
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Aquasafe 500+ liquid scintillator. The intracellular accumulated substrate was quantified 
using a liquid scintillation counter (LS6500).  
 
3.6.2 Fluorescence measurement 
The amount of intracellular accumulated ASP+ was determined by measuring the fluores-
cence. The transport experiments were performed using 12 well plates as described above. 
Finally, cells were lysed in RIPA buffer and were incubated for 10 min at room 
temperature on a shaking platform at 50 rpm. The plate was centrifuged at 700 rpm for 
10 min at room temperature. The supernatant was used for fluorescence measurement and 
to determine protein concentration. For fluorescent measurements, 200 µl of the sample 
was transferred to a well of a black 96 well microplate (Corning®). Each sample was 
measured in duplicates. The fluorescence was measured using the Tecan Ultra Microplate 
Reader with the following parameter settings: 
• Excitation wavelength: 485 nm 
• Emission wavelength: 612 nm 
• Gain: 501 or 452 
• Number of flashes: 10 
• Lag time: 0 
• Integration time: 40 
• Mirror selection: Automatic 
• Plate definition file: COS96fb.pdf 
• Multiple Reads per well: 2 x 2 
• Z-position3: e.g. 7165 µm 
1…Gain of 50 was used for samples of uptake measurements performed at single concentrations 
2… Gain of 45was used for samples from concentration dependent uptake measurements  






Lysis buffer for tropisetron 
Substance Volume 
Acetonitrile  40 ml 
50 mM NaH2PO4, pH 5 10 ml 
Internal standard : 1 ng/µl ondansetron 500 µl 
 
Mobile phase for tropisetron 
Substance Concentration 
Acetonitrile 20 % 
50 mM NaH2PO4, pH 5 80 % 
 
Lysis buffer for debrisoquine 
Substance Volume 
Acetonitrile  40 ml 
50 mM Sodium acetate, pH 5 10 ml 
Internal standard: 1 ng/µl venlaflaxine 500 µl 
 
Mobile phase for debrisoquine  
Substance Concentration 
Acetonitrile 5 % 
50 mM Sodium acetate, pH 5 95 % 
 
The amount of intracellularly accumulated tropisetron and debrisoquine was quantified 
using HPLC as described previously (Saadatmand et al., 2012; Tzvetkov et al., 2012). The 
experiments were performed using poly D-lysine pre-coated 100 mm Petri dishes with 
9 x 106 plated cells cultured for 48 h. The experiment was performed as described above.  
Finally, the cell lysate was centrifuged at 13 000 rpm for 10 min at 4 °C to remove cell 
debris. The supernatant was transferred into a 10 ml glass tube and evaporated to dryness 
under nitrogen stream at 40 °C. The pellet was reconstituted in 200 µl of mobile phase and 
Methods 
86 
the amount of intracellular accumulated substrate was analyzed using HPLC (Saadatmand 
et al., 2012; Tzvetkov et al., 2012). Briefly, the LaChrome HPLC system with interface D-
7000, pump L-7100, autosampler L-7200, degasser L-7614, an ultraviolet detector - L-
7400 and fluorescence detector L-7400 were used for tropisetron and debrisoquine 
detection. Tropisetron was detected by ultraviolet detection at 284 nm. Fluorescence 
detection for debrisoquine was performed using an excitation wavelength of 210 nm and 
emission wavelength of 290 nm. The retention times of the substrate peaks and peaks of 
the internal standard are listed below. The area under the peak was used for quantification 
using external standardization. 
 
Retention times 








The intracellular accumulation of O-desmethyltramadol, proguanil, sumatriptan, and 
metformin was quantified using LC-MS/MS analysis. The uptake of O-desmethyltramadol 
was measured for 1 min, and the uptake of proguanil, sumatriptan, and metformin was 
measured for 2 min. 
The transport experiment was performed in 12 well plates as described above. Finally, 
samples for LC-MS/MS detection were lysed in 500 µl of lysis buffer containing 80 % 
acetonitrile with the appropriate internal standard (see Table 3.4). Cell debris were 
removed by centrifugation at 16 500 g for 15 min and 400 µl of the supernatant was 
transferred to a new 1.5 ml reaction tube. Samples for detection of metformin, sumatriptan, 
and fenoterol were diluted 1:200, 1:10, and 1:8 in 0.1 % of formic acid, respectively. 
Samples for detection of O-desmethyltramadol and proguanil were evaporated as follows: 
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300 µl of lysate was transferred to a 10 ml glass tube and evaporated to dryness under 
nitrogen flow at 40 °C. The pellets for detection of O-desmethyltramadol or proguanil were 
reconstituted in 150 µl and 300 µl of 0.1 % formic acid, respectively.  
Ten µl of the samples were used for analysis. HPLC was performed using a High Pressure 
Liquid Chromatographer Series 200 (Perkin Elmer, Rodgau, Germany) coupled with an 
API 4000 tandem mass spectrometer (Life Technology). For separation a Brownlee SPP 
RP-Amide column (4.6 x 100 mm inner dimension, 2.7 µm particle size; Perkin Elmer) 
with a SecurityGuard C18pre-column (4x2mm; Phenomenex) was used. Substrate peaks 
were detected using substrate-specific mass transitions and retention times (see Table 3.4). 
The area under the peak was used for quantification using a standard curve run in the same 
experiment. 
 
Table 3.4 Substrate-specific experimental conditions using LC-MS/MS 
Substance Mass [Da] 
RT 
[min] 



























































Table 3.5 MS detection parameters 






Metformin 130.0>71.0 40.0 35.0 10.0 12.0 30.0 50.0 60.0 450.0 5500.0 
Burformin 158.0>60.0 40.0 35.0 10.0 12.0 30.0 50.0 60.0 450.0 5500.0 
Proguanil 254.2>170.2 75.0 24.0 3.0 8.0 34.0 55.0 60.0 500.0 5500.0 
Proguanil-d6 260.31>170.2 75.0 25.0 10.0 8.0 34.0 55.0 60.0 500.0 5500.0 
Sumatriptan 296.2>58.2 50.0 30.0 12.0 9.0 25.0 50.0 50.0 450.0 5500.0 
Sumatriptan-
d6 
302.2>64.2 70.0 30.0 12.0 9.0 25.0 50.0 50.0 450.0 5500.0 
O-desme-
thyltramadol 
250.20>58.1 120.0 25.0 10.0 10.0 25.0 50.0 50.0 450.0 5500.0 
Atropine 290.2>142.2 100.0 45.0 12.0 10.0 25.0 50.0 50.0 450.0 5500.0 
Fenoterol 304.1>107.1 70.0 44.0 12.0 4.0 25.0 50.0 50.0 450.0 5500.0 




Statistical analyses were performed using Graph Pad Prism v5.01 and SigmaPlot v12.5. 
Analysis of variance (ANOVA) was applied for multi-group comparisons. In order to test 
two groups among the multiple-group the ANOVA testing was followed by post hoc 
analysis using Tukey’s Honestly Significant Difference (HSD) test. P-values < 0.05 were 





4.1 Functional characterization of genetic polymorphisms in the organic 
cation transporter OCT1 
OCT1 is highly genetically variable. More than 10 years ago a number of common variants 
in OCT1 were identified and data was collected over the years how these variants affect the 
uptake of different OCT1 substrates (Kerb et al., 2002; Shu et al., 2003; Tzvetkov et al., 
2016). However, those were different studies from different laboratories with partially 
contradictive results analyzing only a limited number of substrates (Shu et al., 2003; 
Gorboulev et al., 1997; Kerb et al., 2002; Tzvetkov et al., 2013). As it is known that OCT1 
is a polyspecific transporter, which binds a broad range of structurally different substances, 
substrate-specific differences of different OCT1 variants could be kept undetected. 
Furthermore, using high-throughput massive parallel sequencing of 1079 worldwide DNA 
samples, our group recently identified common and rare single nucleotide polymorphisms 
that lead to a change in the amino acid sequence of OCT1 (Figure 1.2) (Seitz et al., 2015). 
The aim of this part of the thesis was the systematic functional characterization of these 
variants on a broad spectrum of known structurally diverse OCT1 substrates that enables 
comparison of their effects.  
 
4.1.1 Generation and validation of cell lines used to analyze non-synonymous 
substitutions in OCT1 
To this end, HEK293 cells were stably transfected to overexpress the following OCT1 
variants: S14F, S29L, P117L, S189L, R206C/M408V/M420del, T245M, E284K, M408V, 
G414A, G414A/M408V/M420del, M408V/M420del, and I449T. We used these cells 
together with the eight existing cell lines (overexpressing the variants R61C, 
C88R/M420del, F160L, P341L/M408V, G401S, G465R/M420del, R488M, and 
R488M/M408V) to measure the uptake of eight OCT1 substrates and to determine their 
subcellular localization.  
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In order to generate the HEK293 cells overexpressing different allelic variants of OCT1, 
point mutations were introduced via site-directed mutagenesis. Ten mutated pcDNA3.1 
plasmid constructs have been generated (Table 4.1).  
 
Table 4.1 Generated pcDNA3.1 plasmids with point mutations in OCT1 for the analysis of non-
synonymous substitutions in OCT1 












1 generated by Ali Reza Saadatmand, Institute of Clinical Pharmacology, University Medical Center 
Göttingen 
2  provided by Hermann Koepsell, University of Würzburg 
3 generated by Ali Reza Saadatmand, Institute of Clinical Pharmacology, University Medical Center 
Göttingen as described elsewhere (Tzvetkov et al., 2012) 
 
Together with the plasmids pcDNA3.1::hOCT1-S14F, pcDNA3.1::hOCT1-P117L, and 
pcDNA3.1::hOCT1-S189L that were previously generated in our lab (Table 2.5), the 
mutated OCT1 genes were re-cloned in pcDNA5. The generated pcDNA5 plasmids (Table 




Table 4.2 HEK293 cell lines generated by targeted chromosomal integration for the analysis of non-















In order to validate the generated cell lines three integration-specific PCRs were performed 
(chapter 3.1.6). Therefore, eight to ten clones of each variant were selected for testing. Of 
those, two positive clones were saved. PCR 1 and PCR 2 were performed to verify 
integration of pcDNA5 into the genome of HEK293 cells and to detect the gene of interest 
within the integration site. Figure 4.1 shows the results of PCR 1 and PCR 2 of the clone 
that was used for further analyses. PCR 1 resulted in an amplification product of 519 bp. 
PCR 2 resulted in an amplification product of 1376 bp for the empty pcDNA5 vector and 




Figure 4.1 Validation of the correct integration of the constructs overexpressing different OCT1 allelic 
variants into the genome of the HEK293 cells. (A) Schematic presentation of the expression plasmid 
pcDNA5 (black) integrated into the pFRT/lacZeo site of the genome of HEK293 cells (gray). The positions 
of the primers used in PCR 1 and PCR 2 are indicated. (B) PCR 1 resulted in an amplification product of 
519 bp and PCR 2 resulted in an amplification product of about 3137 bp (wild type OCT1 or its allelic 
variants) or 1376 bp (empty pcDNA5 vector). This figure was presented in a slightly modified form in Seitz 
et al. 2015 (Seitz et al., 2015): 
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PCR 3 was performed in order to identify multiple tandem integration of the expression 
vector pcDNA5 containing OCT1 into the genome of HEK293 cells. All of the variants 
tested, except the variants C88R/M420del and T245M, were confirmed as single 
integrands, as no amplification product was obtained (Figure 4.2). The variant 
C88R/M420del was generated previously (Tzvetkov et al., 2012). 
 
  
Figure 4.2 Analysis for potential multiple tandem integration of the constructs overexpressing different 
OCT1 allelic variants into the HEK293 genome. (A) Schematic representation of double tandem 
integration of the OCT1 overexpressing pcDNA5 plasmid (black) into the pFRT/lacZeo site in the HEK293 
genome (gray). Annealing positions of the primers (PFRT_f and PHyr_r) are indicated. (B) In case of 
multiple integrands PCR 3 resulted in an amplification product of 214 bp. All variants, except 
C88R/M420del and T245M, were tested negative for multiple tandem integration. However, there were no 
obvious differences in expression levels in these clones (Figure 4.3).  
 
The correctness of OCT1 allelic variants was validated by SNaPshotTM and capillary 
sequencing. To this end, the PCR product of PCR 2 was purified and subjected either to 
SNaPshotTM genotyping or to re-sequencing. DNA samples of the following OCT1 allelic 
variants have been analyzed using SNaPshotTM genotyping: S14F, S29L, P117L, S189L, 
R206C/M408V/M420del, T245M, E284K, M408V, M420del/M408V, G414A, and I449T. 
The variant G414/M408V/M420del was validated using capillary re-sequencing analysis.  
In order to confirm equal expression levels of OCT1 and its variants in stable transfected 
HEK293 cells, a real-time PCR was performed (Figure 4.3). HEK293 cells overexpressing 
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OCT1 showed 100 % higher expression than HEK293 transfected with the empty control 
vector pcDNA5. The selected clones did not differ more than 10 % in their mRNA level 
compared to wild type OCT1. 
 
 
Figure 4.3 RT-qPCR demonstrating equal mRNA expression levels among the OCT1 allelic variants. 
The mRNA level of HEK293 cells stably transfected with OCT1 allelic variants are shown in relation to the 
levels in HEK293 cells stably transfected with wild type OCT1. The results are based on relative quantifica-
tion using the ∆∆CT method. The mRNA expression was normalized to the expression of TBP and RNA 
samples. Shown is the mean and error of the mean of three independent RNA extractions. This figure was 
presented in a slightly modified form in Seitz et al. 2015 (Seitz et al., 2015). 
 
4.1.2 Functional characterization of OCT1 allelic variants 
In order to characterize allelic variants of OCT1, the transport activity of the 15 major and 
6 minor OCT1 allelic variants was measured using 8 different substances: the model 
substrates MPP+, TEA+, ASP+, and the drugs morphine, metformin, tropisetron, O-
desmethyltramadol, and debrisoquine. The intracellular accumulation of MPP+, TEA+, 
morphine, and metformin was analyzed using scintillation counting, of ASP+ using 
fluorescence measurement and of tropisetron and debrisoquine using HPLC analysis. The 
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uptake of O-desmethyltramadol was analyzed using the LC-MS/MS method. Analyzed 
were single concentrations that were either already reported, in order to compare uptake 
activities with previous studies, or concentrations that were far below or close to the 
reported Km of the substance (Zhang et al., 1997; Takeuchi et al., 2003; Shu et al., 2007; 
Ahlin et al., 2011; Tzvetkov et al., 2011; Saadatmand et al., 2012; Tzvetkov et al., 2012; 
Tzvetkov et al., 2013; Nies et al., 2009). For details about transport measurements see 
chapter 3.6. For all substances tested the uptake was at least 1.9-fold higher in the cells 
overexpressing the wild type OCT1*1 allele compared to the control cells transfected with 
the empty vector pcDNA5 (Figure 4.4).  
 
 
Figure 4.4 Differences in the uptake between HEK293 cells stably transfected with wild type OCT1 and 
with the empty expression vector pcDNA5. Uptake is represented as fold increase of OCT1 wild type in 
comparison to pcDNA5 transfected cells. Shown is the mean and standard error of the mean of at least three 
















Figure 4.5 (previous page) Functional characterization of OCT1 allelic variants. The effects of non-
synonymous substitutions in OCT1 on transport activity were analyzed measuring the uptake of MPP+, 
TEA+, ASP+, morphine, metformin, tropisetron, O-desmethyltramadol, and debrisoquine. HEK293 cells 
transfected to overexpress OCT1 allelic variants were incubated for 2 min with 10 μM MPP+, 5 μM TEA+, 
5 μM ASP+, 1 μM morphine, or 5 μM metformin, or for 1 min with 1 μM debrisoquine or 1 μM O-
desmethyltramadol, or for 3 min with 1 μM tropisetron. The OCT1-mediated uptake was calculated by 
subtracting the uptake of HEK293 cells transfected with the empty expression vector pcDNA5 from HEK293 
cells overexpressing OCT1 allelic variants. The results are shown as a percent of the uptake in wild type 
OCT1 cells (shown in black). Shown is the mean and error of the mean of at least three independent 
experiments. (A) Shows the uptake of the eight substrates by the 15 major OCT1 alleles (designed as 
OCT1*1B, OCT1*2A-3A, OCT1*4B, OCT1*5A-6A, OCT1*7B, OCT1*8 -*15 in Figure 1.2). The results 
shown for the alleles OCT1*3, OCT1*4, OCT1*5, and OCT1*6 for the uptake of morphine and tropisetron 
are from previously published studies of our lab (Tzvetkov et al., 2011; Tzvetkov et al., 2013) and are shown 
here to enable direct comparison. The effect of allelic variants on transport activity is indicated in colors: gain 
of function variants are shown in green, variants with substrate-specific loss of activity in yellow, variants 
with strong substrate-wide decrease in light red, and variants with complete substrate-wide loss of activity in 
dark red. (B) Shows the uptake of the eight substrates by the six most common sub-alleles. The comparison 
of transport activity between the variants OCT1*7A and OCT1*7B (subfigure B) was made after transient 
transfection. All the remaining experiments were performed using stably transfected HEK293 cell lines. 
Shown is the mean and standard error of the mean of at least three independent experiments. A modified 
version of this figure has been presented by Seitz et al. (Seitz et al., 2015). 
The functional analyses identified two gain-of-function OCT1 variants: the alleles OCT1*8 
(R488M) and OCT1*9 (P117L) showed more than 50 % increase in the uptake of at least 
one substrate tested: the allele OCT1*8 showed 70 %, 52 %, and 68 % increase in the 
uptake of TEA+, morphine, and metformin, respectively. The OCT1*9 allele showed 68 % 
increase in the uptake of morphine. Most of the remaining variants tested showed loss of 
activity in OCT1 transport. These variants could be divided into three groups dependening 
on their extent of loss of function: the alleles OCT1*5 (G465R/M420del), OCT1*6 
(C88R/M420del), OCT1*12 (S29L), and OCT1*15 (E284K) showed complete loss of 
activity for all substrates tested. The alleles OCT1*3 (R61C), OCT1*4 (G401S), and 
OCT1*14 (R206C/M420del) showed strong, but not complete loss of activity for all 
substrates tested. The alleles OCT1*2 (M420del), OCT1*7 (S14F), OCT1*10 (S189L), 
OCT1*11 (I449T), and OCT1*13 (T245M) showed substrate-specific loss of activity. For 
example the OCT1*2 allele strongly decreased the uptake of TEA+, metformin, tropisetron, 
and O-desmethyltramadol by 62 %, 74 %, 89 %, and 80 %, respectively. In contrast, the 
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uptake of MPP+, morphine, and debrisoquine was only slightly decreased by 33 %, 25 %, 
and 26 %, respectively. For the uptake of ASP+, OCT1*2 decreased the uptake only by 
8 %. 
The OCT1 variants F160L, P341L, R342H, M408V, and G414A did not cause a more than 
50 % decrease or increase in OCT1 activity with any of the substrates tested (Figure 4.5 B). 
Therefore the haplotypes carrying these variants were designated as sub-alleles.  
 
4.1.3 Subcellular localization and differences in the glycosylation pattern of 
OCT1 allelic variants 
In order to a find potential reason for substrate-wide loss of activity, the subcellular 
localization of OCT1 allelic variants was analyzed. The subcellular localization was ana-
lyzed using immunofluorescence staining with confocal microscopy detection (Figure 4.6). 
In contrast to the control pcDNA5 cells, strong OCT1 signals were detected in all cells 
overexpressing different OCT1 allelic variants. However, the subcellular localization of the 
signals strongly varied among the different allelic variants. For the alleles OCT1*5, 
OCT1*6, OCT1*12 and OCT1*15, which caused complete loss of activity for all substrates 
tested (Figure 4.5), the OCT1 protein was not located in the plasma membrane (Figure 4.6 
A). This was evidenced by a missing co-staining with a Na+/K+ ATPase, which was used as 
a plasma membrane marker. For these allelic variants the OCT1 protein was detected in the 
endoplasmic reticulum. This was demonstrated by co-staining of calnexin; a marker for the 
endoplasmic reticulum. In contrast, allelic variants that caused a strong but not complete 
(OCT1*3, OCT1*4, and OCT1*14) or a substrate-specific (OCT1*2, OCT1*7, OCT1*10, 
OCT1*11, and OCT1*13) loss of activity could be detected in the plasma membrane 
(Figure 4.6 B, C). However, for the allelic variants OCT1*3 and OCT1*14 the amount of 
OCT1 seemed to be less on the plasma membrane than for wild type OCT1 cells when 
directly comparing the staining for OCT1 between these two allelic variants and OCT1 
wild type. The gain-of function variants OCT1*8 and OCT1*9 as well as the sub alleles 
OCT1*1C and OCT1*1D, which were shown not to affect transport activity (Figure 4.5 B), 
did not differ in membrane localization compared to wild type (Figure 4.5 B). Taken 
together, it could be concluded that the major reason for substrate-wide loss of activity was 
improper membrane localization of the OCT1 protein due to its retention in the 












Figure 4.6 Analysis of the subcellular localization of OCT1 allelic variants. The subcellular localization 
was analyzed using confocal microscopy after immunocytochemical staining for OCT1 (green). The exact 
subcellular localization of OCT1 was analyzed using co-staining with Na+/K+ ATPase as a marker for the 
plasma membrane (red, upper part) and calnexin as a marker for the endoplasmic reticulum (red, lower part). 
(A) Shown are the HEK293 cells overexpressing OCT1 allelic variants with complete loss of activity (labeled 
in dark red) and substrate-wide strong decrease in transport activity (labeled in light red). The allelic variants 
with complete loss of activity OCT1*5, OCT1*6, OCT*12 and OCT1*15 lack membrane localization. 
Comparison of the staining intensity suggests that OCT1*3 and OCT1*14 have partially impaired localization 
on the plasma membrane. HEK293 cells overexpressing wild type OCT1 are shown as a reference. (B) The 
membrane localization of OCT1 allelic variants that showed substrate-specific loss of activity was not altered 
(labeled in orange). Control pcDNA5 cells were negative for OCT1 staining. (C) Allelic variants that caused 
gain of OCT1 function are shown in green and variants that did not affect OCT1 activity are shown in black. 





OCT1 allelic variants were further characterized by western blot analysis of total cellular 
lysates. The OCT1-specific antibody (chapter 2.5) used for western blot analysis revealed 
two bands at 50 kDa and 70 kDa (Figure 4.7). Both bands were sensitive to 
deglycosylation (Figure 4.7). The band at 50 kDa was sensitive to both EndoH and 
PNGase F deglycosylation, while the 70 kDa band was sensitive to PNGase F only. The 
allelic variants OCT1*5, OCT1*6, OCT1*12, and OCT1*15 showed a different 
glycosylation pattern compared to the wild type as just the 50 kDa band could be detected 
by western blot analysis. All these allelic variants showed substrate-wide loss of OCT1 
activity (Figure 4.5) and lacked plasma membrane localization (Figure 4.6 A).  
 
 
Figure 4.7 Western blot analysis of OCT1 allelic variants. Western blot analysis of 10 µg total cellular 
protein illustrates differences between the glycosylation patterns of OCT1 variants retained in the 
endoplasmic reticulum (OCT1*5, OCT1*6, OCT1*12, and OCT1*15) and those correctly localized in the 
plasma membrane (the rest). OCT1 was detected using a mouse monoclonal OCT1-specific antibody (2C5) 
and was detected as a double signal of a 70 kDa PNGaseF-sensitive and EndoH-resistant protein and a 
50 kDa EndoH-sensitive glycosylated protein. As a loading control GAPDH was stained using a mouse 
monoclonal GAPDH-specific (6C5) antibody. This figure was presented in a slightly modified form in Seitz 
et al. 2015 (Seitz et al., 2015). 
 
Taken together, we observed strong variability in the effects of OCT1 allelic variants on 
transport activity. Four out of 19 allelic variants tested showed complete loss of transport 
activity due to improper membrane localization. These variants also revealed a different 
glycosylation pattern in western blot analysis. Three allelic variants led to a strong decrease 
in activity independent from the substrate tested. These allelic variants seemed to have no 
aberrant membrane localization although reduced membrane localization could be assumed 
for single variants. A substantial number of allelic variants, five out of 19, showed 
substrate-specific loss of activity. Two allelic variants could be characterized as gain of 
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function alleles, as they show a more than 50 % increase in the uptake of at least one 
substrate tested.  
 
4.2 Prediction of the allele-specific effects on morphine and metformin 
uptake using model substrates 
The allelic variants OCT1*2, OCT1*7, OCT1*10, OCT1*11, and OCT1*13 showing 
substrate-specific loss of activity were further characterized regarding the possibility to 
predict the effect of these variants on the transport of clinically relevant drugs like 
morphine and metformin using model substrates. To this end, the ability of these allelic 
variants to transport the model substrates MPP+, TEA+, and ASP+ was correlated to the 
ability to transport morphine and metformin (Figure 4.8). None of the model substrates 
tested could reflect the effect of these variants on both drugs. The uptake of morphine 
showed the strongest correlation with the uptake of ASP+ (r2= 0.7, P=0.036). In contrast, 
the uptake of metformin correlated better with the uptake of TEA+ (r2=0.84, P=0.0058). 
These results underline again the substrate-specific effects of the number of loss of 
function alleles including the most common one, OCT1*2. The generalized prediction of 
the effects of these variants is not possible and a better understanding of the mechanisms of 




Figure 4.8 Correlation between the effects of the substrate-specific loss-of-function OCT1 allelic 
variants on the uptake of model substrates and the drugs morphine and metformin. The effect of the 
alleles OCT1*2, OCT1*7, OCT1*10, OCT1*11, and OCT1*13 on the transport of the model substrates 
MPP+, TEA+, and ASP+ was correlated to the effect on the transport of morphine and metformin. Shown are 
mean and standard error of the mean of at least three independent uptake measurements. Solid lines represent 
calculated linear regression curves; dashed lines represent an optimal theoretical correlation with identical 
effects of the allelic variants on the model substrates and drugs. * denotes significant correlation (P <0.05). 
This figure was presented in a slightly modified form in Seitz et al. 2015 (Seitz et al., 2015). 
 
4.3 Interaction of M420del with other naturally occurring non-
synonymous polymorphisms in OCT1 
Recently, the M420del-M408 haplotype was associated with increased risk of imatinib 
treatment failure in 336 newly-diagnosed chronic phase patients suffering from chronic 
myeloid leukemia due to decreased imatinib uptake (Giannoudis et al., 2013). In contrast, 
the haplotype M420del-V408 was shown to not affect the uptake of imatinib in vitro 
(Giannoudis et al., 2013). However, PHASE and next-generation sequencing analyses by 
our research group revealed that the M420del only exits in combination with V408 
(Tzvetkov et al., 2014). None of the 371 individuals analyzed carried the haplotype 
M420del–M408. This was also true for further 1092 individuals from the 1000 genomes 
project. It was shown that the M420del exists exclusively together with valine408 (Figure 
1.2). However, for the purposes of this PhD project it was of interest, if there are possible 
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interactions between both amino acids in all theoretically possible haplotype combinations. 
Therefore, HEK293 cells were generated by stable transfection to overexpress all 
theoretically possible haplotype combinations: M420-M408, M420-V408, M420del-M408, 
and M420del-V408. Western blot analysis revealed equal protein expression of all four 
theoretically possible haplotypes (Figure 4.9 A). The subcellular localization of OCT1 was 
analyzed using immunofluorescence confocal microscopy. The OCT1 protein of all 
analyzed haplotype combinations was located in the plasma membrane as suggested by co-













Figure 4.9 (previous page) Western blot and immunocytochemical analysis of OCT1 variants carrying 
all four theoretically possible haplotype combinations of M420del-M408V. (A) Western blot analysis was 
performed using 10 µg of total cellular protein lysates. OCT1 was detected using a mouse monoclonal OCT1-
specific antibody (2C5). As a loading control GAPDH was stained using a mouse monoclonal GAPDH-
specific (6C5) antibody. No apparent differences in protein amount could be detected between all four 
theoretically possible haplotype combinations. (B) Subcellular localization of OCT1 in HEK293 cells 
overexpressing all four theoretically possible M420del-M408V haplotypes was analyzed by immunostaining 
coupled to confocal microscopy. The OCT1 protein (green) was stained with a mouse monoclonal OCT1-
specific antibody (2C5). Na+/K+ ATPase (red, the upper part) was stained using a Na+/K+ ATPase-specific 
rabbit monoclonal antibody (EP1845Y) as a plasma membrane marker and calnexin (red, the lower part) was 
stained with a calnexin-specific rabbit polyclonal antibody, which was used as a marker for the 
endoplasmatic reticulum. The co-staining revealed membrane localization of all four haplotypes. Part of this 
figure was presented in Tzvetkov et al. 214 and Seitz et al. 2015 (Tzvetkov et al., 2014; Seitz et al., 2015)  
 
The cell lines overexpressing all four theoretically possible haplotype combinations of 
M420del-M408V were used to measure the uptake of MPP+, TEA+, ASP+, metformin, 
morphine, and debrisoquine (Figure 4.10). The M420del caused a substrate-specific loss of 
OCT1 transport activity independent of its combination with methionine408 or valine408. 
The M420del did not affect the uptake of MPP+ and debrisoquine, neither in combination 
with methionine408 nor valine408. The M420del significantly decreased the uptake of TEA+ 
by more than 60 %. The decrease was only slightly higher when M420del was in combina-
tion with M408 than with V408 (77 % and 62 %, respectively). However, also without the 
deletion of M420, V408 showed a slightly higher activity than M408, increasing TEA+ 
uptake by 12 %. Similar effects were observed for morphine and metformin. Morphine 
uptake was decreased by 65 % and 25 % in M420del combined with methionine408 or 
valine408, respectively. As for TEA+ the decrease was less strong in M420del cells in 
combination with V408 than with M408. However, also without deletion of M420, V408 
slightly increased morphine uptake by 33 %. The uptake of metformin was reduced by 
82 % and 75 % in M420del cells in combination with methionine408 or valine408, 
respectively.  
In summary, M420deletion showed highly substrate-specific effects that were not affected 





Figure 4.10 Comparison of the uptake activity of OCT1 variants carrying all theoretically possible 
M420del-M408V haplotypes. HEK293 cells stably transfected to overexpress all four possible combinations 
of the M420del-M408V genotypes were incubated for 2 min with 10 µM MPP+, 5 µM TEA+, 5 µM ASP+, 
1 µM morphine, or 5 µM metformin, or for 1 min with 1 µM debrisoquine. The OCT1 mediated uptake was 
calculated by subtracting the uptake of the control cells (HEK293 cells transfected with the empty vector 
pcDNA5) from the uptake of the HEK293 overexpressing the indicated variants. Shown is the mean and error 
of the mean of at least three independent experiments. Part of these data was presented in Tzvetkov et al. 
2014 (Tzvetkov et al., 2014) and part in Seitz et al. 2015 (Seitz et al., 2015). 
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Furthermore, the impact of other natural existing amino acid substitutions on the effect of 
M420del on OCT1 function was analyzed. Therefore, it was analyzed how the glycine to 
alanine substitution at codon 414 (G414A) modified the effects of M420del on transport 
activity of the OCT1 variants. Also in this case only the haplotype combinations G414-
M420 (OCT1*1B), G414-420del (OCT1*2A), and A414-420del (OCT1*2C), but not 
A414-M420, were identified in the worldwide population genetic analysis of OCT1 and 
was characterized as a substrate-specific loss of function variant (Figure 4.5, (Seitz et al., 
2015)). 
However, also in this case for the purposes of this PhD project it was of interest, if there 
are possible interactions between both amino acids in all theoretically possible haplotype 
combinations. Therefore, HEK293 cells stably transfected by chromosomal integration 
were generated to overexpress the following haplotypes: G414-M420, G414-420del, A414-
M420, A414-420del. Due to the findings presented in the previous paragraph, cell lines 
carrying a deletion of methionine420 were generated in combination with valine408. The cell 
lines were used to measure the uptake of MPP+, TEA+, ASP+, morphine, and metformin 
(Figure 4.11). The combination A414-M420 displayed the same transport activity as the 
wild type cells (M420-G414). In contrast, cells carrying the deletion of methionine420 
showed a substrate-specific loss of activity. The effect was independent of glycine414 or its 
substitution to alanine414. The M420del decreased the uptake of MPP+ by 35% and 30 % 
when combined with glycine414 or alanine414, respectively. The uptake of ASP+ was only 
slightly decreased by 25 % and 22 % when M420del was combined with glycine414 or 
alanine414, respectively. In contrast, the uptake of TEA+ was strongly decreased by 82 % 
and 77 % when M420del was combined with glycine414 or alanine414, respectively.  
In summary, these data indicate that M420del determinates the effects of OCT1 transport 
activity both in combination with G414A and M408V. However, as M420del was observed 
only on V408 background all further experiments were performed using constructs 





Figure 4.11 Combined effects of G414A and M420del on OCT1-mediated uptake. HEK293 cells stably 
transfected to overexpress all four theoretically possible M420del-G414A haplotypes were incubated for 
2 min with 10 µM MPP+, 5 µM TEA+, 5 µM ASP+, 1 µM morphine, or 5 µM metformin. The OCT1-
mediated uptake was calculated by subtracting the uptake of the control HEK293 cells stably transfected with 
the empty vector pcDNA5 from HEK293 cells overexpressing the indicated OCT1 variants. Shown is the 
mean and error of the mean of at least three independent experiments.  
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4.4 In-depth analysis of the effects of M420del on OCT1 function 
The M420del is the most frequent and the only ubiquitously observed loss of function 
polymorphism in OCT1 (Figure 1.3; (Kerb et al., 2002; Shu et al., 2003; Seitz et al., 2015). 
The affected methionine420 is located in the 9th transmembrane domain of the protein 
(Figure 1.1). Up to now it is not reported that the 9th transmembrane domain is involved in 
substrate binding or in the transport mechanism of OCT1. However, our substrate-wide 
analyses of OCT1 transport activity revealed highly substrate-specific effects ranging from 
limited reduction in the uptake of ASP+ (92% of the reference OCT1*1 allele) to close to 
complete loss of transport of O-desmethyltramdol and tropisetron (20 % and 11 % of the 
reference allele, respectively, Figure 4.5). The aim of this part of the thesis was the in-
depth analysis of the effects of the deletion of methionine420 on OCT1 activity. 
 
4.4.1 Substrate-specific effects of the M420del variant 
The substrate-wide analysis revealed highly substrate-specific effects of the M420del 
variant (Figure 4.5). Here these substrate-specific effects were analyzed in-depth by deter-
mining the effects of M420del variant on the uptake kinetics of different OCT1 substrates. 
Determined were Km and vmax of TEA+, MPP+, ASP+, metformin, sumatriptan, and 
proguanil transport. Ranitidine was analyzed by Marleen Meyer and fenoterol was 
analyzed by Sherin Pojar, colleagues from our working group, but the data was also 





Figure 4.12 Substrate-specific effects of M420del. HEK293 cells stably transfected to overexpress wild 
type OCT1 (OCT1*1A) or the M420del allelic variant (OCT1*2) were incubated for 2 min with increasing 
concentrations of TEA+, MPP+, ASP+, metformin, sumatriptan, or proguanil. The OCT1-mediated uptake was 
calculated by subtracting the uptake of cells stably transfected with the control vector pcDNA5 from wild 





The concentration dependence of the uptake for the different substrates was measured and 
the Km and vmax values were calculated in comparison between wild type OCT1 (reference 
allele OCT1*1A) and OCT1 variant carrying M420del (OCT1*2A). M420del showed 
saturable uptake kinetics for all substrates tested. However, as expected from the single 
concentration measurements (chapter 4.1.2, Figure 4.5), M420del variant showed strong 
substrate-specific differences in the uptake. The vmax was reduced for all substrates tested, 
except for metformin, in M420del cells in comparison to wild type OCT1. The degree of 
decrease was also strongly substrate-specific. The vmax was reduced by 30 % for TEA+ and 
by 85 % for fenoterol in M420del cells (Figure 4.13). For metformin the apparent vmax was 
similar between M420del and wild type cells (5671 pmol/mg protein/min and 
6240 pmol/mg protein/min, respectively). In relation to wild type, the Km for MPP+, ASP+, 
sumatriptan, proguanil as well as for fenoterol and ranitidine is reduced in M420del cells. 
The decrease in Km ranges from 17 % for MPP+ up to 65% for proguanil (Figure 4.13). In 
contrast, the Km for TEA+ and metformin increased in M420del cells by 200 % and 400 %, 
respectively, compared to wild type (Figure 4.13). This demonstrates a highly substrate-




Table 4.3 Kinetic parameters of wild type OCT1 and M420del HEK293 cells for different substrates  
 Km [µM] 
Variant MPP+ TEA+ ASP+ 
Suma-
triptan 
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1 Data generated by Sherin Pojar and 2 in tight collaboration with Marleen Meyer  






Figure 4.13 Differences in Km (upper part) and vmax (lower part) of the M420del in relation to wild type 
OCT1. Shown is the mean and error of the mean of the differences between M420del and wild type from at 
least three independent experiments. Km and vmax are based on results shown in Figure 4.12. Fenoterol values 
were obtained from the work of Sherin Pojar (Pojar, 2015). Ranitidine results were obtained in close 




In order to ensure that inter-day differences like different cell passages did not affect the 
extent of the observed substrate-specific loss of activity of the M420del variant, simul-
taneous uptake measurements with fenoterol and sumatriptan were performed. The two 
drugs were chosen as fenoterol was strongly affected and sumatriptan was weakly affected 
by M420del. The uptake at three different concentrations (below Km, close to Km, and 
close to vmax) on the same day using identical cell passages was measured. The effect of 
M420del on the uptake of fenoterol and sumatriptan did not differ in three independent 
experiments (Figure 4.14). The M420del variant decreased the uptake of fenoterol and 
sumatriptan at the lowest concentration tested (0.1 µM for fenoterol and 1 µM for 
sumatriptan) by 41.2 % and 3.6 %, respectively. For the uptake of 1 µM sumatriptan, clear 
variability for the impact of M420del on sumatriptan uptake due to experimental conditions 
was observed: in two of three experiments the M420del decreased the uptake of 1 µM 
sumatriptan by 9.3 % and 3.9 %. In one experiment the M420del increased the uptake by 
2.7 %. However, the data fluctuate around zero, indicating that the M420del does not affect 
the uptake of 1 µM sumatriptan. The M420del variant decreased the uptake of 2 µM and 
25 µM fenoterol on average by 70.4 % and 71.3 %, respectively. The M420del variant 
decreased the uptake of 60 µM and 400 µM sumatriptan on average by 41.2 % and 47.2 %, 
respectively. The values observed were in line with the ones measured for sumatriptan and 
fenoterol in the early experiments (Figure 4.12 and (Pojar, 2015)). This experiment 
confirmed that the observed highly substrate-specific effects of M420del on OCT1 activity 





Figure 4.14 Simultaneous uptake measurements of fenoterol and sumatriptan in wild type and 
M420del cells. In order to exclude inter-day differences, the uptake of sumatriptan and fenoterol was 
measured at three different concentrations (below Km, close to Km, and close to vmax) on the same day using 
identical cell passages.  
 
4.4.2 Reduction of the extracellular loop between the 9th and the 10th TMD 
cannot explain the effect of M420del  
The M420del polymorphism is a deletion of a single amino acid. One hypothesis to explain 
the effects of the M420del variant is that not the methionine420 specifically, but the deletion 
itself causes the effects. A deletion of an amino acid at this position causes a reduction of 
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the extracellular protein chain between the 9th and the 10th transmembrane domain. This 
may change the positions of amino acids in the 10th transmembrane domain. The amino 
acids A443, L447, Q448, and C451 in the 10th transmembrane domain were suggested to 
be involved in formation of the substrate binding cleft (Gorboulev et al., 2005; Sturm et al., 
2007). Hence, changes of amino acid positions in the 10th transmembrane domain may 
affect substrate binding and affinities. To test this hypothesis, two artificial mutations, 
L427del and H428del, were generated on wild type background (Figure 4.15). These two 
amino acids are located directly in the loop between the 9th and the 10th transmembrane 
domain. Additionally, an insertion mutant was generated on M420del background: An 
insertion of alanine after proline425 (A426ins), which should restore the length of the loop 
between the 9th and the 10th transmembrane. In case that the observed effect of the 
M420del is due to the shortening of the extracellular protein chain, OCT1 L427del or 
H428del should cause the same effect on transport activity as M420del. In contrast, the 
insertion of alanine426 on M420del background should restore transport activity to the 
levels of the wild type.  
 
 
Figure 4.15 Secondary structure of OCT1 showing the mutations, which were used to analyze if the 
substrate-specific effects of M420del are caused by reduction of the protein chain resulting in 





The artificially mutated constructs were generated and stably transfected in HEK293 cells. 
Briefly, point mutations were introduced into pcDNA3.1::hOCT1 using site-directed muta-
genesis PCR (Table 2.5). The mutated OCT1 gene was re-coned into the pcDNA5 
expression vector. The generated pcDNA5 plasmids (Table 2.6) were used for stable 
transfection into HEK293 cells.  
In order to validate the generated cell lines three integration-specific PCRs were performed 
(chapter 3.1.6). PCR 1 and PCR 2 were performed to verify integration of pcDNA5 into the 
genome of HEK293 cells and to detect the gene of interest within the integration site. 
Figure 4.16 shows results of PCR 1 and PCR 2 of the clone that was used for further 
analyses. PCR 1 resulted in an amplification product of 519 bp. PCR 2 resulted in an 
amplification product of 1376 bp for the empty pcDNA5 vector and of 3137 bp for 
pcDNA5 containing OCT1 or its variants, respectively. PCR 3 was performed in order to 
identify possible multiple tandem integration of the expression vector pcDNA5 containing 
OCT1 into the genome of HEK293 cells. All of the variants tested were confirmed as 
single integrands, as no amplification product was obtained (data not shown). The strong 
and homogenous mRNA expression of the clones was confirmed by real-time qPCR 





Figure 4.16 Validation of HEK293 cells overexpressing the OCT1 mutants L427del, H428del, 
A426ins/M420del (A) Schematic representation of the expression plasmid pcDNA5 (black) integrated into 
the pFRT/lacZeo site of the genome of HEK293 cells (gray) as represented in Seitz et al. (Seitz et al., 2015). 
The positions of the primers and the amplicons of PCR 1 and PCR 2 are indicated. (B) PCR 1 resulted in an 
amplification product of 519 bp and PCR 2 resulted in an amplification product of 1376 bp (for the control 
cells transfected with the empty pcDNA5 vector) or 3137 bp (transfected with pcDNA5 containing OCT1). 
(C) Relative mRNA expression using real-time qPCRs demonstrating high and equal OCT1 mRNA levels 
among wild type OCT1 and the generated mutants. Shown is the mean and error of the mean of three 





The OCT1 mutants were compared with M420del and wild type variants in their ability to 
transport TEA+, MPP+, and ASP+ at single concentration (Figure 4.17). Neither L427del 
and H428del on wild type background caused a decrease in TEA+ uptake that could be 
compared to those observed by M420del, nor A426ins increased the uptake of the M420del 
variant (Figure 4.17 A). The uptake in the L427del mutant was not significantly different to 
wild type cells. The uptake of TEA+ in H428del cells was decreased by 39 %, but this 
decrease was not statistically significant. More importantly, the TEA+ uptake of A426ins 
on M420del background did not differ from the M420del uptake (4.33 and 
4.32 pmol/min/mg protein, respectively). No significant differences in the uptake of MPP+ 
and ASP+ were observed between wild type and M420del cells: M420del decreased the 
uptake of MPP+ by 22 % (Figure 4.17 B); the uptake of ASP+ did not differ from wild type 
cells (Figure 4.17 C). Therefore these substrates were only of limited use in this 
experiment.  
The mutants L427del, H428del as well as A426ins did not show significant differences in 
the uptake of MPP+ and ASP+ compared to wild type and M420del cells, respectively, 
indicating that these mutations did not have an impact on MPP+ and ASP+ uptake 
themselves. These results suggest that the substrate-specific effects observed for the 
M420del are not caused by unspecific effects of the amino acid deletion but rather by the 





Figure 4.17 Effects of single amino acid deletions or insertion within the extracellular loop between 
TMD 9 and TMD 10 on OCT1-mediated uptake of MPP+, TEA+, and ASP+. HEK293 cells stably 
transfected to overexpress the wild type, the M420del variant as well as the mutants L247del, H428del, and 
A426ins were incubated for 2 min with 5 µM TEA+(A), 10 µM MPP+ (B), or 5 µM ASP+ (C). The OCT1-
mediated uptake was calculated by subtracting the uptake of the control cells stably transfected with the 
empty expression vector pcDNA5. The gray area highlights the difference in the uptake between the wild 




4.4.3 The observed substrate-specific effects of the M420del variant are 
caused by loss of the methionine side chain  
After it could be excluded that the effects of M420del are caused by simple reduction of 
the protein chain, the interaction of methionine420 with other amino acids and the methio-
nine side chain properties were analyzed in detail.  
First, the interaction of methionine420 with amino acids in the 7th transmembrane was ana-
lyzed. Based on the homology model of rat Oct1, it was suggested that due to protein 
folding the 9th and the 7th transmembrane domain are in close contact (Figure 4.18). The 7th 
transmembrane is known to be involved in substrate binding (Popp et al., 2005). By 
deletion of methionine420 the more bulky amino acid isoleucine421 is suggested to be roped 
into the membrane. This may change the interaction and position of amino acids in the 7th 
transmembrane domain. Especially, based on the model (Figure 4.18) a potential steric 
conflict was suggested between I420 and the amino acids L364 and H367. To test this 
hypothesis, mutants of OCT1 were generated leading to substitution of leucine364 or 
histidine367 against alanine on M420del background, respectively. As alanine has a very 
short side chain, the suggested steric interference should be avoided in these mutants. If 
this is the case, the mutants L364A and H367A on M420del background should display the 








Figure 4.18 (previous page) Secondary and 3D structure of OCT1 showing the mutations L364A and 
H367A as well as F159Y, W217Y, and D474E that were generated to test whether the substrate-specific 
effects of M420del are caused by sterical interactions with amino acids in TMD 7 or key amino acids 
involved in the substrate binding or translocation. A) Secondary structure of human OCT1. Mutations that 
were generated to test if M420del interacts with amino acids in the 7th transmembrane domains are shown in 
orange. Mutations that were generated in order to analyze possible interactions of M420del with amino acids 
previously reported to be involved in the transport mechanism of rat Oct1 are shown in grey. B) Homology 
model of the outward open conformation of rat Oct1. The amino acids L365 and H368 (nitrogen shown in 
blue) in the 7th transmembrane domain and M421 (sulfur shown in yellow) in the 9th transmembrane domain 
are indicated. C) Homology model of open outward (left) and open inward (right) conformation of rat Oct1. 
The amino acids F160, W218, Y222, R440, L447, Q448, and D475, which are known to be involved in 
transport mechanism, are presented as spheres in the substrate binding cleft and are shown from the 
extracellular and intracellular side. Possible interactions between the amino acids F160, W218, and D475 and 
M421 (shown in bold) were analyzed. The transmembrane domains are colored as indicated. The 3D model 
of rat Oct1 is based on the crystal structure of LacY of E.coli (Popp et al., 2005; Gorbunov et al., 2008). The 
PDB file was kindly provided by Thomas Mueller from the University of Würzburg. Presentation and editing 
was made using PyMOL with kind support of Ralph Krätzner from the Department of Pediatrics and 
Adolescent Medicine, University Medical Center Göttingen  
 
HEK293 cells were generated by targeted chromosomal integration to overexpress the 
mutants L364A and H367A on M420del background. The correct integration of the 
expression plasmid into the genome of HEK293 cells, the strong and homogenous mRNA 












Figure 4.19 (previous page) Validation of HEK293 cells overexpressing the mutants L364A and H367A 
on M420del background (A) Schematic presentation of the expression plasmid pcDNA5 (black) integrated 
into the pFRT/lacZeo site of the genome of HEK293 cells (gray) as represented in Seitz et al. (Seitz et al., 
2015). The positions of the primers and the amplicons of PCR 1 and PCR 2 are indicated. (B) PCR 1 resulted 
in an amplification product of 519 bp and PCR 2 resulted in an amplification product of 1376 bp (for the 
control cells transfected with the empty pcDNA5 vector) or 3137 bp (transfected with pcDNA5 containing 
OCT1). (C) Relative mRNA expression using real-time qPCRs demonstrating high and equal OCT1 mRNA 
levels among wild type OCT1 and the generated mutants. Shown is the mean and error of the mean of three 
independent RNA extractions. (D) Immunocytochemical staining of OCT1 (green) co-stained with Na+/K+ 
ATPase (red, upper part) as a plasma membrane marker, or calnexine (red, lower part) as a marker of 
endoplasmic reticulum. 
 
The OCT1 mutants were compared with M420del and wild type variants for their ability to 
transport TEA+, MPP+, and ASP+ at single concentrations (Figure 4.20). The M420del did 
not significantly affect the uptake of MPP+ and ASP+ compared to wild type OCT1 (Figure 
4.20 A). In contrast, the mutants L364A and H3647A significantly decreased the uptake of 
MPP+ (P ≤ 0.01 and P ≤ 0.001, respectively) and ASP+ (P ≤ 0.01 and P ≤ 0.001, 
respectively) compared to wild type OCT1. L364A and H367A decreased the uptake of 
MPP+ by 53 % and 82 %, respectively, and the uptake of ASP+ was decreased by 16 % and 
62 %, respectively. The results suggested involvement of L364 and H367 in transport of 
MPP+ and H367 in transport of ASP+.  
To test whether the observed effect of L364A and H367A mutants is independent of wild 
type or M420del background, the amino acid substitution leucine364 and histidine367 against 
alanine were introduced on both backgrounds. The mutants were overexpressed in 
HEK293 cells by transient transfection. The uptake of TEA+ was measured (Figure 4.20 
B). M420del significantly decreased the uptake of TEA+ by 70.3 % (P ≤ 0.01). The 
mutants L364A and H367A strongly decreased the uptake of TEA+ independent of the 
background tested. L364A and H367A significantly decreased TEA+ uptake to the level of 
M420del cells showing a decreased by 73.5 % and 73.3 %, respectively. When L364A and 
H367A were expressed on M420del background, the mutation L364A and H367A 





Figure 4.20 Analysis of the interaction of methionine420 with the amino acids L364 and H367 in TMD 7. 
(A) HEK293 cells stably transfected to overexpress wild type OCT1 and the M420del variant as well as the 
mutants L364A and H367A on M420del background were incubated with 10 µM MPP+ and 5 µM ASP+ for 
2 min. (B) HEK293 cells transiently transfected with the expression plasmid pcDNA5 containing OCT1 wild 
type, M420del, and L364A and H367A on both backgrounds were incubated with 5 µM TEA+ for 2 min. The 
OCT- mediated uptake was calculated by subtracting the uptake of control cells transfected with the empty 
expression vector pcDNA5 from the uptake in the cells transfected with the wild type or variant OCT1. 
Shown is the mean and error of the mean of three independent experiments. The gray area highlights the 
difference in the uptake between the wild type OCT1 and the M420del variant. 
 
Due to the very strong decrease of OCT1 activity especially for the H367A mutant, the 
correct membrane localization of these mutants was analyzed by immunostaining and 
analysis by confocal microscopy was performed (Figure 4.19 D). L364A and H367A 
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mutants did not affect membrane localization of OCT1 in M420del cells suggesting that 
the observed strong decrease in the activity is not due to improper membrane localization. 
In summary, the results indicate that L364 and H367 themselves are important for the 
transport of TEA+, MPP+, and ASP+. Therefore, with this experiment we were not able to 
correctly address the hypothesis of sterical interaction with these two variants as a reason 
for the substrate-specific effects of M420del.    
Next, the importance of the methionine side chain properties for the substrate-specific 
effects of the M420del variant was analyzed. Therefore, HEK293 cells were generated by 
targeted chromosomal integration to overexpress mutants characterized by substitution of 
methionine420 against alanine, threonine, isoleucine, or cysteine (M420A, M420T, M420I 
and M420C, respectively). The correct integration of the clones, the strong and 
homogenous mRNA expression and the correct membrane localization of the clones were 









Figure 4.21 (previous page) Validation of HEK293 cells overexpressing the OCT1 mutants M420A, 
M420I, M420I, and M420C. (A) Schematic presentation of the expression plasmid pcDNA5 (black) 
integrated into the pFRT/lacZeo site of the genome of HEK293 cells (gray) as represented in Seitz et al. 
(Seitz et al., 2015). The positions of the primers and the amplicons of PCR 1 and PCR 2 are indicated. (B) 
PCR 1 resulted in an amplification product of 519 bp and PCR 2 resulted in an amplification product of 
1376 bp (for the control cells transfected with the empty pcDNA5 vector) or 3137 bp (transfected with 
pcDNA5 containing OCT1). (C) Relative mRNA expression using real-time qPCRs demonstrating high and 
equal OCT1 mRNA levels among wild type OCT1 and the generated mutants. Shown is the mean and error 
of the mean of three independent RNA extractions. (D) Immunocytochemical staining of OCT1 (green) co-
stained with Na+/K+ ATPase (red, upper part) as a plasma membrane marker, or calnexine (red, lower part) as 
a marker of endoplasmic reticulum. 
 
As alanine has next to glycine the shortest side chain among the proteinogenic amino acids, 
substitution of methionine420 to alanine should not affect the position of adjacent amino 
acids, but represents a complete lack of the active amino acid side chain. If not the 
methionine itself, but the shortage of the amino acid chain or an unspecific steric 
interaction were the reasons for the M420del effects, then the M420A mutant should have 
transport activities similar to the wild type. However, the M420A mutant showed no 
significant differences to M420del in respect to uptake the of MPP+, TEA+, ASP+, 





Figure 4.22 Comparative analysis of the uptake activity of M420del and the M420A mutant measured 
at single concentration of the substrate. HEK293 cells stably transfected to overexpress wild type OCT1, 
the M420del variant, as well as the M420A mutant were incubated for 2 min with 1 µM MPP+, 5 µM TEA+, 
5 µM ASP+, 1 µM morphine, 5 µM metformin, 10 µM tyramine, or 80 µM proguanil. The OCT1-mediated 
uptake was calculated by subtracting the uptake of the control cells stably transfected with the empty control 
vector pcDNA5 from the cells overexpressing OCT1 and its variants. Shown is the mean and error of the 
mean of at least three independent experiments. The gray area highlights the difference in the uptake between 





Furthermore, also detailed transport kinetic analyses showed no significant differences in 
uptake rates between the M420del and M420A mutants (Figure 4.23 and Table 4.4). TEA+ 
was the only substrate for which the Km significantly differed between M420del and 
M420A. However, the difference was marginally significant with P= 0.028.  
Taken together, these results indicate that the side chain at position 420 is responsible for 
the observed substrate-specific effects of M420del.  
 
 
Figure 4.23 Comparative analyses of the transport kinetics of M420del and M420A. HEK293 cells 
stably transfected to overexpress wild type OCT1, M420del, or M420A were incubated for 2 min with 
increasing concentrations of TEA+, MPP+, metformin, and sumatriptan. The OCT1-mediated uptake was 
calculated by subtracting the uptake of control cells stably transfected with the empty control vector pcDNA5 
from the uptake of the cells overexpressing wild type or variant OCT1. Shown is the mean and error of the 




Table 4.4 Kinetic parameters of the M420A variant 
Variant 






































































































Next, the specific structural properties of the methionine side chain were analyzed. 
Therefore, it was analyzed whether alanine, threonine, isoleucine, or cysteine may mimic 
the function of methionine at position 420. Threonine has a relatively short side chain, but 
possesses a polar although uncharged hydroxyl group. Isoleucine like methionine is a 
nonpolar, uncharged amino acid and has an almost comparable side chain length to 
methionine. Cysteine possesses a thiol group and therefore contains a sulfur atom like me-
thionine. Due to its highly reactive thiol group, the mutation of methionine420 to cysteine 
was expected to lead to the formation of untypical disulfide bonds and to lead to miss 
folding of the protein and improper membrane localization. However, using immuno-
fluorescence confocal microscopy, the M420C mutant was shown to be correctly localized 
in the plasma membrane (Figure 4.21). 
Similar to M420A, the mutants M420T, M420I, and M420C did not differ from M420del 
in their ability to transport TEA+, MPP+, ASP+, morphine, and metformin. No significant 
difference in the uptake between the M420del variant and the mutants could be detected for 
all substrates tested (Figure 4.24). For the uptake of MPP+ and ASP+ no significant 
difference between wild type, the M420del and the mutants was observed. The M420del 
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and the mutants significantly decreased the uptake of TEA+ at least by more than 54 % 
(P ≤ 0.01). M420del significantly decreased morphine uptake by 49 % (P ≤ 0.05). The 
decrease in morphine uptake was not significant for the mutants 420A, 420T, 420I, and 
420C. The M420del significantly decreased metformin uptake by 68 % (P ≤ 0.01). The 
mutants showed different effects on metformin uptake: the mutants 420A and 420I did not 
significantly decrease the uptake of metformin compared to wild type cells (P = 0.1026 and 
P = 0.2187 for 420A and 420I, respectively). Although for the 420A mutation metformin 
uptake was only decreased by 43 % compared to a decrease by 68 % for M420del at single 
concentration, analysis of metformin uptake kinetics revealed no difference between 
M420A and M420del (Figure 4.23). The mutants M420T and M420C significantly 
decreased metformin uptake by 65 % and 55 %, respectively. However, none of the 
mutants tested showed significant differences in substrate uptake compared to M420del 





Figure 4.24 Comparative analyses of the effect of M420del, M420A, M420T, M420I, and M420C on the 
uptake of TEA+, MPP+, ASP+, morphine, and metformin. HEK293 cells stably transfected to overexpress 
wild type OCT1, the M420del variant as well as the mutants M420A, M420T, M420I, and M420C were 
incubated for 2 min with 5 µM TEA+, 1 µM MPP+, 5 µM ASP+, 1 µM morphine, and 5 µM metformin. The 
OCT1-mediated uptake was calculated by subtracting the uptake of control cells stably transfected with the 
empty control vector pcDNA5 from the cells overexpressing the wild type or variant OCT1. Shown is the 
mean and error of the mean of three independent experiments. The light brown area highlights the difference 
in the uptake between wild type OCT1 and the M420del variant. 
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Furthermore, the mutants M420T, M420I, and M420C showed a concentration-dependent 
uptake of TEA+ similar to M420del and not to the wild type (Figure 4.25, Table 4.5). 
M420del did not significantly decrease vmax of TEA+ uptake compared to wild type cells. 
Equally, none of the mutants significantly affected the vmax for TEA+ uptake, except 420A. 
The vmax was significantly decreased (vmax = 2848 ± 208 pmol/mg protein/min and vmax = 
2013 ± 139 pmol/mg protein/min uptake for wild type and 420A, respectively; P= 0.008). 
However, the focus was on the strong effect of M420del on Km of TEA+ showing a 
significant increase compared to wild type cells. All the mutants tested showed similar Km 
values as M420del, except M420A. As shown before, 420A showed a slightly significant 
decrease in Km compared to M420del cells (Km= 1064 ± 53 for 420A and Km= 1778 ± 165 
µM for M420del; P= 0.028).  
 
 
Figure 4.25 Comparative analyses of the effects of M420del, M420A, M420T, M420I, and M420C 
mutants on the uptake kinetics of TEA+. HEK293 cells stably transfected to overexpress wild type OCT1, 
the M420del variant, or the mutants M420A, M420T, M420I, or M420C were incubated for 2 min with 
increasing concentrations of TEA+. The OCT1-mediated uptake was calculated by subtracting the uptake of 
control cells stably transfected with the empty expression control vector pcDNA5 from the uptake in the cells 












Wild type 589.5 ± 44.0 2848.7 ± 207.6 
M420del 1778.4 ± 164.5 2114.8 ± 206.8 
420A 1063.9 ± 53.3 2013.1 ± 138.7 
420T 1420.2 ± 268.7 2480.7 ± 330.1 
420I 1587.0 ± 48.4 2707.3 ± 284.0 
420C 1160.9 ± 233.4 2259.7 ± 99.7 
 
 
In conclusion, none of the amino acids with different functional properties in their side 
chain could restore wild type transport activity for the uptake of TEA+, MPP+, ASP+, 
morphine, and metformin. For TEA+ uptake, M420del caused a significant increase in Km 
that was not significantly changed in the mutants M420T, M420I, and M420C. Indeed, in 
respect to TEA+ uptake the substitution M420A did not behave as M420del. The Km value 
of M420A was 1064 ± 53 µM which is between the Km values of the M420del and the wild 
type. However, this effect was not observed for other substrates and especially for 
metformin for which M420del also caused a strong variation in Km (Figure 4.13, Table 
4.3). The other substitutions on position 420 tested also did not significantly differ to 
M420del in their ability to transport TEA+. The data indicates that the side chain of 
methionine420 is essential for the observed effects of the M420del mutant. Hence, with the 
analyzed mutants the substrate-specific effects caused by the loss of the methionine side 
chain at position 420 could not be explained. 
Finally, the interactions between M420del and amino acids known to play an important 
role in substrate binding and translocation were analyzed. Based on the homology model 
no direct interaction could be suggested between methionine420 and any of the amino acids 
in the substrate binding cleft of OCT1 (Figure 1.1). However, at this point possible indirect 
(functional) interactions with the amino acids D474, W217, and F159 were analyzed. 
These amino acids were chosen as in rat Oct1 the respective amino acids D475, W218, and 
F160 were shown to be involved in substrate binding and in transport of TEA+ and binding 
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of corticosterone (Gorboulev et al., 1999; Gorboulev et al., 2005; Popp et al., 2005; 
Gorbunov et al., 2008; Volk et al., 2009). The mutants D474E, W217Y, and F159Y were 
generated on wild type and M420del background of human OCT1. The mutants were 
overexpressed in HEK293 cells stably transfected by targeted chromosomal integration of 
the expression plasmid and validated as described in chapters 3.1.6, 3.1.3, and 3.2.3. The 
correct chromosomal integration was confirmed by PCR and capillary sequencing, the 





Figure 4.26 Validation of HEK293 cells overexpressing the OCT1 mutants D474E, W217Y, and F159Y 
on the wild type and M420del OCT1 background (A) Schematic presentation of the expression plasmid 
pcDNA5 (black) integrated into the pFRT/lacZeo site of the genome of HEK293 cells (gray) as represented 
in Seitz et al. (Seitz et al., 2015). The positions of the primers and the amplicons of PCR 1 and PCR 2 are 
indicated. (B) PCR 1 resulted in an amplification product of 519 bp and PCR 2 resulted in an amplification 
product of 1376 bp (for the control cells transfected with the empty pcDNA5 vector) or 3137 bp (transfected 
with pcDNA5 containing OCT1). (C) Relative mRNA expression using real-time qPCRs demonstrating high 
and equal OCT1 mRNA levels among wild type OCT1 and the generated mutants. Shown is the mean and 
error of the mean of three independent RNA extractions. (D) Immunocytochemical staining of OCT1 (green) 
co-stained with Na+/K+ ATPase (red, upper part) as a plasma membrane marker, or calnexine (red, lower 
part) as a marker of endoplasmic reticulum. 
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The mutants were characterized regarding their transport activity for the uptake of ASP+, 
MPP+, TEA+, morphine, metformin, tyramine, and proguanil at single concentrations. The 
mutations W217Y and F159Y did not significantly affect the uptake of ASP+, MPP+, 
TEA+, morphine, metformin, and tyramine neither on wild type nor on M420del 
background. F159Y in wild type OCT1 cells only slightly insignificantly decreased the 
uptake of TEA+ and tyramine by 26 % and 25.7 %, respectively (Figure 4.27). The 
mutation W217Y increased the uptake of proguanil by 23 % and 33 % in wild type and 
M420del cells, respectively. The increase was significant in wild type cells (P ≤ 0.05), but 
not in M420del cells.  
In contrast, the mutation D474E had strong effects on the uptake of all substances tested. 
On wild type background, D474E significantly decreased the uptake of all substrates tested 
by between 31 % and 76 % (P ≤ 0.01). On M420del background, D474E significantly 
decreased the uptake of ASP+, MPP+, and proguanil by 79 % to 93 % (P ≤ 0.05). However, 
also the uptake of TEA+, morphine, tyramine, and metformin was strongly decreased in 
D474E mutants by at least 73 %. More importantly, interaction between the mutation 
D474E and M420del was observed for some of the substrates: even though M420del cells 
without the D474E mutation showed only limited decrease in the uptake of ASP+ and 
MPP+, in combination with the D474E mutation much stronger effects of the M420del 
were observed. Without the mutation D474E, M420del showed only 7 % and 12 % 
decrease in the uptake of ASP+ and MPP+, respectively. In the presence of the D474E 








Figure 4.27 (previous page) Comparative analyses of the effect of D474E, W217Y, and F159Y 
mutations on transport activity of wild type or M420del OCT1. HEK293 cells stably transfected to 
overexpress wild type OCT1, the M420del variant as well D474E, W217Y, and F159Y mutants on wild type 
and M420del background were incubated for 2 min with 5 µM ASP+, 1 µM MPP+, 5 µM TEA+, 1 µM 
morphine, 80 µM proguanil, 10 µM tyramine, or 5 µM metformin. The OCT1-mediated uptake was 
calculated by subtracting the uptake of control cells stably transfected with the empty control vector pcDNA5 
from the uptake of the cells overexpressing wild type or different variant OCT1. Shown is the mean and error 
of the mean of at least three independent experiments. The light brown area highlights the difference in the 
uptake between wild type OCT1 and the M420del variant.  
 
Concentration-dependent uptake measurements were performed to determine Km and vmax 
for the uptake of TEA+, MPP+, ASP+, metformin, and sumatriptan for the D474E mutants 
on wild type and M420del background (Figure 4.28 and Table 4.6). The mutation D474E 







Figure 4.28 Comparative analyses of the combined effects of the M420del polymorphism and the 
D474E mutation on the uptake kinetics of TEA+, MPP+, ASP+, metformin, and sumatriptan. HEK293 
cells stably transfected to overexpress wild type OCT1, the M420del variant, and the D474E mutant on wild 
type and M420del background were incubated for 2 min with increasing concentrations of TEA+, MPP+, 
ASP+, metformin, and sumatriptan. The OCT1-mediated uptake was calculated by subtracting the uptake of 
control cells stably transfected with the empty expression control vector pcDNA5 from the uptake cells 
overexpressing wild type or variant OCT1. Shown is the mean and error of the mean of at least three 





Table 4.6 Kinetic parameters of D474E mutant on wild type and M420del background. 
Variant 

































































































































































Figure 4.29 Comparative presentation of the differences in Km (top panel) and vmax (lower panel) 
caused by the D474E mutation on the OCT1 wild type (left site, black bars) or M420del background 
(right site, blue bars). Shown is the mean and error of the mean of the differences between D474 and E474 
from at least three independent experiments. Km and vmax are based on results shown in Figure 4.28. 
 
The graphs shown in Figure 4.29 illustrate the effect of D474E on Km and vmax of OCT1 
wild type or M420del. 
On wild type background the D474E mutation decreased vmax at least by 66 % for all 
substrates tested, except for metformin. For metformin, vmax was slightly but insignificantly 
increased by 27 %. On M420del background, the D474E mutant strongly decreased the 
vmax by between 68 % and 79 % compared to M420del alone, with exception of metformin. 
For metformin uptake, the D474E mutation did not significantly change the vmax in 
M420del cells (Figure 4.29). Therefore, it could be concluded that there were strong, but 
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also substrate-specific effects of D474E on the transport capacity of human OCT1 and 
these effects were not dependent on M420del.   
The effects of the D474E mutation on Km were more complex and dependent on the 
M420del: D474E decreased the Km for ASP+ by 68 %. The decrease was similar to the 
effect of D474E on wild type background (Km decreased by 81 %). In contrast, on the 
M420del background, D474E increased the Km for MPP+, TEA+, and sumatriptan, by 
41 %, 34 %, and 105 %, respectively. The increased Km suggested a decrease in affinity for 
these substances. In comparison, on wild type background, D474E did not change or even 
caused a decrease of the Km (by 41 % for TEA+ and by 81 % for ASP+) (Figure 4.29). For 
metformin, the D474E mutation caused a strong increase of the Km. This increase, how-
ever, was much stronger on the wild type (679 %) than on M420del background (133 %). 
Because the effects of D474E on the affinity for the substrates (besides for metformin) 
were observed only together with M420del, one may speculate about interactions between 
D474E and M420del in the uptake of TEA+, MPP+, and sumatriptan. Regarding the effect 
on Km of metformin, the effect of D474E and M420del does not seem to be additive as 
M420del and D474E increased the Km by 424 % (Figure 4.13) and 679 % (Figure 4.29) in 
wild type cells, respectively, but D474E increased the Km only by 133 % together with 
M420del (Figure 4.29). The data more likely indicate that the effect of D474E on the Km of 





Figure 4.30 Graphical representation of the differences in Km (upper part) and vmax (lower part) caused 
by the M420del polymorphisms on mutant D474E background. Shown is the mean and error of the mean 
of the differences between the M420 and 420deletion alleles on E474 background from at least three 
independent experiments. Km and vmax are based on results shown in Figure 4.28. 
 
Next, it was analyzed how M420del affects Km and vmax in the presence of the D474E 
mutation (Figure 4.30). M420del caused a strong decrease of vmax (by between 43 % and 
60 %) for all substrates tested, except for TEA+. The vmax of TEA+ was not affected.  
M420del did not affect the Km values of MPP+ and ASP+ in the D474E mutants. In 
contrast, the Km of sumatriptan increased in the presence of M420del on D474E 
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background by 76 %. The increase was even stronger for the Km of TEA+, which showed 
an increase of 523 % when M420del was present together with D474E. This effect was 
comparable with the effect of M420del on wild type background (217 % increase, Figure 
4.13). This is in line with the lack of effects of D474E itself on the Km for TEA+ (Figure 
4.29).  
The effects of the mutations D474E, W217Y, and F159Y observed here in human OCT1 
differed from the ones previously reported for the rat ortholog. The amino acids D475, 
W218, and F160 are known to have strong effects on MPP+ and TEA+ uptake in rat Oct1 
(Gorboulev et al., 1999; Popp et al., 2005; Volk et al., 2009). However, in human OCT1 
D474E strongly decreased the uptake of MPP+ and TEA+ and other substrates tested, but 
no effects were observed for W217Y and F159Y (Figure 4.27 and Figure 4.28). Therefore, 
the species-specific differences in the uptake of TEA+, MPP+, ASP+, and morphine 
between human OCT1 and its orthologs in mouse and rat were analyzed in more details. 
Second, differences in the effects of the mutations D475E, W218Y, and F160Y on the 
activity in mouse and human OCT1 orthologs were analyzed. 
There were no significant differences in the uptake between mouse and rat Oct1 for any of 
the substrates tested (Figure 4.31). In contrast, there were strong differences in the uptake 
of TEA+ and ASP+ between human OCT1 and its rodent orthologs (Figure 4.31). TEA+ 
uptake was 2.3-fold higher in rodent compared to human OCT1 (P ≤ 0.05). In contrast, the 
ASP+ uptake was decreased by 2.7-fold (P ≤ 0.01) and 3.6-fold (P ≤ 0.01) in mouse and rat 





Figure 4.31 Differences between human OCT1 and mouse and rat orthologs in the uptake of MPP+, 
TEA+, ASP+, and morphine. HEK293 cells stably transfected to overexpress human OCT1 or its rodent 
orthologs were incubated for 2 min with 1 µM MPP+, 5 µM TEA+, 5 µM ASP+, and 1 µM morphine. The 
OCT1-mediated uptake was calculated by subtracting the uptake of control cells stably transfected with the 
empty control vector pcDNA5 from the cells overexpressing human OCT1 or its orthologs. Shown is the 
mean and error of the mean of three independent experiments.  
 
Next, the effect of the mutants D475E, W218Y, and F160Y on transport activity for the 
uptake of TEA+, MPP+, ASP+, and morphine in mouse and human OCT1 ortholog was 
analyzed. The D475E mutation in mouse Oct1 significantly decreased the uptake of ASP+ 
and morphine by 78 % and 42 %, respectively (Figure 4.32). The decrease in ASP+ uptake 
was stronger in mouse Oct1 than in the human ortholog, in which ASP+ uptake was 
decreased by 31 %. In contrast to human OCT1, in mouse Oct1 D475E did not 
significantly affect the uptake of TEA+ and MPP+. Hence, in humans the mutation D474E 
seems to have stronger effects on the uptake of TEA+, MPP+, and morphine than the 
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mutation in mouse ortholog. In contrast, the uptake of ASP+ seemed to be more strongly 
affected by the mutation in mouse Oct1.  
In human OCT1 the mutations W217Y and F159Y did not affect substrate uptake. In 
contrast, in mouse Oct1, the uptake of ASP+ and morphine was strongly affected by 
W218Y and F160Y. The ASP+ uptake was significantly decreased in these mutants. For 
morphine uptake, W218Y significantly increased the uptake by 121 %, whereas F160Y 
significantly decreased the uptake by 37 %. In line with human OCT1, the uptake of TEA+ 
and MPP+ was not significantly affected by W218Y and F160Y in mouse Oct1. 
In summary, next to species-specific differences between human OCT1 and rodent 
orthologs in the uptake of TEA+, MPP+, ASP+, and morphine, also the amino acids D474, 
W217, F159 in human OCT1 and their mouse orthologs have different impact on the 




Figure 4.32 Species-specific differences in the effects of D474E, W217Y, and F159Y mutants on 
substrate uptake. HEK293 cells stably transfected to overexpress wild type and D474E, W217Y, and F159Y 
mutated human and mouse OCT1 were incubated for 2 min with 5 µM TEA+, 1 µM MPP+, 5 µM ASP+, or 1 
µM morphine. The OCT1-mediated uptake was calculated by subtracting the uptake of the control cells 
stably transfected with the empty control vector pcDNA5 from the uptake of the cells overexpressing the wild 






This work describes, in detail, a functional analysis of globally existing genetic variants of 
OCT1. Genetic analyses revealed strong variation in the frequency of loss of OCT1 activity 
worldwide. In this work, a comparative analysis of the genetic variants on a broad 
spectrum of structurally diverse substrates was performed. With this data, a substantial 
number of genetic variants that caused substrate-specific loss of OCT1 function were 
identified. This reflects the polyspecificity of the OCT1 transporter and suggests different 
substrate binding sites and transport mechanisms for different OCT1 substrates. 
Furthermore, it could be shown that the reason for complete substrate-wide loss of 
transport activity was improper membrane localization.  
The most frequent and only ubiquitous loss-of function variant, M420del, was analyzed in 
detail. The M420del variant caused highly substrate-specific effects regarding loss of 
OCT1 function. Using targeted mutagenesis it could be shown that these effects were not 
caused by reduction of the protein chain due to deletion of methionine, but rather were 
caused by loss of the methionine side chain. OCT1 activity could not be restored by 
inserting threonine, isoleucine, or cysteine at the position of missing methionine420. 
Complex interactions between methionine420 and aspartate474, an amino acid known to be 
involved in substrate binding in rat Oct1, were also observed.  
 
5.1 Strong variations in the effects of OCT1 allelic variants on transport 
activity 
In this work, a detailed functional characterization of 21 OCT1 allelic variants, which were 
previously reported or predicted to strongly affect OCT1 activity, was performed. Of the 
21 allelic variants analyzed in this study, 16 major alleles were found to strongly affect 
OCT1 activity, whereas the 5 most common sub alleles did not affect transport activity of 
OCT1 (Figure 4.5). The 16 major alleles could be divided into four different groups 
according to their effect on OCT1 activity: alleles leading to complete substrate-wide loss 
of activity, alleles leading to strong but not complete substrate-wide loss of activity, alleles 
causing substrate-specific loss of activity, and alleles causing gain of OCT1 activity.  
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Firstly, the four alleles OCT1*5 (G465R/M420del), OCT1*6 (C88R/M420del), OCT1*12 
(S29L), and OCT1*15 (E284K) were characterized as complete substrate-wide loss-of-
function variants. They did not show transport activity with any of the substrates tested 
(Figure 4.5). In line with our observations, the variant alleles OCT1*5 and OCT1*6 were 
previously reported as loss of function variants (Shu et al., 2003; Shu et al., 2007; 
Tzvetkov et al., 2009; Ahlin et al., 2011; Saadatmand et al., 2012; Tzvetkov et al., 2012). 
The variant alleles OCT1*12 (S29L) and OCT1*15 (E284K) were newly identified as very 
rare OCT1 variants and were predicted by several bioinformatic tools to cause loss of 
OCT1 function (Seitz et al., 2015). Hence, this work provides the first characterization of 
S29L and E284K as complete substrate-wide loss of function variants. 
Secondly, the three allelic variants of OCT1 characterized by a strong reduction in 
transport activity for all substrates tested were: OCT1*3 (R61C), OCT1*4 (G401S), and 
OCT1*14 (R206C/M420del). The allelic variants R61C and G401S were commonly 
observed in Caucasians and were functionally characterized in detail before as variants that 
strongly decrease OCT1 activity (Shu et al., 2003; Tzvetkov et al., 2009; Tzvetkov et al., 
2011; Tzvetkov et al., 2012; Tzvetkov et al., 2013) The allele OCT1*14 was recently 
identified in Asians and has been shown to significantly decrease the uptake of metformin, 
MPP+, and TEA+ (Chen et al., 2010). In this work the number of substrates analyzed was 
extended and R206C/M420del was confirmed as a variant with strong substrate-wide 
reduction in transport activity. 
Thirdly, a substantial number of allelic variants tested revealed substrate-specific loss of 
activity: OCT1*2 (M420del), OCT1*7 (S14F), OCT1*10 (S189L), OCT1*11 (I449T), and 
OCT1*13 (T245M) (Figure 4.5). Substrate-specific effects for the allelic variants M420del, 
S14F, and S189L have been reported before (Shu et al., 2003; Shu et al., 2007; Tzvetkov et 
al., 2009; Ahlin et al., 2011; Tzvetkov et al., 2011; Saadatmand et al., 2012; Tzvetkov et 
al., 2012). The allelic variants I449T and T245M have been previously identified and were 
predicted by several bioinformatics tools to cause loss of OCT1 activity (Seitz et al., 2015). 
However, detailed functional characterization revealed that the alleles OCT1*11 and 
OCT1*13 (characterized by the variants I449T and T245M, respectively) caused substrate-
specific loss of activity. The allele OCT1*11 strongly reduced the uptake of metformin and 
almost abolished tropisetron uptake, but the uptake of MPP+, ASP+, and O-
desmethyltramadol was not altered compared to the wild type. The allele OCT1*13 
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strongly decreased the uptake for most of the substances tested, but decreased MPP+ uptake 
only by 44 % and no differences were observed in the uptake of debrisoquine (Figure 4.5). 
Hence, the bioinformatic prediction of loss of function of the variants I449T and T245M 
could not be confirmed. This finding emphasizes the need for functional testing of newly 
identified variants.  
Finally, the last group identified contained the two variants OCT1*8 (R488M) and 
OCT1*9 (P117L) that caused gain of activity for some of the substrates tested. They 
caused a more than 50 % increase in the uptake of at least one substrate tested (Figure 4.5). 
Previously, the variant R488M was reported not to affect the uptake of metformin (Shu et 
al., 2007; Chen et al., 2014). Here it could be shown that allele OCT1*8 (containing the 
R488M variant) increased metformin uptake by 68 %. Moreover the uptake was also 
increased by more than 50 % for TEA+ and morphine (Figure 4.5). For all the other 
substances tested, R488M showed at least 74 % of wild type transport activity. The sub-
allele OCT1*8B was characterized by combination of R488M and M408V. In line with 
previous findings, the presence of M408V did not affect the transport activity of the 
R488M variant (Figure 4.5) (Shu et al., 2003).  
In contrast to our findings, in the study of Chen et al., the allele OCT1*9 (P117L) was 
shown to significantly decrease the uptake of metformin, MPP+, and TEA+ (Chen et al., 
2010). In this work P117L increased the uptake of metformin and MPP+ by 39 % and 
30 %, respectively, and no significant differences were observed in the uptake of TEA+ 
(92 % of wild type transport activity) (Figure 4.5). Uptake activity for a broader range of 
substrates than previously investigated by Chen et al was analyzed in the work. OCT1*9 
was shown not to decrease the uptake of any of the substrates tested, except for tropisetron 
and debrisoquine. And for these substrates, OCT1*9 decreased the uptake by 49 % and 
14 %, respectively. Additionally, the coding region of the OCT1 clone used was re-
sequenced and confirmed that the leucine117, but not any other unwanted mutation was 
present. 
Several differences between these measurements and those seen in Chen et al. should be 
noted. In contrast to Chen et al,. in which the uptake measurements were performed with 
10 µM of [14C] metformin and [14C] TEA+ as well as with 1 µM of [3H] MPP+ for 5 min, 
the measurements of the uptake of [14C] metformin and [14C] TEA+ in this work were made 
using 5 µM of the substrates as well as 10 µM of [3H] MPP+ and were performed for 2 
minutes. However, the differences in the observed uptake activity of OCT1*9 cannot be 
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due to differences in the concentrations used as they were both far below the apparent Km 
values for the respective substrate that were previously reported or determined in this thesis 
(Km of 2.42 mM, 109 µM, and 590 µM for wild type OCT1 for metformin MPP+ and 
TEA+, respectively; see Table 4.3) (Shu et al., 2007). If the substrate concentration used is 
far below the Km of the substance, effects on transport kinetics might remain undetected if 
Km or vmax are affected by the polymorphism to the same extent. Chen et al. analyzed the 
uptake kinetics for metformin of the P117L variant compared to wild type OCT1 (P117L: 
Km = 1.51 mM and vmax = 2.02 nmol/mg protein/min; wild type: Km = 1.18 mM and vmax = 
3.96 nmol/mg protein/min) (Chen et al., 2010). Based on the Michaelis Menten equation 
we would have expected a 60 % decrease in metformin uptake at the concentration we used 
in our study. However, in our uptake experiments P117L showed an increase in metformin 
uptake by 39 % (Figure 4.5), which is contradictory to the results of Chen et al. 
Moreover, Chen et al. used OCT1 with a C-terminal GFP-tag (Chen et al., 2010). The 
OCT1 used in this work did not contain a GFP-tag and therefore better represents the 
conditions found in vivo. Other than Chen et al, no other studies have analyzed the effect of 
P117L on transport activity so far. More detailed analyses of the uptake kinetics for 
substrates like MPP+ and morphine, which showed a strong increase in uptake, would be 
needed in order to verify the impact of P117L on transport activity. 
Another example of contradictory observations is the S14F variant, which was reported to 
cause an increase of function. Shu et al. was the first group to characterize S14F transport 
activity. In their study, S14F was characterized as a variant with increased function 
showing an almost 2-fold increase in the uptake of MPP+ compared to wild type (Shu et al., 
2003). This observation is contradictory to observations in this work, as analysis found a 
27 % decrease of MPP+ uptake (Figure 4.5). Based on previous and current findings, the 
variant S14F can be characterized as a substrate-specific loss of function variant whereby 
making artifacts from the cloning strategies or transport assays unlikely (Shu et al., 2003; 
Shu et al., 2007; Chen et al., 2014; Seitz et al., 2015).  
Taken together, neither in this work nor in previous studies, an OCT1 allelic variant could 
be identified as a gain of function allele, in which the uptake of all substrates was 
increased. Data regarding the effect on transport activity is still contradictory. Hence, it is 
necessary to validate the observed effects of an increased uptake activity by determining 
the uptake kinetics of different substrates. Moreover, one should compare at least two 
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different clones of wild type, R488M, and P117L variants in order to exclude that the 
observed effects were caused by the expression system used. 
My analyses were performed using stable transfected HEK293 cell lines generated by 
targeted chromosomal integration, which were validated in order to verify constant and 
equal overexpression of OCT1 variants used in this work. However, some discrepancies 
were observed in the generated constructs.  
According to haplotype inferring analysis, P117L occurs in combination with F160L 
(Figure 1.2; (Seitz et al., 2015)). The construct that was used for transfection in this work 
contained phenylalanine160. However, the F160L variant was shown not to affect OCT1 
transport activity (Kerb et al., 2002; Sakata et al., 2004; Shu et al., 2007; Chen et al., 2014). 
Hence, it can be expected that the transport activity of P117L is not affected by the 
presence of phenylalanine160.  
The substrate-specific loss-of-function variants S14F and T245M exist in combination with 
M408V according to haplotype inferring analyses (Figure 1.2). In this thesis the plasmid 
constructs used for stable transfection contained a methionine408 instead of a valine408. 
However, it was shown that the variant M408V does not affect the impact of other 
polymorphisms (Shu et al., 2003; Tzvetkov et al., 2014). Additionally, cells overexpressing 
T245M were shown to have at least a double tandem integration of the respective 
expression plasmid (Figure 4.2). As the variant showed clear substrate-specific effects 
(Figure 4.5) it can be assumed that multiple tandem integration did not affect functional 
characteristics of T245M. So far no studies analyzing the effect of multiple tandem 
integrations into HEK293 cells after stable transfection are available. However, it needs to 
be considered that the allelic variants were selected based on equal overexpression of 
OCT1 (Figure 4.3).  
According to haplotype inferring analyses the complete loss-of-function variants S29L and 
E284K exist in combination with P341L and M408V, respectively (Seitz et al., 2015) 
(Figure 1.2). The constructs that were used in this work contained proline341 and 
methionine408 instead. However, the amino acid substitutions in P341L and M408V were 
shown not to affect OCT1 transport activity in vitro or in vivo (Shu et al., 2003; Takeuchi 
et al., 2003; Sakata et al., 2004; Shu et al., 2007; Yoon et al., 2013; Chen et al., 2014). As 
the S29L and E284K variants showed complete lack of activity it is unlikely that proline341 
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or methionine408 could restore transport activity. This assumption is supported by the 
previous finding that M408V does not alter the impaired transport activity of M420del 
(Shu et al., 2003). Therefore, it can be concluded that it is unlikely that the complete loss of 
activity for the allelic variant S29L could be restored in combination with P341L.  
Cells overexpressing C88R/M420del were previously generated and characterized in our 
lab (Tzvetkov et al., 2012). In this work a refined validation strategy was used in order to 
characterize the generated cell line in detail and tested for multiple tandem integration of 
the expression plasmid. This method has been previously established in the lab of Clinical 
Pharmacology (Pojar, 2015). It could be shown that the allelic variant C88R/M420del has 
at least a double tandem integration with the respective expression plasmid (Figure 4.2). 
However, despite the multiple-integration, the cells did not show transport for any of the 
substrates tested. Therefore it could be concluded that the multiple tandem integration does 
not affect the functional characteristics of C88R/M420del.  
In summary, this work provides a detailed, functional characterization of global OCT1 
genetic variants using a broad spectrum of structurally diverse substrates including both, 
typical model substrates as well as clinically relevant drugs. With this, a substantial 
number of substrate-specific variants could be identified. As a broad range of structurally 
diverse OCT1 substrates were tested, it could be shown that it is not sufficient to test single 
OCT1 substrates in order to predict the effect of identified OCT1 variants. This is 
especially true concerning the high number of variants showing substrate-specific loss of 
activity. 
 
5.1.1 Complete loss of transport activity is caused by improper membrane 
localization 
Analysis was performed on the 15 major alleles regarding their subcellular localization of 
OCT1 using immunofluorescent staining and confocal microscopy. It could be shown that 
the allelic variants OCT1*5 (G465R/M420del), OCT1*6 (C88R/M420del), OCT1*12 
(S29L), and OCT1*15 (E284K) were not located in the plasma membrane, but rather 
seemed to be retained in the endoplasmic reticulum (Figure 4.6 A). Therefore, this data 
clearly shows that the reason for the complete lack of transport activity observed for these 
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variants is improper membrane localization and that complete loss of function of the 
polyspecific transporter OCT1 can only be achieved by lack of membrane localization. 
Additionally, the allelic variants that lack correct membrane localization showed a different 
glycosylation pattern of the OCT1 protein (Figure 4.7). The mouse monoclonal anti-human 
OCT1 specific antibody (2C5) used in the western blot analysis of whole cell protein 
lysates revealed two bands for OCT1 at approximately 50 kDa and 70 kDa. As suggested 
earlier, the bands represent different glycosylation forms of OCT1 as shown by 
deglycosylation using PNGaseF (Denk et al., 2004). The glycosylated form of OCT1 at 
50 kDa could be specified as being EndoH and PNGaseF sensitive and the 70 kDa form 
could be specified as being EndoH resistant and PNgaseF sensitive (Figure 4.7). EndoH 
only cleaves within the chitobiose core of high mannose and some hybrid oligosaccharides 
from N-linked glycoproteins (Capell et al., 2000; Hagglund et al., 2004). These sugar 
residues are formed at the beginning of the glycosylation process of the protein in the 
endoplasmic reticulum, when the active dolichol transfers sugar residues on asparagine 
(Hart, 1992). Higher glycans can only be cleaved by PNGaseF (Plummer et al., 1984) and 
appear after removal of mannose residues and the addition of sugar residues in the Golgi-
apparatus (Hart, 1992; Helenius, 1994; Harding et al., 1999). The allelic variants 
C88R/M420del, G465R/M420del, S29L, and E294K showing complete loss of activity 
only revealed the EndoH sensitive form at approximately 50 kDa in western blot analysis 
suggesting abortion of protein maturation (Figure 5.1). In contrast, all other variants tested 
showed a glycosylation pattern similar to wild type OCT1.  
Western blot analysis of human liver samples revealed only one band for OCT1 at 
approximately 70 kDa (Nies et al., 2009). Accordingly it can be interpreted that this band 
represents the EndoH resistant and PNgaseF sensitive glycosylated form of the protein, 
whereas the EndoH and PNgaseF sensitive form at 50 kDa is missing. As transfected 
HEK293 cells were used to overexpress OCT1 for western blot analysis, this observation 
underlines the assumption that the observed glycosylated form at 50 kDa represents an 





Figure 5.1 Processing of N-linked oligosaccharides of the glycosylated protein in the endoplasmic 
reticulum (ER) and in the Golgi apparatus. Shown is the processing pathway of N-linked oligosaccharides 
starting in the lumen of the endoplasmic reticulum. During the highly ordered processing sugar residues are 
removed or added by specific enzymes as indicated in order to finally generate highly complex 
oligosaccharides. The EndoH resistant oligosaccharide consists of a core of three mannoses that is present in 
all complex oligosaccharide. The resulting complex oligosaccharides are EndoH-resistant but remain 
PNGaseF-sensitive. As suggested by immunostaining the allelic variants S29L, C88R/M420del, E284K, and 
G465R/M420del are retained in the endoplasmic reticulum and revealed a glycosylated form of 50 kDa in 
western blot analysis, which is sensitiv to EndoH. This result indicates oligosaccharide processing of the 
glycosylated protein in these variants is terminated in the endoplasmic reticulum. All other variants were 
shown to be located in the plasma membrane and revealed a high glycosylated form at 70 kDa in western blot 
analysis, which in EndoH-resistant and PNGaseF-sensitive. 
 
The G465R variant was reported to strongly decrease plasma membrane localization of 
OCT1 in MDCK and HEK293 transfected cells (Shu et al., 2003; Ahlin et al., 2011). The 
studies analyzed the membrane localization by confocal microscopy of cells transfected 
with GFP-tagged OCT1 constructs. Additionally, Ahlin et al. performed western blot 
analysis of membrane fractions. As a control they showed staining of Na+/K+ ATPase as a 
plasma membrane marker. However, contamination with cytosolic protein could not be 
excluded as an appropriate marker such as GAPDH (as a cytosolic protein) or calnexin (as 
a marker for the endoplasmic reticulum) was not included in their study. It needs to be 
pointed out that in the present thesis, both, immunofluorescence and western blot analysis 
of whole cell lysates, only allow qualitative statements about OCT1 membrane 
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localization. So far, it is not possible to obtain pure membrane fractions using different 
protocols, which included membrane isolation via ultracentrifugation or biotinylation of 
plasma membrane proteins and subsequent isolation via streptavidin coated columns (data 
not shown). But although qualitative analysis was performed, the observations of a lack of 
membrane localization using immunofluorescence were in line with western blot analysis. 
Assuming that the different glycosylation pattern of the allelic variants with complete lack 
of transport activity represent differences in protein maturation that further affects 
membrane trafficking, the different glycosylation patterns support the idea of improper 
membrane localization. In order to clarify the obtained observation of a lack of membrane 
localization it should be noted that the establishment of a protocol for membrane isolation 
and the verification of the purity of membrane fractions with appropriate controls is 
required. 
The allelic variants with a strong substrate-wide decrease, but not complete loss, in 
transport activity OCT1*3 (R61C), OCT1*4 (G401S), and OCT1*14 (R206C/M420del) 
were shown to be located on the plasma membrane (Figure 4.6 A). In comparison to 
staining of wild type, R61C and R206C, but not G401S, there seems to be less expressed in 
the plasma membrane. This observation is in line with previous studies that analyzed 
membrane localization of R61C and R206C in membrane fractions of stable transfected 
HEK293 cells and showed strong reduction of membrane localization for these variants 
(Chen et al., 2010; Ahlin et al., 2011). However, as the protein was not totally absent in the 
plasma membrane (Figure 4.6 A), one may conclude that the substrate-wide decrease in 
uptake activity is due to the reduced membrane localization. This would be in line with the 
observation that R206C decreased the uptake of metformin and R61C decreased the uptake 
of debrisoquine due to reduced vmax whereas the Km was not affected for either variants 
(Chen et al., 2010; Saadatmand et al., 2012). 
All variants showing substrate-specific loss of activity or no changes in the activity 
compared to wild type showed no aberrant plasma membrane localization (Figure 4.6 B, 
C). For the variants P117L, R488M and M420del correct membrane localization was 
shown before (Shu et al., 2003; Chen et al., 2010) whereas subcellular localization of the 




5.1.2 Evolutionary conservation as a predictor of loss of function 
The amino acid scoring systems Grantham and BLOSUM62 were previously used in order 
to predict the effect of identified OCT1 allelic variants on transport activity (Leabman et 
al., 2003). Lower Grantham values indicate chemical similarity, whereas higher values 
indicate radical chemical changes (Grantham, 1974). A more negative BLOSUM62 value 
indicates an evolutionary unfavorable change (Cargill et al., 1999; Shu et al., 2003).  
Changes of evolutionarily conserved amino acids in OCT1 were predicted to cause OCT1 
loss of function as evolutionarily conserved amino acids were suggested to be important 
for the structure of the transporter and hence its function (Shu et al., 2003).  
 
 
Figure 5.2 Evolutionary conservation of amino acids in OCT1 orthologs (upper part) and paralogs 
(lower part). Substitutions in OCT1 that caused complete loss of function are shown in dark red, 
substitutions causing substrate-wide strong decrease in transport activity are shown in light red, substitutions 
causing substrate-specific loss of function are shown in yellow and substitutions that cause gain of OCT1 
function are shown in green.This figure was presented in a slightly modified form in Seitz et al. 2015 (Seitz 
et al., 2015) 
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In this study, complete loss of function was observed for the allelic variants 
C88R/M420del, G465R/M420del, S29L, and E284K as these variants lack plasma 
membrane localization (Figure 4.6). One might speculate that the affected amino acids are 
important for OCT1 structure and that changes of these amino acids prevent correct 
membrane localization. The affected amino acids are highly conserved among mammalian 
OCT1 orthologs (Figure 5.2). Moreover, serine29 is conserved in organic cation members 
of the SLC22 family OCT2 and OCTN1-2, but not in OCT3. Serine29 is located in the first 
transmembrane domain of the OCT1 protein (Figure 5.3). One may speculate about the 
involvement of the 1st transmembrane domain in trafficking of OCT1 to the plasma 
membrane as it was shown that the big extracellular loop between the 1st and the 2nd 
transmembrane domain is important for oligomerization and membrane localization of 
OCT1 (Keller et al., 2011). The exchange of the hydrophilic, polar serine29 to the 
hydrophobic, non-polar leucine may affect amino acids interactions in the 1st trans-
membrane domain and hence impair correct protein folding that disable correct membrane 
localization. 
Cysteine88 and glutamic acid284 are strongly conserved both in mammalian OCT1 orthologs 
and in the other members of the SLC22 family (Figure 5.2). The affected cysteine88 is 
located in the big extracellular loop between the 1st and the 2nd transmembrane domain 
(Figure 5.3). Cysteines in the big extracellular loop were shown to be important for homo-
oligomerization of OCT1 by formation of disulfide bonds (Keller et al., 2011). The homo-
oligomerization is important for plasma membrane localization (Keller et al., 2011). The 
importance of extracellular cysteines for protein folding and oligomerization by formation 
of disulfide bonds and correct membrane localization has been shown for OCT2 (Brast et 
al., 2012). Therefore, substitution of cysteine88 to arginine in OCT1 may prevent formation 
of disulfide bonds, which impairs plasma membrane localization.  
Glutamic acid284 is located at the beginning of the big intracellular loop between the 6th and 
the 7th transmembrane domain (Figure 5.3). The substitution of the negatively charged 
glutamic acid against the positively charged lysine represents a radical chemical change. 
The adjacent amino acid serine285 is one of the proposed phosphorylation sides of protein 
kinase C and would possess a negative charge when phosphorylated (Zhang et al., 1997). 
Therefore, the exchange to a positively charged lysine284 may strongly disturb theoretically 
possible charge interactions. This may impair protein folding and thus membrane 
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trafficking. However, according to prediction software analyzing potential serine 
phosphorylation sites, the potential serine285 phosphorylation site is not altered by the 
E284K variant (using NetPhos 2.0; http://www.cbs.dtu.dk/services/NetPhos). 
The conservation of glycine465 was previously analyzed in detail. Glycine465 is highly 
conserved among OCT1 orthologs, OCT2 and OCT3, and even in OAT1-3 (Figure 5.2) 
(Shu et al., 2003). The variant G465R was predicted as a loss of function variant due to its 
high Grantham value of 125, indicating radical chemical changes, and a negative 
BLOSUM62 value of -2, indicating evolutionarily unfavorable changes (Shu et al., 2003). 
One reason for the extreme effect of the G465R variant may be the radical chemical 
change from uncharged glycine to positively charged arginine. Alanine is the only other 
amino acid observed at codon 465 among OCT1 orthologs and paralogs (Figure 5.2). 
When glycine465 was substituted against alanine, this artificial variant exhibited normal 
transport activity (Shu et al., 2003).  
Additionaly, the affected amino acids of variants showing a substrate-wide decrease of 
transport activity (R61C, G401S, and R206C/M420del) are highly conserved among OCT1 
orthologs, and also in OCT2 and OCT3. The affected glycine401 and arginine206 are also 
conserved in OAT1-5 and some other members of the SLC22 family (Figure 5.2).  
For R206C it is suggested that a decrease in transport activity is caused by reduced 
membrane localization (Chen et al., 2010). Using confocal microscopy analysis also in this 
work a decrease in membrane localization for the R206C variant could be suggested as the 
immunofluorescence staining intensity was decreased compared to wild type OCT1 (Figure 
4.6). Chen et al. suggested that reduced membrane localization was due to the possible 
involvement of arginine206 in the arginine-based endoplasmic reticulum localization signal 
(Chen et al., 2010). Another possibility is that substitution of arginine206 in the extracellular 
loop between the 3rd and the 4th transmembrane domain against cysteine may lead to 
interactions with other extracellular cysteines. Formation of additional disulfide bonds may 
change protein structure and impair structural changes necessary for membrane trafficking. 
In order to emphasize the importance of the conserved arginine206 for OCT1 membrane 
localization, Chen et al. mutated the respective amino acid in OCT3 (R212C) and OAT2 
(R202C). Both mutants revealed strong reduction in membrane localization similar to 




Figure 5.3 Localization of functional OCT1 polymorphisms within the secondary structure of the 
OCT1 protein. Substitutions that caused complete loss of function are shown in dark red, substitutions 
causing substrate-wide strong decrease in transport activity are shown in light red, substitutions causing 
substrate-specific loss of function are shown in yellow and substitutions that cause gain of OCT1 function are 
shown in green. The amino acids threonine516 and lysine517 are suggested to interact with serine401 (see 
below) and are shown in gray. This figure was presented in a slightly modified form in Seitz et al. 2015 (Seitz 
et al., 2015) 
 
The conservation of glycine401 has been previously noted (Shu et al., 2003). In line with the 
observations in this work and previous studies in our lab, Shu et al. observed strong 
decrease in transport activity for G401S and also a strong decrease in the vmax for the 
uptake of metformin and debrisoquine whereas, the Km of these substrates was not affected 
(Figure 4.5) (Shu et al., 2007; Saadatmand et al., 2012). It can be inferred that the strong 
decrease in transport activity was not due to decreased membrane localization (Figure 4.6 
A). However, so far structural reasons for the strong decrease of the G401S variant are not 
known. Shu et al. suggested that the conserved glycine residue may be of high importance 
for OCT1 structure and therefore substitution of glycine401 may strongly affect OCT1 
function (Shu et al., 2003). But so far, the structural mechanism underlying the observed 
effect of G401S on transport activity is not known.  
A first approach to explain the effect of the G401S variant was made together with Ralf 
Krätzner from Department of Pediatrics and Adolescent Medicine, University Medical 
Center Göttingen, using an inward open homology model of OCT1 (Model-ID Q9NQD4, 
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http://modbase.compbio.ucsf.edu), that was derived from the crystal structure of LacY 
from E.coli (PDB number 1pv6) (Figure 5.4) (Seitz et al., 2015). The 3D model suggested 
close contact of serine401, which is located in the intracellular loop between the 8th and the 
9th transmembrane domain, with threonine516 or lysine517 at the C-terminal end of the 12th 
transmembrane domain. This close contact could lead to formation of a hydrogen bond 
between the hydroxyl group of serine401 and the carbonyl oxygen of threonine516 or the 
amino group of the lysine517 side chain, respectively (Figure 5.4). Due to the hydrogen in 
the side chain of glycine401 there is much more conformational flexibility than all the other 
amino acids. Due to the formation of a hydrogen bond when an exchange to serine401 is 
performed there may be a reduction in protein plasticity, which is suggested to be 









Figure 5.4 (previous page) Predicted 3D model of the OCT1 protein showing the position and possible 
interactions of serine401. The homology model of the inward facing conformation of OCT1 
(Model-ID Q9NQD4, ModBase ) based on homology with lactose permease LacY of 
E.coli (PDB number: 1pv6). The model was visualized using the PyMol software version 
1.3 (Schrödinger, LLC, München, Germany). The red sphere represents the G401S amino 
acid substitution between the 8th and the 9th transmembrane domain (left). The detailed 
representation on the right shows the predicted interaction via formation of a hydrogen 
bond between the hydroxyl oxygen of serine401 and carbonyl oxygen threonine516 or the 
side chain amino group of lysine517, respectively. Oxygen atoms are represented in red and 
nitrogen atoms in blue. Figure taken from (Seitz et al., 2015) 
 
The allelic variants I449T and T245M were newly identified and predicted by several 
bioinformatics tools to cause loss of OCT1 function (Seitz et al., 2015). However, these 
variants were shown to cause substrate-specific loss of activity (Figure 4.5). This finding 
emphasizes that bioinformatic prediction is not sufficient and a functional characterization 
of newly identified variants is essential. In case of threonine245, which is highly conserved 
among OCT1 orthologs, OCT2 and OCT3, this strong evolutionary conservation is not 
sufficient to predict the effect of an amino acid exchange at position 245. Moreover the 
substitution of threonine245 to methionine is a radical chemical change from a hydrophilic 
to a hydrophobic amino acid. Radical chemical changes of amino acids were predicted to 
strongly affect OCT1 activity (Shu et al., 2003). However, the variant T245M did not 
caused a complete loss of OCT1 activity, but a substrate-dependent loss of activity. 
Similar observations were made for the variant P117L, which was shown not to affect 
OCT1 activity (Figure 4.5). Proline117 is highly conserved among OCT1 orthologs, OCT2 
and OCT3 (Figure 5.2). Proline residues are known to be important for protein structure. 
However, substitution of proline117 to leucine did not affect transport activity. 
Taken together, the evaluation of evolutionary conservation can be used as an indicator for 
the effects of newly identified variants on OCT1 function, but does not replace the need for 




5.2 Strong worldwide variations in the frequency of loss of OCT1 
activity 
Together with the results from the global analyses of OCT1 genetic variability, previously 
performed by Robert Stalmann and Nawar Dalila, and the functional data of OCT1 allelic 
variants presented in this thesis a world map is able to be created illustrating the global 
distribution of loss-of function variants in OCT1 (Figure 5.5; (Seitz et al., 2015)). With this 
in mind it was possible to analyze the frequency of the identified OCT1 variants in a 
sample set of 1079 DNA probes as well as the available data from the 1000 Genomes 
project (Seitz et al., 2015). 
 
 
Figure 5.5 Map illustrating the global distribution of loss of function of OCT1 activity. According to the 
functional analyses the OCT1 allelic variants OCT1*1, OCT1*8, and OCT1*9 were regarded as active, 
whereas the remaining major alleles OCT1*2, OCT1*3, OCT1*4, OCT1*5, OCT1*6, OCT1*7, OCT1*10, 
OCT1*11, OCT1*12, OCT1*13, OCT1*14, and OCT1*15 were regarded as loss of function variants as they 
decreased the uptake by more than 65 % for at least one of the substrates tested (Figure 4.5). Frequencies of 
carriers with two (green), one (orange), and zero (red) active OCT1 alleles are shown for different regions 




In European populations, on average, 53 % carried two, 38 % one and 8 % carried zero 
active OCT1 alleles (Figure 5.5). Similar frequencies to the European population have been 
reported before (Kerb et al., 2002; Shu et al., 2003; Tzvetkov et al., 2012). However, 
outside of Europe a strong variability in the frequency of loss-of-function OCT1 variants 
was observed (Figure 5.5). In populations of Japan and Oceania all individuals carried two 
active OCT1 allelic variants. In Han Chinese peoples, the major population in China, more 
than 98 % of the individuals carried two fully active OCT1 alleles and the remaining 2 % 
carried only one active allele (Seitz et al., 2015). In contrast, 87 % of the Surui Indians, a 
Native American tribe in the Amazon, carried two loss-of-function OCT1 alleles. The 
OCT1 variant OCT1*2 (M420del) was the most frequent loss-of-function variant observed 
in this population.  
Surui Indians are a small tribe in the Amazon of South America. Only eight DNA samples 
from this Native American population were available for this study suggesting possible 
overestimation of the number of carriers of loss-of-function OCT1 alleles in this 
population. However, the probability that the observation of 7 out of 8 Surui Indians are 
carriers of two loss-of-function alleles is made by chance and that the frequency of loss of 
OCT1 function would be similar to Europe is 6.3 x 10−8 according χ2 testing (chi-squared 
test) (Seitz et al., 2015). Other populations in South America were also found to have high 
frequencies of loss of function variants in OCT1. From the Karitina Indians, 29 % carried 
two and 64 % carried one loss-of-function OCT1 variant. Only 7 % of the Karitina Indians 
carried two fully active OCT1 alleles (Seitz et al., 2015).  
The examples of East Asian populations in which almost all individuals carry two active 
OCT1 alleles and the native populations in South America with very high frequency of loss 
of function OCT1 activity illustrate the big difference in the frequencies of OCT1 loss of 
function globally (Figure 5.5). This observation was further supported by analyzing the 
pairwise fixation index (FST value) that represents the divergence of loss of OCT1 activity 
among different world regions. The highest FST value was observed between populations 
of East Asia and South America indicating strong divergence between these two world 
regions (Seitz et al., 2015). As the populations in South America and East Asia shared a 
common ancestor, one reason for the observed high genetic variability could be due to a 
Discussion 
169 
selection pressure for either keeping or losing OCT1 activity (Li et al., 2008; Seitz et al., 
2015). A previous study from Raghavan et al. indicated that the ancestor of Native 
Americans is more likely found in the Siberian Upper Palaeolithic population indicating 
that the separation from East Asians and Japanese may have occurred earlier than expected 
(Raghavan et al., 2014). However, in this region two active OCT1 alleles were observed 
with extreme frequency in the individuals that have been analyzed (Figure 5.5).  
So far, the reason for the strong variation in loss of function of OCT1 activity between East 
Asian and South American populations is not known. One might speculate about a 
selection pressure that either favored keeping OCT1 activity in East Asia or losing it in 
South America. Population genetic analyses were performed to test for neutrality of the 
observed loss of OCT1 function. Based on the results from the functional analyses of 
OCT1 allelic variants, it is possible to analyze separately the nucleotide diversity for the 
amino acid substitutions causing loss of OCT1 function (LOF) and the ones not causing 
loss of function (non-LOF) (Seitz et al., 2015) (Table 5.1). The latter should represent the 
neutral effects on the distribution. The nucleotide diversity is used as a quantification 
parameter for the observed genetic variability. When comparing the observed (π) and 
expected nucleotide diversity of the OCT1 LOF variants (θ Teta), the observed loss-of-
function nucleotide diversity in East Asia and Oceania was significantly lower than the 
expected value as shown by the significant negative values in the Tajima’s D test (Tajima’s 
D = −1.64, P <0.01). This analysis delivered the strongest support for the existence of a 





Table 5.1 Population genetic statistics for the OCT1 gene in different world regions. Table was taken 
with modifications from (Seitz et al., 2015) 
 
 
The selective agent for keeping OCT1 activity has not yet been identified. For other 
polymorphic genes that are involved in the uptake and metabolism of drugs, exogenous 
toxins were suggested as a selective agent (Nebert, 1997; Ingelman-Sundberg, 2001). One 
may speculate that in the case of OCT1, organic cations or hydrophilicly weak organic 
bases as components of nutrition could act as selective agents. For example, 
monoctrotaline is a pyrrolizidine alkaloid derived from the Crotalaria genus, which 
undergoes hepatic biotransformation resulting in toxic pyrrole derivates (Adams and 
Rogers, 1939; Petry et al., 1984). Monocrotaline is a known substrate of OCT1 and genetic 
variants of OCT1 allelic variants were shown to affect uptake of monocrotaline (Tu et al., 
2013; Seitz et al., 2015). Except for the gain of function allelic variants OCT1*8 and 
OCT1*9 all allelic variants analyzed in this work strongly decreased monocrotaline uptake 
by at least more than 67 % (Seitz et al., 2015). Individuals with reduced hepatic uptake of 
monocrotaline due to loss of function OCT1 allelic variants may be protected from 
monocrotaline induced hepatotoxicity. However, monocrotaline-containing plants are used 
in the traditional Chinese herbal medicine and in food supplements, but as unwanted 
contaminations Crotalaria is also found in beverages (Huxtable, 1980; Fu et al., 2002). 
Although the global occurrence of monocrotaline and the distribution of loss of function 
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OCT1 variants do not overlap, this example may illustrate how a certain natural toxin may 
act as a selective agent.  
Another selection pressure may be the potential role of OCT1 in the development of 
Beriberi, a disease caused by deficiency of thiamine (vitamin B1). The clinical picture of 
beriberi is very complex: with common symptoms being loss of weight, emotional 
disturbance, impairment of sensory perception, weakness and pain in the limbs, periods of 
irregular heart rate, and edema (Williams et al., 1940; Whitfield, 1947; Minicucci et al., 
2004). The first clear reports about the clinical picture of beriberi were found in the 10th 
century in China. But in the 18th century it became a serious problem in Japan (Carpenter, 
2012). Good sources of thiamine are milk and milk products, pork, grain products, and 
eggs (Batcher and Nichols, 1984). Possibly due to their diet, high in consumption of 
polished rice, Asian populations have a thiamine undersupply which can lead to beriberi 
(Strong and Crowell, 1912). Thiamine was recently shown to be a substrate of OCT1 and 
loss-of-function genetic variants of OCT1 were shown to affect thiamine transport (Chen et 
al., 2014). Oct1 deficient mice have increased triglyceride levels in the liver caused by 
reduced hepatic uptake of thiamine (Chen et al., 2014). This loss of OCT1 activity may 
increase sensitivity towards thiamine malnutrition. Therefore, one may speculate that it is 
an advantage to keep OCT1 activity especially in East Asia, where polished rice is a 
dietary staple. However, retaining OCT1 activity seems to not be sufficient considering the 
high incidence of beriberi in China and Japan due to severe thiamine undersupply. Most 
importantly, as cultivation of rice started about 11 000 – 12 000 BC or later and the 
production of white rice is suggested to be begun around 1700 in Japan, polished rice may 
not be considered as a selective agent (Carpenter, 2000; Sweeney and McCouch, 2007). 
However, it is not known if the reported individuals that died of beriberi were carriers of 
loss-of function OCT1 alleles and hence more susceptible to vitamin B1 malnutrition.  
Although the examples of monocrotaline toxicity and the beriberi disease can theoretically 
explain the advantage for either losing or keeping OCT1 activity, respectively, they cannot 
explain the observed differences in the frequency of loss of OCT1 activity between East 
Asia and South America. The selective agent for keeping OCT1 activity in East Asia 
remains unknown.  
Discussion 
172 
Besides a certain selection pressure for keeping OCT1 activity in East Asia, also a genetic 
drift could be taken into consideration trying to explain the strong global variability in loss 
of OCT1 function. A genetic bottleneck may have caused the high frequency of loss of 
OCT1 activity in South America. In accordance to the Out of Africa hypothesis, the South 
American Indians have traveled the longest migration distance among the modern Homo 
sapiens (Nei and Roychoudhury, 1993; Goebel et al., 2008). Population genetic analysis 
revealed positive correlation of loss of OCT1 activity and the migration distance of the 
modern Homo sapiens from Addis Ababa, which is assumed as the starting point according 
to the Out of Africa model (Liu et al., 2006; Seitz et al., 2015). Moreover, genetic diversity 
decreased betwen North to South America (Hunley and Healy, 2011). The genetic 
bottleneck may have occurred when the Surui Indians came in contact with diseases of 
civilization like measles, influenza, and chicken pox to which they were not resistant to, 
e.g. the Surui Indians of Rondonia suffered mortality rates up to 50 % following 
colonialization in the first decades of the 20th century (Moran, 1996).  
Although we can speculate only about probable causes, we can draw certain conclusions 
from the observed variability in loss of OCT1 function globally. Inter-individual 
differences in response to commonly used drugs like morphine, metformin, tropisetron, 
debrisoquine, and O-desmethyltramadol were observed due to loss-of function 
polymorphisms in OCT1 (Tzvetkov et al., 2009; Tzvetkov et al., 2011; Saadatmand et al., 
2012; Tzvetkov et al., 2012; Tzvetkov et al., 2013). Hence, one might speculate that in East 
Asia, the inter-individual differences in plasma concentrations of drugs that are substrates 
of OCT1 are smaller than in Europe. Indeed, Zouh et al. found higher renal clearance of 
morphine in Chinese individuals than in Caucasian individuals due to increased 
glucuronidation of morphine to its metabolites morphine-3-glucuronide and morphine-6-
glucuronide (Zhou et al., 1993). Based on the current knowledge one might speculate that 
the high frequency of carriers of two active OCT1 alleles in East Asia can be taken into 
consideration to describe the observed effect in the study of Zhou et al. Morphine is a 
substrate of OCT1 and needs to be taken up into hepatocytes in order to be metabolized to 
prior to excretion (Sadhasivam et al., 2012; Fukuda et al., 2013; Tzvetkov et al., 2013). As 
in the Chinese population almost all individuals have two active OCT1 alleles, the OCT1-
mediated morphine uptake might be higher in the studied individuals of Zhou et al. and 
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hence more of its metabolites could be produced leading to generally lower plasma 
concentrations of morphine. Moreover, the Chinese individuals were less sensitive to the 
adverse effects of morphine such as respiratory depressant or the hemodynamic effects of 
morphine like vasodepression. Contradictory, Chinese individuals were more sensitive to 
nausea (Zhou et al., 1993). Next to East Asia, the majority of individuals from African 
populations carried two active OCT1 alleles (Seitz et al., 2015). Fukuda et al. analyzed the 
higher incidence of morphine adverse effects in children from Caucasian population in 
comparison to children from African-American populations. They found that in 
homozygous carries of loss of function OCT1 allelic variants morphine clearance was 
significantly lower than in heterozygous carriers or carriers of two active OCT1 alleles 
(Fukuda et al., 2013). This is in line with recent findings that in African populations the 
majority of individuals have two active OCT1 alleles (Seitz et al., 2015).  
In contrast to Chinese, Cepeda et al. reported that Native Americans were more susceptible 
to morphine induced respiratory suppression (Cepeda et al., 2001). One possible 
explanation could be the reduced OCT1-mediated uptake due to higher frequency of loss of 
function OCT1 polymorphism in this ethnic group (Figure 5.5, Table 5.1). Unfortunately, 
the study does not specify the affiliation of the Native Americans studied. However, in the 
Karitiana tribe, a native Indian tribe of Brazil, the frequency of OCT1 loss of function was 
high with 29 % and 64 % of the individuals carrying two and one loss of function alleles, 
respectively (Seitz et al., 2015).  
In conclusion, we observed strong global variation in the frequency of loss of OCT1 
activity. The reason for the observed variability remains unknown. However, the genetic 
variability might account for the observed inter-individual differences in drug response for 
drugs that are substrates of OCT1. Inter-individual differences in drug response due to 
inter-ethnical genetic variability were also described for other enzymes responsible for 
drug uptake and metabolism (Xie et al., 2001; Burroughs et al., 2002). Hence, the 
knowledge of the individual genotype might help to improve adjustment of drug 
medication in order to achieve the best therapeutic efficacy while reducing adverse effects 




5.3 Model substrates are not sufficiently to predict allele-specific effects 
on morphine and metformin uptake 
The substrate-specific loss-of-function allelic variants M420del, S14F, S189L, I449T, and 
T245M were analyzed for their ability to predict their effect on the uptake of morphine and 
metformin by measuring the uptake of model substrates (MPP+, TEA+, ASP+). None of the 
model substrates analyzed was able to predict the effect of both drugs (Figure 4.8). 
Whereas, the uptake of morphine correlated better with the uptake of ASP+, the uptake of 
metformin correlated better with the uptake of TEA+. Hence, using model substrates for the 
prediction of the functionality of new identified genetic variants for uptake of divers drugs 
cannot lead to reliable conclusions.  
Similar observations were recently made in a study by Hacker et al. in which they screened 
for inhibitors of OCT2 and analyzed if the inhibition of the uptake of the model substrates 
MPP+ and ASP+ could be used to predict the effect of the inhibitors on the uptake of 
clinically relevant drugs that are substrates of OCT2 such as metformin. They found a 
moderate correlation between the inhibition of the OCT2-mediated uptake of MPP+, ASP+, 
and metformin (Hacker et al., 2015). According to their analyses, the inhibition of ASP+ 
mediated uptake correlated better with the metformin-mediated inhibition than MPP+. 
However, inhibition of ASP+-mediated uptake could only partially predict the effect of the 
inhibitor on metformin mediated uptake. Hacker et al. concluded that the inhibition of 
clinically relevant drugs is strongly substrate-dependent and that in vitro inhibition assays 
for the respective substrate are necessary to predict possible drug-drug interactions in vivo 
(Hacker et al., 2015). 
Taken together, it is not sufficient enough to characterize the functionality of newly 
identified genetic variants by measuring the uptake of model substrates in order to predict 
their effects on the uptake of diverse drugs. As a crystal structure of OCT1 is not yet 
available and the structural mechanism behind OCT1-mediated transport is not fully 
understood, it is indispensable to evaluate the effects of substrate-specific loss-of-function 




5.4 Prediction of multiple binding sites in OCT1 
Five out of 19 variants tested (26 %) showed substrate-specific loss of activity, which 
supported the analyses of Urban et al., in which they reported that 17 % of non-
synonymous variants in drug transporter causing substrate-specific effects (Urban et al., 
2006). As their study only analyzed the effect on two substrates, the percentage of substrate 
specific loss-of-function variants may be even higher. Interestingly, most of the variants 
showing substrate-specific loss of activity, except S14F, are located in the transmembrane 
domains of the protein (3rd, 5th, 9th, and 10th, Figure 5.3). Of these transmembrane domains 
the 5th and the 10th are known to be involved in formation of the substrate binding cleft 
(Gorboulev et al., 2005; Popp et al., 2005; Koepsell, 2011), but so far none of the variants 
located in these domains (S14F, S189L, I449T, T245M) are known to be involved in 
substrate binding. The fifth substrate-specific variant characterized in this thesis, M420del, 
is located at the end of 9th transmembrane. Up until now, it has not been reported that the 
9th transmembrane is involved in the formation of the substrate binding cleft.  
These five allelic variants showed up to 100 % loss of transport activity for some substrates 
tested and no difference to the wild type for others (Figure 4.5). Substrate-specific effects 
are another manifestation of the polyspecificity of OCT1. Therefore, detailed analyses of 
polymorphisms causing substrate-specific loss of function could give an insight into the 
mechanisms enabling the polyspecificity of OCT1 and its transport mechanisms in general.  
The correlation between different effects of OCT1 allelic variants and different structural 
properties of the substrates was tested. For this purpose, two-dimensional hierarchical 
clustering analyses were performed by the biostatistician Prof. Beißbarth from the 
department of Statistical Bioinformatics, University Medical Center Göttingen (Figure 
5.6). The analyses were based on the functional data of the genetic variants and their effect 
on uptake activity of several substrates and the structural differences between these 
substrates. A majority of this functional data was generated for this thesis. One dimension 
was the substrates and the other the genetic variants analyzed. The variants showing 
substrate-specific effects: S14F, M420del, S189L, I449T, and T245M are clustered 
together. These variants showed a decrease in the uptake of O-desmethyltramadol, 
tyramine, monocrotaline, TEA+, metformin, and tropisetron (Figure 4.5). These substrates 
are clustered as substrate group B according to their chemical and molecular properties 
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(Figure 5.6). In contrast, the uptake of ranitidine, MPP+, morphine, sumatriptan, ASP+, and 
debrisoquine (substrate group A) was not affected by these variants.  
As OCT1 is polyspecific, there is no single binding site but rather several binding sites that 
are forming a binding cleft. This makes it difficult to define distinct structural properties of 
a potential substrate. The substrate clustering in group A and B in this analysis is just a first 
approach to classify different substrates according to their different properties. So far it was 
not possible to define specific molecular or chemical determinants for classification. 
However, the more substrates are tested, the more this analysis could be refined. This 
presentation might help to identify structural properties of different substrates that could be 
affected be specific amino acids exchanges. With this one might identify possible multiple 








Figure 5.6 (previous page) Two-dimensional hierarchical clustering analysis. On the right are the 
different OCT1 variants clustered according to their effect on transport activity. On the bottom are the 
substrates tested, which are clustered according to their structural properties into substrate group A and B 
(table on the right). The different colors of the analysis represent the effect of the variants on OCT1 uptake 
activity ranging from dark red, which means complete loss of activity, to white and light blue, which means 
uptake activity like OCT1 wild type, up to dark blue, which means gain of activity. The analysis was 
performed with kind support of Prof. Beißbarth from the department of Statistical Bioinformatics, University 
Medical Center Göttingen. 
 
 
5.5 M420del caused highly substrate specific effects in OCT1 loss of 
function 
The M420del polymorphism is the most common and the only ubiquitously observed loss-
of-function OCT1 variant showing highly substrate specific-effects (Figure 1.3, Figure 
4.5). Characterization of the substrate specificity of M420del was performed in detail by 
determining the kinetic parameters Km and vmax for the uptake of TEA+, MPP+, ASP+, 
metformin, sumatriptan, and proguanil (Figure 4.12, Figure 4.13). 
In order to ensure that inter-day differences, like different cell passages, did not affect the 
extent of the observed substrate-specific loss of activity of the M420del variant uptake 
measurements with HEK293 cells overexpressing M420del and wild type were performed 
in parallel and were used for determination of the variation of Km and vmax of M420del 
from wild type OCT1 in each single experiment. Therefore, simultaneous uptake 
measurements with fenoterol and sumatriptan with three different concentrations (below 
Km, close to Km, and close to vmax) on the same day using identical cell passages was 
performed. The effect of M420del on the uptake of fenoterol and sumatriptan did not differ 
in three independent experiments (Figure 4.14).  
Highly substrate-specific effects of M420del were observed on the uptake kinetics of 
TEA+, MPP+, ASP+, metformin, sumatriptan, and proguanil (Figure 4.12, Figure 4.13). 
M420del decreased vmax for all substances tested except for metformin. The decrease 
varied from 30 % for TEA+ up to 85 % for fenoterol. Also substrate-specific of M420del 
on the Km were observed. M420del decreased the Km of MPP+, ASP+, sumatriptan, and 
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proguanil (Figure 4.13) in a range from 20 % for MPP+ to 65 % for proguanil. In contrast, 
the Km of TEA+ and metformin increased by 200 % and 400 %, respectively.  
Previously, the effect of M420del on the uptake kinetics of metformin, ASP+, and 
sumatriptan was analyzed by different groups (Shu et al., 2007; Ahlin et al., 2011; Matthaei 
et al., 2015). 
In the study of Shu et al., M420del increased the Km nearly 2-fold (Km = 2.42 ± 0.52 mM 
and 4.56 ± 1.08 mM for wild type and M420del, respectively), whereas in a study of Ahlin 
et al no effect of M420del on the Km (Km = 5.45 ± 0.29 mM and 5.19 ± 11.6 mM for wild 
type and M420del, respectively) was observed (Shu et al., 2007; Ahlin et al., 2011). In this 
work it could be shown that M420del increased the Km of metformin by 400 % (Figure 
4.13) demonstrating a strong decrease in metformin affinity. In both studies M420del 
significantly decreased the vmax by at least 2-fold (Shu et al.: vmax = 6.74 ± 0.88 
nmol/min/mg protein and 3.31 ± 0.56 nmol/min/mg protein for wild type and M420del, 
respectively; Ahlin et al.: (vmax = 31.9 ± 0.72 nmol/min/mg protein and 11.6 ± 0.16 
nmol/min/mg protein for wild type and M420del, respectively) (Shu et al., 2007; Ahlin et 
al., 2011). Contradictory to these findings, no differences in vmax for metformin between 
wild type and M420del could be observed in this work (Figure 4.12, Figure 4.13). 
In a study from Ahlin et al. it is reported that M420del did not affect uptake kinetics of 
ASP+ and hence the transport efficacy, determined as the quotient Km/vmax (Ahlin et al., 
2011). In this work, M420del insignificantly decreased the Km of ASP+ by 50 % (Figure 
4.13). However, it was observed that M420del affected the vmax to the same extent as Km 
showing a decrease by 50 %. Hence, in line with Ahlin et al. the resulting transport 
efficacy did not differ between wild type and M420del (vmax/Km of 4271.8 and 4154.2, 
respectively). It needs to be pointed out that at single concentration measurements, 
M420del showed 92 % of wild type activity (Figure 4.5). For these uptake measurements a 
substrate concentration of 5 µM was used, which is far below the Km determined in this 
study (Table 4.3). Hence, the effect of M420del on ASP+ uptake was not detected at single 
concentration measurements as M420del decreased the vmax and Km to the same extent (by 
50 %).  
Recently, sumatriptan has been shown to be a substrate of OCT1 and that sumatriptan 
uptake was not affected by M420del (Matthaei et al., 2015). In line with Matthaei et al. no 
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difference in the Km between wild type and M420del were observed in this work (Table 
4.3). Contradictory to the findings of Matthaei et al. a 44% decrease in vmax was observed. 
However, in line with the observations of Matthaei et al. the intrinsic clearance did not 
differ between wild type and M420del in this work (37 x 10-3 ml/min/mg protein and 26 x 
10-3 ml/min/mg protein for wild type and M420del, respectively). In vivo analyses of 
sumatriptan kinetics revealed that the sumatriptan plasma concentration was not affected in 
carriers of the M420del variant (Matthaei et al., 2015). However, also different in vivo data 
point to substrate-specific effects of M420del. Whereas the kinetics of sumatriptan were 
not affected, carriers of the M420del variant showed significantly higher plasma 
concentrations of morphine and O-desmethyltramadol (Tzvetkov et al., 2011; Tzvetkov et 
al., 2013; Matthaei et al., 2015). The increased plasma concentrations were associated with 
increased risk of adverse effects of morphine (e.g. nausea, dizziness, headache) or 
prolonged miosis, which was used as a surrogate parameter for the effect of O-desmethyl-
tramadol at the µ-opioid receptor (Tzvetkov et al., 2011; Tzvetkov et al., 2013). 
Taken together, analyzing several previous studies, which observed an effect of M420del 
on the uptake of a distinct substrate, highly substrate-specific effects of M420del were 
found. Whereas M420del impaired the uptake of metformin, no affects were observed on 
the uptake of ASP+ and sumatriptan (Shu et al., 2007; Ahlin et al., 2011; Matthaei et al., 
2015). However, so far a comparative analysis showing the effect of M420del on the 
uptake of different substrates is missing. In this work a detailed comparative analysis has 
been provided by determining the impact of M420del on a broad spectrum of substrates 
and the substrate-specific effect of M420del has been demonstrated. It needs to be pointed 
out, that in line with the previous studies, ASP+ and sumatriptan are two substrates that 
were not strongly affected by M420del. However, as a broad spectrum of substrates, was 
used it could be shown that the uptake of such as TEA+ and proguanil were strongly 
decreased by M420del due to reduced affinity or transport rate, respectively. Hence, these 
data demonstrate the highly substrate-specific effect of M420del. 
The deletion of methionine420 resulted in the decrease of vmax between 25 % and 85 % for 
all substrates tested, except for metformin (Figure 4.13). The vmax of metformin was not 
changed compared to wild type. In line with previous studies a reduced membrane locali-
zation of the M420del could not be observed (Figure 4.6 B) (Ahlin et al., 2011). Hence, the 
decrease in vmax was not due to aberrant membrane localization but rather an effect of 
Discussion 
180 
M420del on transporter turnover. However, the observation regarding membrane 
localization of M420del is still controversial (Giannoudis et al., 2013). So far pure mem-
brane fractions of protein lysates using different protocols for membrane isolation have not 
been successful. Therefore, the next aim is to improve protocols for membrane isolation for 
western blot analysis in order to verify the obtained results. 
The effects of the M420del variant on Km were highly variable among the substrates tested. 
For the majority of the substrates tested, M420del decreased the Km and the extent of 
decrease was substrate-dependent. Furthermore, the extent of decrease correlated with the 
two-dimensional hierarchical clustering analysis (Figure 5.6), which was used to analyze 
the effects of OCT1 variants in correlation with structural properties of different substrates. 
M420del only slightly decreased the Km of ranitidine, MPP+, and sumatriptan by on 
average of 20 %. According to the clustering analysis these substrates were found to be 
similarly affected. The Km of ASP+ was more affected by M420del causing a decrease by 
50 %. Similar effects were observed for fenoterol and proguanil showing a decrease by 
58 % and 64 %, respectively. It would be interesting to include these substrates in the 
clustering analysis, measuring the effects of different variants on the uptake of fenoterol 
and proguanil. On assumption that the uptake of these substrates would be similarly 
affected like the uptake of ASP+ this would verify that the M420del effects correlate with 
the effects of other genetic variants analyzed in the clustering analysis. 
A strong increase in Km by 200 % and 400 % was observed in the M420del variant for 
TEA+ and metformin, respectively (Figure 4.13). Hence, the affinity for TEA+ and 
metformin was decreased by deletion of M420. A decrease in affinity might be caused by 
indirect effects on amino acids that are involved in substrate binding (Koepsell and Keller, 
2016). TEA+ and metformin have similar chemical structures that strongly differ from 
those of the other OCT1 substrates tested. TEA+ and metformin are both aliphatic acyclic 
compounds, whereas the remaining substrates are aromatic compounds. TEA+ and 
metformin were also found to be similarly affected by other OCT1 variants as suggested by 
clustering analysis (Figure 5.6). Hence, M420del might have specific effects on OCT1 
substrates with similar chemical structures as TEA+ and metformin e.g. choline. Like 
TEA+, choline is an aliphatic acyclic, quaternary ammonium compound. Choline was 
shown to be transported by rOct1 (Gorboulev et al., 1999). It might be interesting to 
analyze the effect of M420del on choline uptake kinetics and to compare them with the 
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obtained data for TEA+ and metformin. This could reveal insight in how M420del changes 
OCT1 affinity in a substrate-dependent manner. In conclusion, the highly substrate-specific 
effects of M420del on OCT1 affinity were observed with cationic substrates with an 
aliphatic structure showing a strong decrease in affinity whereas more aromatic substrates 
showed either no change or a slight increase in affinity. 
 
5.5.1 Effects of M420del are caused by the specific loss of the methionine side 
chain 
Methionine420 is located in the 9th transmembrane domain of OCT1. So far, no amino acids 
of the 9th transmembrane have been reported to be involved in substrate binding or in 
transport mechanism of OCT1. Hence, one might speculate that indirect effects of a 
M420del are responsible for the observed substrate-specific effects. According to the 
homology model of rat Oct1, methionine421 is located at the end of the 9th transmembrane 
domain and may stabilizes the arrangement of the 9th and the 10th transmembrane domain 
within the three dimensional structure of the protein (Figure 4.18). Methionine is very 
flexible due to its low energy barrier between the different rotamer forms at the C-S bond 
(Gellman, 1991). Thus it was suggested that the flexibility is more due to the sulfur atom 
than to the lack of branching (Gellman, 1991). The sulfur atom of methionine is highly 
polarizable which makes the hydrophobic environment of methionine malleable (Gellman, 
1991; Yuan et al., 2000). Hence, methionine420 in human OCT1 might be important for the 
structural integrity and plasticity.  
In order to reveal insights into the mechanism underlying the observed M420del specific 
effect, together with Prof. Hermann Koepsell and Prof. Thomas Mueller from the 
University of Würzburg two hypotheses were generated based on the structural homology 
model of the inward and outward conformation of rat Oct1 (Popp et al., 2005; Gorbunov et 
al., 2008). The first hypothesis analyzed, if M420del specific effects are caused by an 
unspecific deletion of an amino acid at codon 420 (in this case methionine) that could lead 
to reduction in size of the protein chain between the 9th and the 10th transmembrane 
domain. A reduction in the size of the protein chain could change the position of amino 
acids or the flexibility of the 10th transmembrane domain, which is known to be involved in 
the translocation process (Gorboulev et al., 2005).  
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Data from several experimental tests resulted in the rejection of this hypothesis. Firstly, 
leucine427 or histidin428 were deleted in the wild type in order to simulate the shortening of 
the protein chain between the 9th and the 10th transmembrane domain caused by M420del 
(Figure 4.15). These mutants were expected to lead to substrate-specific loss of activity as 
observed in the M420del variant. However, the mutants L247del and H428del did not 
affect OCT1 activity for the uptake of TEA+ (Figure 4.20). The uptake was performed with 
5 µM TEA+, which is below the reported Km of TEA+ (Table 5.2). As discussed earlier, 
when measuring the uptake of a single concentration that is far below the respective Km of 
the substance, an impact on Km and vmax might be undetected if both parameters are 
affected to the same extent. Therefore, it might be interesting to analyze the effect of 
L427del and H428del on TEA+ uptake kinetics in order to analyze their effect on OCT1 
transport.  
Secondly, a mutant A426ins on M420del background was generated. The insertion of 
alanine after proline425 was expected to restore transport activity in M420del cells as the 
insertion should avoid the reduction in size of the protein chain between the 9th and the 10th 
transmembrane domain. However, the A426ins mutant could not restore transport activity 
in M420del cells for the uptake of TEA+ (Figure 4.17).  
Finally and most importantly, a mutant in which methionine420 was exchanged by alanine 
was generated in an attempt to avoid possible structural changes caused by deletion of 
methionine420. Alanine is a hydrophobic amino acid with the second shortest side chain 
with minimal functional role among amino acid. The mutant was tested with regards to its 
uptake activity for single concentrations of MPP+, TEA+, ASP+, morphine, metformin, 
tyramine, and proguanil. No differences in the uptake between M420A and M420del were 
observed (Figure 4.22). Kinetic studies for the uptake of TEA+, MPP+, metformin, and 
sumatriptan did not reveal differences in transport efficacy between M420del and M420A 
for all substances tested (Figure 4.23, Table 4.4). These results confirmed the assumption 
that the observed effects of M420del are caused by the specific loss of the methionine side 
chain. 
Taken together, the substrate-specific loss of function activity of M420del could not be 
explained by reduction of the protein chain and future work should be focused on the 
specific loss of the methionine amino acid side chain.  
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Methionine is a hydrophobic, aliphatic amino acid containing sulfur, which is not highly 
nucleophilic due to the methyl substituent. Due to its hydrophobicity methionine is more 
likely to be located in the protein core. The methionine side chain is non-reactive and it 
was difficult to suggest a direct role of methionine420 in substrate binding and translocation 
of OCT1.  
To experimentally clarify the potential role of the methionine420 side chain, M420 was 
substituted with different amino acids. The amino acids were chosen according to their side 
chain length or their chemical properties being similar or totally different to methionine 
(Figure 5.7). Methionine420 was exchanged against threonine, isoleucine or cysteine. 
Isoleucine is an uncharged hydrophobic amino acid with a non-reactive side chain having a 
similar length to methionine. However, in contrast to methionine it is more bulky close to 
the amino acid backbone due to its two substituents at the C-beta carbon. Thus, isoleucine 
is more conformational restricted. Therefore, it is more difficult for isoleucine to adopt in 
alpha helical conformations. Similar to isoleucine, threonine has two substituents at the C-
beta carbon making threonine more bulky than methionine. However, in contrast to 
isoleucine, threonine is a polar although uncharged amino acid and has a reactive hydroxyl 
group. Cysteine was tested as it is the only amino acid other amino acid besides methionine 





Figure 5.7 BLOSUM62 matrix. The substitution matrix illustrates evolutionary divergence between 
methionine and alanine, cysteine, threonine or isoleucine, respectively. A negative BLOSUM value indicates 
evolutionary unfavorable changes. BLOSUM62 matrix was obtained from http://www.ncbi.nlm.nih.gov 
 
The effect of the mutants M420T, M420I, and M420C on the uptake of MPP+, TEA+, 
ASP+, morphine, and metformin was investigated. None of the mutants tested could restore 
wild type activity (Figure 4.24). Moreover, none of the mutants showed significant 
difference in substrate uptake compared to M420del. Analysis of Km and vmax for the 
uptake of TEA+ showed no difference to M420del (Figure 4.25). Taken together none of 
these amino acids was functionally suitable to substitute methionine at position 420.  
Interestingly, the mutant M420C was suggested to lead to miss-folding of the protein due 
to assumed formation of disulfide bonds with adjacent cysteines e.g. cysteine419. This could 
have resulted in aberrant plasma membrane localization of the protein. However, M420C 
did not change subcellular localization of OCT1 (Figure 4.21). One explanation is that the 
cysteine residue was not exposed outside of the cell membrane and therefore was not in the 
highly oxidative milieu outside of the cell. This is an indirect indication that the 
methionine420 residue is localized within the 9th transmembrane domain and not on the loop 




Wild type activity was unable to be restored by substituting methionine420 against 
threonine, isoleucine, or cysteine. However, it could be possible that other amino acids 
than the ones tested could substitute for methionine. Therefore, it is interesting to analyze 
the conservation of methionine420 among other OCTs or other members of the SLC22A 
family. Methionine420 is highly conserved among OCT1 orthologs, but not in OCT2 and 
OCT3 or other paralogs (Figure 5.2). Evolutionary conservation was suggested to 
determinate the importance of an amino acid for transporter function (Shu et al., 2003). 
Methionine420 is not highly conserved among different OCT1 paralogs. However, one 
cannot exclude an essential role in OCT1 function. Several examples are known. However, 
as discussed earlier threonine245 is highly conserved among OCT1 orthologs and in OCT2 
and OCT3. However, the allelic variant T245M was shown to cause substrate-specific 
effects comparable to M420del (Figure 4.5). Hence, substitution of threonine245 did not 
cause a complete lack of transport activity. Moreover, although proline117 is highly 
conserved among OCT1 homologs, OCT2, and OCT3, substitution against leucine did not 
affect OCT1 activity in these analyses. Nevertheless, the knowledge about the homology 
between different members of the SLC22A family especially between the OCTs might help 
to understand the effects of M420del.  
At the position 420 in OCT2 and OCT3 are the amino acid serine and threonine, 
respectively. One of the mutants tested in this thesis was M420T. It is interesting to 
speculate if this mutant would behave as OCT3 concerning transport activity and substrate 
binding. Previous studies analyzed the uptake kinetics of morphine and metformin for 
OCT1 and OCT3 (Nies et al., 2009; Tzvetkov et al., 2013). Morphine is a substrate of 
OCT1, but it is not transported by OCT3 (Tzvetkov et al., 2013). In contrast, OCT3 had a 
2-fold higher transport capacity for metformin than OCT1, whereas the affinity for 
metformin did not differ between the two paralogs (Nies et al., 2009). However, the mutant 
M420T transported both, morphine and metformin (Figure 4.24). Additionally, whereas 
TEA+ is not a substrate of OCT3, it is transported by M420T (Grundemann et al., 1998). 
These examples demonstrate that the mutant M420T and OCT3 differ in their substrate 
specificity. Furthermore, it was recently shown that OCT1 has a 10-fold higher transport 
capacity for sumatriptan uptake and that OCT1 wild type and M420del did not differ in 
their uptake kinetics (Matthaei et al., 2015). As it could be shown that the mutant M420T 
did not significantly differ from M420del in the uptake of several substrates (Figure 4.24), 
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one might speculate that similar results would be obtained for the uptake of sumatriptan. 
Hence, the mutant M420T is also suggested to have a different uptake rate than OCT3.  
One has to consider that OCT1 and OCT3 only share 48 % identical amino acids. Hence, 
the amino acids that differ between OCT1 and OCT3 may have an impact on transporter 
structure and subsequently on its function. OCT1 and OCT2 share 68 % identical amino 
acids. As OCT2 has a serine at the respective position of methionine420 in OCT1 it may be 
interesting to test the effect of a M420S mutation in OCT1 on substrate uptake. 
In a previous study similar mutagenesis analyses were performed in order to analyze and 
characterize the importance of OCT1 function. Chen et al. analyzed the importance of 
arginine206. R206C is a polymorphism found in Asians that strongly decreased metformin 
uptake and impaired membrane localization (Chen et al., 2010) (Figure 4.6 A). They 
generated two mutants with either similar (R206K) or different (R206E) chemical 
properties to arginine206. Lysine is a positively charged amino acid like arginine and has a 
similar side chain length, whereas glutamic acid is negatively charged. The strong decrease 
of R206C in transport activity was suggested to be due to decrease membrane localization 
of the variant (Chen et al., 2010). The mutant R206K increased the amount of OCT1 in the 
plasma membrane and was shown to increase substrate uptake. However, R206K was not 
able to fully restore transport activity. In contrast, the substitution against the negatively 
charged glutamic acid caused a stronger decrease in substrate uptake than R206C and no 
appreciable membrane localization was detected for R206E (Chen et al., 2010). 
Another example is the study of Popp et al. in which the group generated mutants using 
structurally different amino acids in order to characterize the involvement of tryptophan218 
in the transport mechanism of rat Oct1 (Popp et al., 2005). In order to characterize 
tryptophane218, the amino acid was exchanged against phenylalanine (W218F), tyrosine 
(W218Y) or leucine (W217L). Phenylalanine and tyrosine are structurally similar to 
tryptophan, whereas substitution with leucine is a more radical chemical change. The 
mutant W218L decreased vmax for both, MPP+ and TEA+, in a similar range. The affinity 
for TEA+ was decreased, but the affinity for MPP+ was not affected. The mutant W218F 
did not change the Km or vmax for MPP+. In contrast, although the Km for TEA+ was not 
changed, the vmax was decreased by 50 %. Popp et al. concluded that the Km independent 
changes of vmax in the mutants W218L and W218F might suggest involvement of 
tryptophan218 in structural changes during the translocation process (Popp et al., 2005). In 
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contrast to W218F, the mutant W218Y showed significant decreases in Km and vmax for 
MPP+ and TEA+. The higher affinity for both substrates compared to the W218F mutant 
was suggested to be due to the hydroxyl group of tyrosine218 (Popp et al., 2005). Based on 
their data Popp et al. concluded that tryptophan218 is involved in binding of both, TEA+ and 
MPP+, and in translocation TEA+. 
Taken together, it could be shown that the substrate-specific effect of M420del is caused 
by the specific loss of the methionine side chain, but the structural mechanism underlying 
the effect of loss of the methionine side chain remains elusive.  
An alternative approach to reveal the role of the methionine420 side chain was to take an 
advantage from the existing homology models of OCT1 and try to validate potential 
interactions of methionine420 with distal amino acids. Possible interactions between 
methionine420 and amino acids of transmembrane domains, which are known to be 
involved in substrate binding, were analyzed. According to the homology model of rat 
Oct1 it was suggested that by deletion of methionine420 the more bulky amino acid 
isoleucine421 could be roped into the membrane and could interact with leucine364 and 
histidine367 in the 7th transmembrane domain, which could affect substrate uptake. The 7th 
transmembrane domain is known to be involved in formation of the substrate binding cleft 
(Popp et al., 2005). However, until now no amino acids in the 7th transmembrane domain 
were identified to be involved in substrate binding or in transport mechanism.  
The mutants L364A and H367A on M420del background were generated. Due to exchange 
of leucine364 and histidine367 against alanine the supposed interaction with the “roped” 
isoleucine421 should be avoided (Figure 4.18). Therefore, it was expected that these 
mutants will restore OCT1 wild type activity. However, it was observed that there was a 
significant decrease in the uptake of MPP+ and ASP+ in these mutants, although the uptake 
of MPP+ and ASP+ was not affected by M420del (Figure 4.20 A). The subcellular 
localization in these mutants was analyzed to ensure that the observed decrease was not 
caused by a decrease in membrane localization of the transporter. According to microscopy 
analysis the mutants L364A and H367A did not change the subcellular localization of 
OCT1 on M420del background (Figure 4.19). Hence, it is suggested that L364 and H367 
might be important for substrate uptake independently from M420del. To test this 
assumption, the mutants L364A and H367A on wild type and M420del backgrounds were 
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generated, respectively, and the uptake of TEA+ was measured. L364A and H367A 
strongly decreased TEA+ uptake independent from the background tested (Figure 4.20 B).  
Taken together, this data shows that an experimental validation for potential interaction of 
the “roped” isoleucine421 or M420 with L364 and H367, respectively, could not be 
generated. However, the amino acids L364 and H367 themselves seem to be involved in 
binding or translocation of TEA+, MPP+, and ASP+. In order to reveal insights into the 
involvement of L364 and H367 in substrate binding or transport mechanism, analyses of 
uptake kinetics are needed to investigate their effect on substrate affinity and transport rate.  
 
5.5.2 The D474E substitution in human OCT1 strongly affects substrate 
uptake  
The amino acids D475, W218, and F160 are known to be located in the binding cleft and to 
be involved in transport mechanism of rat Oct1 (Gorboulev et al., 1999; Popp et al., 2005; 
Volk et al., 2009). This work aimed to analyze first, the impact of the respective amino 
acids in human OCT1 and second, to analyze possible interactions of these amino acids 
with M420. 
In rat Oct1, D475 is suggested to be important for cation selectivity as D475E drastically 
decreases the vmax for the uptake of TEA+, MPP+, and choline by 98 %, 87 %, and 97 %, 
respectively (Gorboulev et al., 1999). The Km for TEA+ and choline was significantly 
decreased by 88 % and 93 %, whereas the Km of MPP+ was not affected showing only a 
slight decrease by 19 % (Gorboulev et al., 1999). Gorboulev et al. concluded that the 
turnover for MPP+ was decreased. Furthermore they suggested that the increased affinity 
for TEA+ and choline in the D475E mutant may lead to impaired intracellular release of 
TEA+ resulting in a decreased transport rate (Gorboulev et al., 1999). Western blot analysis 
revealed an increase of protein of D475E mutants in plasma membrane fractions. However, 
according to visual inspections no differences in membrane localization between wild type 
Oct1 and the D475E mutants were observed using immunofluorescence analysis 
(Gorboulev et al., 1999). Independent homology modeling suggested also human D474 as 
the essential amino acid involved in the interaction of the positive charge of the substrate 
with OCT1 (Pedersen et al., 2013). 
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The function of W218 in rat Oct1 was characterized in detail in a study of Popp et al. The 
mutant W218Y significantly reduced the Km and vmax for TEA+ and MPP+. Based on their 
results Popp et al. suggested that W218 interacts with both, TEA+ and MPP+ (Popp et al., 
2005).  
Until now, the mutation F160Y has not been analyzed in rat Oct1. A study from Volk et al. 
analyzed the exchange of phenylalanine160 to alanine. Their data indicates that 
phenylalanine160 interacts with corticosterone and tetrabutylammonium (TBuA) (Volk et 
al., 2009).  
These studies demonstrate the important role of D475, W218, and F160 in the function of 
rat Oct1.  
For this work the mutants D474E, W217Y, and F159Y were generated. The mutations 
were chosen according the chemical similarity to the exchanged amino acid in order to 
avoid differences in uptake activity caused by radical chemical changes. Analysis of the 
mutants regarding their transport activity for the uptake of TEA+, MPP+, ASP+, morphine, 
proguanil, tyramine, and metformin at single concentrations was performed (Figure 4.27).  
The mutants W217Y and F159Y did not affect the uptake of any of the substrates tested 
(Figure 4.27). It needs to be pointed out that the substrate concentrations used for MPP+, 
TEA+, ASP+, tyramine, and metformin were far below the determined or previously 
reported Km of these substrates (see Table 4.3 and Table 5.2 for MPP+, TEA+, ASP+ and 
metformin; for tyramine: Km= 94.7 µM and vmax= 380.9 pmol/mg protein/min (Seitz et al., 
2015)). As Popp et al. showed that W218Y in rat Oct1 effects Km and vmax of MPP+ and 
TEA+ transport to the same extent, we would expect no effect on the uptake MPP+ and 
TEA+ at single concentration measurements when using substrate concentrations far below 
the Km. Hence, in order to clarify the effect of W217Y and F159Y in human OCT1 uptake 
kinetics for these substrates needs to be determined.  
The substrate concentrations for morphine and proguanil (1 µM and 80 µM, respectively) 
were similar to the reported Km value for morphine (Km = 3.4 µM, (Tzvetkov et al., 2013)) 
and to the Km of proguanil determined in this thesis (Km = 21.7 µM, Table 4.3). As 
W217Y and F159Y did not affect the uptake of morphine and proguanil, it is assumed that 
these amino acids are not critically involved in the transport of morphine and proguanil. 
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In contrast, the mutant D474E strongly decreased the uptake of all substrates tested (Figure 
4.27). Immunofluorescence staining and confocal microscopy analysis revealed that the 
observed decrease in transport activity was not due to aberrant membrane localization of 
the mutants (Figure 4.26). D474E decreased the vmax of TEA+ and MPP+ uptake by 82 % 
and 67 %, respectively (Figure 4.29), showing a similar decrease in TEA+ uptake as 
previously reported for rat Oct1 (Gorboulev et al., 1999). In contrast, the effect of D474E 
on the vmax of MPP+ was lower in humans than observed in rat Oct1 (67 % and 87 % 
respectively, Figure 4.29 and (Gorboulev et al., 1999)). D474E did not affect the Km of 
sumatriptan and MPP+. The Km of MPP+ was only slightly, but insignificantly, increased 
by 17 %. This result is in line with the observation that D475E in rat Oct1 did not affect the 
Km of MPP+ (Gorboulev et al., 1999). In contrast, the Km values of TEA+ and ASP+ were 
significantly decreased by 41 % and 81 %, respectively (Figure 4.29). For rat Oct1 it was 
reported that D475E affected the Km of TEA+ much stronger showing a decrease by 88 % 
(Gorboulev et al., 1999). Hence, although D474 in human OCT1 seems to be involved in 
binding of TEA+, the effect of D474E is not as strong as observed in rat Oct1. As in human 
OCT1 both, the Km and vmax for ASP+ was strongly decreased in D474E mutants by 81 % 
and 77 %, respectively, one might speculate that according to Gorboulev et al., D474 is 
involved in binding of ASP+. 
D474E caused an increase in the Km by 679 % for metformin suggesting a strong decrease 
in the affinity for metformin. This result was unexpected as previous observations showed 
that e.g. for M420del affected the uptake kinetics of TEA+ and metformin to the same 
extent.  
Taken together, D474E strongly impaired OCT1 activity. The functional data of D474E in 
human OCT1 obtained in this study were similar to the data for D475E in rat Oct1 in the 
study of Gorboulev et al. However, the decrease in affinity for TEA+ due to D474E 
mutation in humans was not as strong as observed in rat Oct1. Hence, the decrease of vmax 
for TEA+ uptake of D474E mutants in human OCT1 might not be caused by impaired 
intracellular release of TEA+ due to the increased affinity as previously suggested for rat 
Oct1 (Gorboulev et al., 1999). This is another indication for species-specific differences 
and the exact role of D474 in humans needs further investigation. As choline is structurally 
similar to TEA+, it might be interesting, if similar effects of D474E in human OCT1 could 
be observed for choline uptake as previously reported for the rat ortholog. In contrast to the 
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strong effects of D474E in humans, no effect of W217Y and F159Y on OCT1 function was 
observed in this study. However, it is necessary to determine Km and vmax of the substrates 
in order to evaluate the impact of W217Y and F159Y in human OCT1 on transport 
function.  
Next, possible interactions of D474E, W217Y, and F159Y with M420 were analyzed. 
Therefore, the mutants D474E, W217Y, and F159Y were generated and overexpressed in 
combination with M420del and their transport activity for the uptake of TEA+, MPP+, 
ASP+, morphine, proguanil, tyramine, and metformin at single concentrations was analyzed 
(Figure 4.27). The mutants W217Y and F159Y in combination with M420del did not affect 
the uptake of any of the substrates tested. In contrast, D474E in combination with M420del 
strongly decreased the uptake of all substrates tested. As the results were similar to the 
effects observed on wild type background, it was concluded that W217Y and F159Y did 
not interact with M420del and that D474E independent from M420del strongly affects 
transport activity.  
However, detailed analyses of uptake kinetics revealed possible interactions between D474 
and M420. The effect of D474E in combination with M420del on the uptake kinetics of 
TEA+, MPP+, ASP+, metformin, and sumatriptan was analyzed (Figure 4.28, Figure 4.29). 
D474E in combination with M420del strongly decreased the vmax for all substrates tested 
by at least 68 %, except for metformin. The vmax for metformin was not affected by D474E. 
D474E in combination with M420del increased the Km of metformin by 133 %. This 
increase was less strong when D474E was expressed on wild type background showing an 
in the Km of metformin by 679 %. As M420del increased the Km by 400 % (Figure 4.12) 
and D474E by 679 % one may assume that the observed effect of D474E in combination 
with M420del on Km of metformin is not an additive one. More likely, the effect of D474E 
on Km of metformin is stronger than the effect of M420del. Similar effects were observed 
for the Km of TEA+: M420del increased the Km by 200 % (Figure 4.12), whereas D474E 
decreased the Km by 41 %. D474E in combination with M420del increased the Km of TEA+ 
only by 34 % (Figure 4.29). This suggested that the effect of M420del on Km of TEA+ was 
abolished in combination with D474E. These data indicate that impact of D474E for the 
transport of TEA+ and metformin is stronger that the effect of M420del. 
One might also speculate about complex interactions between M420del and D474E when 
analyzing the effect on the Km of MPP+ and sumatriptan. In wild type, D474E did not 
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affect the Km of MPP+ and sumatriptan. In contrast, when D474E was expressed in 
combination with M420del the Km for MPP+ and sumatriptan increased by 102 % and 
105 %, respectively. These results suggested that both mutations in combination decreased 
the affinity for MPP+ and sumatriptan. However, the exact interaction remains elusive.  
Additional analyses on the effect of M420del on Km and vmax in the presence of the D474E 
mutation were performed (Figure 4.29). According to the previous analyses in the presence 
of M420del, the vmax was decreased for all substrates tested. M420del did not affect the Km 
of MPP+ and ASP+ in D474E mutants. For MPP+ it could be suggested that D474E did not 
strongly affect the affinity for MPP+ as the mutation also in wild type cells did not change 
the Km. For ASP+ it is difficult to interpret the obtained data, as both M420del and D474E 
on wild type and M420del background rather lead to an decrease of Km for ASP+. In 
contrast, the Km of sumatriptan and metformin increased in the presence of M420del on 
D474E background by 76 % and 125 %, respectively. This increase is similar to the 
increase caused by D474E in combination with M420del (Figure 4.29). This data suggests 
that D474E and M420del affected the Km of sumatriptan and metformin to the same extent.  
In conclusion, it was observed that strong effects of D474E on the affinity for different 
substrates were present. As D474E strongly decreased affinity for metformin, involvement 
of D474 in metformin uptake needs further investigations. Furthermore, complex 
interactions were suggested between D474E and M420del especially concerning the uptake 
of metformin, MPP+ and sumatriptan. However, so far the structural mechanism and 
possible interactions are still unknown. A 3D model of human OCT1 might help to shed 
light on the structural mechanism of the observed effects of M420del on wild type OCT1 




Table 5.2 Uptake kinetic parameters of different substrates in different in vitro systems 
Substrate Km vmax Expression system Reference 
MPP+     
Human 14.6 ± 4.39 μM 3.69 ± 0.409 pmol/oocyte/h oocytes (Zhang et al., 1997) 
Rat n.s. 97 ± 5 pmol/oocyte/hr oocytes 
(Grundemann et 
al., 1994) 
 3-19 µM n.s. oocytes (Arndt et al., 2001) 
 2.7 ± 1.1 µM 41 ± 3 pmol/oocyte/h oocytes 
(Gorboulev et al., 
1999) 
 5.6 ± 1.0 µM n.s oocytes (Gorboulev et al., 2005) 
 3.9 ± 1.1 µM 122 ± 30 pmol/oocyte/h 
oocytes 
 
(Gorbunov et al., 
2008) 
 37 µM ± 12 n.s. oocytes (Sturm et al., 2007) 
 13 µM 40.1 ± 2.6 pmol/min/mg protein 
HEK293, 
 transiently transfected 
(Martel et al., 
1996) 
 30 ± 17 µM 324 ± 68 nmol/mg protein/s 
Proteoliposomes 
cell free expression (Keller et al., 2005) 
TEA+     
Human 229 ± 78.4 μM 2.89 ± 0.448 nmol/mg protein/30 min HeLa (Zhang et al., 1998) 
 1.27 ± 0.09 mM 4.09 ± 0.29 nmol/mg protein/ min 
HEK293, 
 transiently transfected 
(Takeuchi et al., 
2003) 
Rat 95 ± 10 µM 
81 ± 5 pmol/oocyte/hr, 
148 ± 4 pmol/oocyte/h oocytes 
(Grundemann et 
al., 1994) 
 95-129 µM n.s. oocytes (Arndt et al., 2001) 
 129 ± 17 µM 569 ± 27  pmol/oocyte/h oocytes 




94± 27 µM 
60-420 
pmol/oocyte/h oocytes (Popp et al., 2005) 
 75 ± 11 µM n.s oocytes (Gorboulev et al., 2005) 
 52 ± 21 µM 503 ± 73 pmol/oocyte/h oocytes 
(Gorbunov et al., 
2008) 
Mouse 38 μM 585  pmol/oocyte/h oocytes (Green et al., 1999) 
ASP+     
Human 2.32 ± 0.29 µM 696± 198  RFU/min/mg protein 
HEK293,  
stably transfected (Ahlin et al., 2008) 
 9.21 ± 0.9 µM 23900± 708  RFU/min/mg protein 
HEK293,  
stably transfected (Ahlin et al., 2011) 
Rat 1 µM > 10 µM HEK293,  stably transfected 
(Mehrens et al., 
2000) 
Mouse 9 ± 0.5 µM 24 ± 0.6 a.u. HEK293,  stably transfected 




Metformin     
Human 2.42±0.52 mM 6.74± 0.88  nmol/min/mg protein 
HEK293,  
stably transfected (Shu et al., 2007) 
 1.18 ±0.18mM 3.47 ± 0.12  nmol/min/mg protein 
HEK293,  
stably transfected (Chen et al., 2010) 
 5.45 ± 0.29 mM 31.9 ± 0.72  nmol/min/mg protein 
HEK293,  
stably transfected (Ahlin et al., 2011) 
 2.16 ± 0.36 mM 4.84 ± 1.15  nmol /mg protein/min 
CHO K1,  
stably transfected (Nies et al., 2009) 
Thiamine     
Human 0.78 ± 0.064 mM 2.77 ± 0.14  mol /mg protein/min 
HEK293,  
stably transfected (Chen et al., 2014) 
Mouse 0.49 ± 0.035 mM 5.80 ± 0.37  nmol/mg protein/min 
HEK293,  
stably transfected (Chen et al., 2014) 
 
 
5.5.3 Species-specific differences in transport activity between human OCT1 
and rodent orthologs for different substrates  
Most of the studies that analyzed OCT1 structure-function relationship or OCT1-mediated 
drug transport were performed using rat or mouse Oct1 (Shu et al., 2007; Koepsell, 2011; 
Li et al., 2011; Chen et al., 2014). The data obtained in this thesis enables the identification 
of whether similar effects were observed in humans. In order to analyze species-specific 
differences in the transport activity of human OCT1 and rodent orthologs we measured and 
compared the uptake of MPP+, TEA+ ASP+, and morphine. We found substantial species-
specific differences between human OCT1 and rodent orthologs. In contrast, mouse and rat 
Oct1 did not differ in their uptake activity (Figure 4.31). Compared to human OCT1, 
mouse and rat Oct1 increased the uptake of TEA+ 2.3-fold, whereas uptake of ASP+ 
decreased 2.7-fold and 3.6-fold, respectively (Figure 4.31). This observation was supported 
by Dresser et al. who showed that human OCT1 had a lower affinity for TEA+ then rodent 
Oct1 (Dresser et al., 2000).  
Most of the studies have been performed analyzing the uptake kinetics of the model 
substrates MPP+, TEA+, ASP+ or individual drugs such as metformin and thiamine in 
human OCT1 or rat Oct1. Studies analyzing mOct1 are still rare (Table 5.2). Until now 
only a few comparative studies regarding differences in substrate affinities and transport 
rates between these OCT1 orthologs are available (Dresser et al., 2000; Chen et al., 2014): 
For example Chen et al. analyzed uptake differences of thiamine in human OCT1 and 
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mouse ortholog. In mouse Oct1 the Km of thiamine significantly decreased, whereas vmax 
was significantly increased compared to human OCT1 (Chen et al., 2014) (Table 5.2).  
Additionally, different studies were performed using different in vitro systems such as 
stably or transiently transfected HEK293 cells or injected oocytes from Xenopus laevis 
(Table 5.2). That makes it difficult to compare the obtained results as for example the lipid 
environment of the in vitro system may affect the binding site of the transporter (Koepsell 
and Keller, 2016). It is also suggested that differences in experimentally determined Km 
values in either oocytes or HEK293 cells may be due to differences in intracellular 
concentrations of endogenous cations or differences in post-translational modifications 
(Gorboulev et al., 1999). Even within the same in vitro system (especially using injected 
oocytes) strong variations in the obtained kinetic parameters Km and vmax were observed 
(Popp et al., 2005). However, the available studies already indicated species-specific 
differences between OCT1 orthologs. Species-specific differences are getting even more 
important when considering that some substances that are substrates for human OCT1 act 
as inhibitors on rat Oct1, e.g. tetrabutylammonium (TBuA) (Dresser et al., 2000; Koepsell 
et al., 2007; Sturm et al., 2007). The molecular and structural mechanisms underlying these 
species-specific differences are still unknown (Dresser et al., 2000). 
Applying protein sequence alignment, human OCT1 shares 78 % amino acid identity with 
mouse and rat Oct1 (human: NP_003048, rat: NP_036829, mouse: NP_033228, protein 
alignment using http://blast.ncbi.nlm.nih.gov). Similar numbers were published by Dresser 
et al. who found that 80 % and 78 % of the amino acids are identical between human 
OCT1 and mouse and rat orthologs, respectively (Dresser et al., 2000). One might 
speculate that the unequal amino acids among OCT1 orthologs may lead to structural 
changes that furthermore affect substrate binding and translocation. This is even more 
likely as the amino acids that are different between the orthologs have different chemical 
properties (Dresser et al., 2000). However, the observed species-specific differences may 
also be due to the tissue specific expression of human OCT1 and rodent orthologs: human 
OCT1 is predominantly expressed in the basolateral membrane of hepatocytes, whereas 
rodent Oct1 is found to be expressed next to the liver also in kidney and the intestine 
(Gorboulev et al., 1997; Jonker et al., 2001; Nies et al., 2009). Hence, species-specific 




It was observed that species-specific differences exist between human OCT1 and the rat 
ortholog in the involvement of D474, W217, and F157 in substrate uptake, and analyses on 
the effect of these amino acids in mouse Oct1 were performed. The uptake of MPP+, TEA+, 
ASP+, and morphine at single concentrations in the mutants D475E, W218Y, and F160Y of 
mouse Oct1 and the respective mutations in humans was measured (Figure 4.32).  
In mouse Oct1, the mutant D475E did not affect the uptake of TEA+ and MPP+, whereas 
the uptake of ASP+ and morphine was significantly decreased. In contrast, in human OCT1 
the D474E mutant significantly reduced the uptake of all substrates tested. As discussed 
earlier one might suggest that D474 in humans could be involved in TEA+ binding, 
whereas in mouse D475E seems not.  
In mouse Oct1, the mutant W218Y did not affect the uptake of TEA+ and MPP+. In 
contrast, the uptake of ASP+ was significantly decreased and the uptake of morphine was 
significantly increased. In human OCT1, W217Y did not affect the uptake of any of the 
substances tested.  
In mouse Oct1 the mutant F160Y did not affect the uptake of TEA+ and MPP+. In contrast, 
the uptake of ASP+ and morphine was significantly decreased. In human OCT1, F159Y did 
not affect the uptake of any of the substances tested.  
Taken together, strong differences in the effects of D474E, W217Y, and F159Y between 
human OCT1 and the mouse orthologs on substrate uptake were observed. One might 
speculate about species-specific differences in substrate specificity and involvement of 
amino acids participating in translocation mechanism. However, in order to reveal the role 
of these amino acids in mouse Oct1, uptake kinetic studies are necessary, because the 
effects in mouse Oct1 could have been undetected as substrate concentrations far below the 




5.6 The M408V and G414A polymorphism do not alter the effect of 
M420del 
Haplotype inferring analyses revealed that M420del exists in combination with several 
other OCT1 polymorphisms like M408V and G414A (Tzvetkov et al., 2014; Seitz et al., 
2015). 
Recently, the M420del variant was associated with increased risk of imatinib treatment 
failure in chronic myeloid leukemia (Giannoudis et al., 2013). This observation was 
confirmed by in vitro studies in which M420del expressing CML cell lines decreased 
imatinib uptake. Similar results were obtained for the uptake of TEA+ and ASP+. This 
decrease was not observed in combination of M420del with V408. Furthermore, lower 
protein expression of M420del in combination with M408 was observed in western blot 
analysis of membrane fractions, but not in combination with V408 (Giannoudis et al., 
2013). However, analyses of 371 Caucasians regarding their M420del-M408V genotype 
made by our group could show that M420del exclusively existed in combination with 
V408 (Tzvetkov et al., 2014). Furthermore, in contrast to the study of Giannoudis et al. it 
was shown in this work that V408 did not affect the impact of M420del on the uptake of 
TEA+ and ASP+ but also MPP+, morphine, metformin, and debrisoquine (Figure 4.10). 
M420del with M408 or V408 did not affect membrane localization or protein amount in 
whole cell lysates (Figure 4.9). As Giannoudis et al. used plasma membrane fractions and 
this work analyzed whole protein lysates, protein analyses by western blotting might not be 
comparable. However, these results were in line with Ahlin et al., who could also not show 
differences in subcellular localization or protein expression of the M420del variant using 
confocal microscopy analysis and western blot analysis of membrane fractions (Ahlin et 
al., 2011). Additionally, the lack to modulate the effect of M420del by V408, which were 
observed, is in line with previous studies of Shu et al. in which they could show that MPP+ 
uptake in M420del cells is not affected by the presence of V408 (Shu et al., 2003). Shu et 
al. also showed that the presence of V408 did not affect the impact of other non-
synonymous amino acid exchanges like R61C and G401S that strongly decreased MPP+ 
uptake independently from M408 and V408 (Shu et al., 2003). 
In line with the observations of Shu et al., it could be shown that the effect of M420del is 
also not altered by another non-synonymous amino acid exchange: the G414A variant. 
Haplotype inferring analyses revealed that the G414A variant only exists in combination 
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with M420del (Seitz et al., 2015). However, uptake measurements using HEK293 stably 
transfected to overexpress all theoretically possible combination of M420del-G414A 
revealed that no differences were observed in the uptake of MPP+, TEA+, ASP+, 
metformin, morphine, and O-desmethyltramadol in M420del cells in combination with 
G414 or A414. In contrast, M420 in combination with A414 revealed uptake activity 
comparable to wild type reference cells (Figure 4.11). However, a slight increase in the 
uptake was observed in the presence of V408 independently of M420del or A414. But this 
increase was also present in combination with M420 or G414.  
Taken together, functional data demonstrated highly substrate-specific effects of M420del 
that are only marginally affected by V408 and A414; another two variants that are 
commonly inherited with M420del next to C88R and G465R. Recently, haplotype inferring 
analyses revealed that the variants C88R and G465R exit in combination with M420del 
(Seitz et al., 2015). Both variants were characterized as complete loss-of-function variants 
in previous studies in vitro and in vivo (Shu et al., 2003; Shu et al., 2007; Ahlin et al., 
2011; Tzvetkov et al., 2011; Saadatmand et al., 2012; Tzvetkov et al., 2012; Tzvetkov et 
al., 2013). The studies of Shu et al. and Ahlin et al. characterized G465R as complete loss-
of-function variant, but it is not pointed out if these studies were performed considering 
that G465R exist in combination with M420del. In contrast, the studies of Tzvetkov et al. 
and Saadatmand et al. considered the actual haplotype of C88R and G465R in combination 
with M420del. However, as all studies showed complete loss of function for these variants, 
one might speculate that C88R and G465R strongly affect protein structure (see chapter 
5.1.2), which lead to lack of membrane localization.   
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6 Summary and outlook 
A major part of this thesis was the functional characterization of common and newly 
identified OCT1 genetic variants. Nineteen OCT1 variants were functionally characterized 
regarding their uptake activity of a broad range of known OCT1 substrates including model 
substrates (MPP+, TEA+, and ASP+) as well as clinically relevant drugs like morphine, O-
desmethyltramadol, tropisetron and metformin. A substantial number of OCT1 variants, 5 
out of 19 tested, showed substrate-specific loss of activity. This finding emphasizes the 
need to test each OCT1 genetic variant on a broad range of substrates in order to 
characterize them correctly. Furthermore, the high number of substrate-specific variants 
reflects the polyspecificity of OCT1 and suggests different substrate binding sites and 
transport mechanisms for different substrates.  
More substrates and further mutations in OCT1 should be characterized in the future. This 
is one alternative strategy to identify the multiple binding sites and to reveal the 
mechanisms conferring OCT1 polyspecificity. A first approach was made in this thesis by 
correlating the effect of OCT1 variants on substrate uptake to the structural properties of 
the different substrates tested using the two-dimensional hierarchical clustering analysis. 
These were, however, only preliminary prove-of-principle analyses and more data both 
regarding additional substrates and regarding additional mutations is needed.  
The detailed functional analyses of worldwide existing OCT1 genetic variants revealed 
strong variation in loss of OCT1 activity among different populations. This knowledge 
could help to explain population-specific differences in the pharmacokinetics and efficacy 
of drugs like morphine, metformin, and O-desmethyltramadol and may lead to therapy 
optimization for specific populations in the future. The functional data obtained in this 
work suggest that Surui Indians, as a population with extremely frequent loss of OCT1 
activity, have a higher risk of adverse effect when treated with morphine. Systematic 
analyze the pharmacokinetics of drugs like morphine in populations with frequent loss of 
OCT1 activity are needed in order to “translate” our in vitro data into therapeutic 
recommendations. 
So far the reason for the strong worldwide differences in the loss of OCT1 activity is not 
known and the possible selective agent(s) remain unknown. Future studies may focus on 
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endogenous substances, e.g. vitamin B1, which was recently identified as an OCT1 
substrate, or hormones and metabolites that could be tested as potential OCT1 substrates 
and may differ between the populations due to environmental or nutritional differences 
among world regions. 
The second part of this thesis was the in-depth analysis of the highly substrate-specific 
M420del variant as the most frequent and ubiquitously observed loss-of-function variant. 
M420del showed highly substrate-specific effects on substrate affinity. By deletion of 
methionine420 the affinity to TEA+ and metformin was strongly decreased, whereas the 
affinity to the majority for the substrates, including MPP+, ASP+ and morphine, was 
increased. As TEA+ and metformin have similar structures one might speculate that the 
effect of M420del on substrate affinity may be restricted to substrates with a similar 
structure, e.g. strong bases or quaternary amines with aliphatic and not aromatic residues.  
It would be interesting to test in the future the effect of M420del on structurally similar 
substrates. These may include substrates that are structurally similar to TEA+ (tetra-
methylammonium, tetrabutylammonium, tetrapentylammonium, choline) and to metformin 
(debrisoquine, buformin, phenformin, agmatine) in order to specify the observed substrate-
specific effects of M420del. 
The deletion of methionine420 caused a substrate-dependent decrease of vmax for all 
substrates tested. As reduced membrane localization for the M420del could not be 
detected, the decrease in vmax was not due to aberrant membrane localization. However, the 
observation regarding membrane localization of M420del is still controversial. One of the 
next aims will be to improve protocols for membrane isolation in order to validate the 
obtained results using more quantitative methods like LC-MS-based protein quantification.  
So far mutagenesis analyses revealed that the substrates-specific effects of M420del were 
caused by loss of the methionine420 side chain. The specific properties of the methionine 
side chain could not be explained by substituting methionine against threonine, isoleucine 
or cysteine. Further substitutions like M420S could be tested. Furthermore, a general 
involvement of L364 and H367 in the transport process was observed that was independent 
of M420del. 
In order to investigate the importance of these two amino acids in OCT1 function, uptake 
kinetics using of structural different substrates should be performed. Further mutants could 
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be generated (e.g. L364I, L364V, H367Y) in order to ensure that the observed effect was 
not due to the radical chemical changed caused by substitution of the native amino acids to 
alanine.  
This work suggested also indirect interactions of M420 with D474, but not with W217 and 
F159. Kinetic studies of F159Y and W217Y mutants in combination or without the 
M420del are necessary to exclude that the lack of effects on single concentrations tested is 
not due to simultaneous effects of these mutations on Km and vmax. Furthermore, the 
mutants D474N and D474R should be generated with or without M420del in order to 
characterize the effects of D474 in humans and potential interaction with M420 in more 
details. Together with the recent published homology model of human OCT1 from 
Pederson et al. these efforts shall confirm the importance of D474 as the amino acid that 
determines the substrate charge specificity of OCT1. 
Strong species-specific differences were observed between human OCT1 and its rodent 
orthologs. Further kinetic studies using a broad range of substrates should be performed in 
order to analyze species-specific differences in detail. Furthermore, chimeric constructs of 
human and mouse OCT1 could be used to analyze the structural differences between these 
two orthologs and to map the important transmembrane domains responsible for the 
observed species-specific differences. All together this shall help to interpret data obtained 
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